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Mesenchymal  stem  cells  (MSC)  represent an  adult stem  cell  population 
isolated  from  the  bone  marrow  with  the  ability  to  differentiate  down  various 
mesenchymal  lineages  including  cartilage.  The  development  of  cartilage  is  a 
complex  multiphase  process  regulated  by the  interplay  of factors  such  as  cell 
density  and  oxygen  availability  as  well  as  many  signalling  pathways  including 
TGFp,  MAPK,  FGF  and  Wnt.  Using  microarrays,  the  temporal  transcriptional 
changes occurring in the in vitro MSC chondrogenesis model were analysed. The 
results obtained support the validity of the MSC  model  system for the study of 
chondrogenesis, as genes known to play a role in the process such as collagens 
2,  9 and  11,  aggrecan  and the transcription factor Sox9,  are expressed  in the 
chronological  pattern  expected.  Genes  were  also  identified  that  had  been 
previously  noted  to  be  expressed  in  limb  development  but  whose  role  in 
chondrogenesis  remains  unknown,  as  well  as  a  group  of  novel  factors  not 
previously associated with chondrogenesis. Hes1  and Hey1, the targets of Notch 
signalling  were  both  found  to  be  upregulated  early,  and  their  role  in 
chondrogenesis  was  investigated  by  inhibiting  Notch  signalling.  Abolishing  the 
expression of Hes1 and Hey1  had a deleterious effect on the accumulation of the 
chondrogenic matrix,  indicating that these transcription factors are implicated  in 
chondrogenesis.
Microarray analysis was also used to compare the expression profiles of a 
broad  range  of mesenchymal  tumours,  resulting  in  the  identification  of factors 
specific to each. The brachyury gene was found to be specifically expressed on 
chordomas, a tumour derived from notochordal remnants often misdiagnosed for 
a  chondrosarcoma.  Immunohistochemistry  was  performed  using  a  polyclonal 
antibody to this molecule and was found to distinguish chordomas from over 300 
other  lesions,  including  a  wide  variety  of  chondroid  neoplasms.  Brachyury  is 
therefore a specific marker for chordomas,  and can  be exploited for diagnostic 
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131. INTRODUCTION
1.1  MESENCHYMAL STEM CELLS
Mesenchymal  stem  cells  (MSC)  are  an  adult  progenitor  cell 
population,  isolated  from  the  bone  marrow,  that  have  the  ability  to 
differentiate towards various mesenchymal  lineages.  They provide a  useful 
tool  for  modelling  differentiation  in  vitro  and  may  also  have  clinical 
applications in treating conditions ranging from  bone fracture to myocardial 
ischemia. Here, a review is given of the history of research on MSC, followed 
by a description of their phenotype and conditions required for maintaining 
and  differentiating  them  in  vitro.  A  discussion  of  the  MSC  differentiation 
potential as well as the reported sources of MSC follows.
1.1.1  History
The first experiments suggesting that a cell capable of osteogenesis 
resides in adult bone marrow were performed  by Urist and  Mclean  in  1952 
(1).  They were  interested  in  studying the osteogenic potency of cells from 
different  tissues  and  performed  autologous  transplants  of  bone  marrow, 
periosteum,  callous bone as well as blood clots into the eyes of rats. They 
discovered  that  all  these  tissues,  with  the  exception  of  blood  clots,  had 
osteogenic potential.  In  addition,  the  bone  marrow transplants also formed 
cartilage  and  bone  marrow  stroma,  in  fact forming  an  ossicle  -  a  primary 
marrow  cavity  surrounded  by  bone  and  cartilage.  Further  bone  marrow 
transplants were performed  by Tavassoli and Crosby using large  pieces of 
undisrupted tibia bone marrow, which they would scoop out with a spatula 
and  implant  into other tissues such  as  spleen,  liver or muscle.  Again,  the 
development of osteoid at the site of transplantation was noted, and within a 
few weeks the development of bone marrow stroma surrounded by a layer of
14bone was observed, just as occurred  in the Urist and  McLean experiments 
(2).
The cells responsible for this osteogenic response were isolated from 
guinea pig  bone marrow and cultured in vitro by Friedenstein  in  1974, who 
named  them fibroblast colony forming  cells  (FCFC).  FCFC  are  extremely 
adherent cells,  and this is the  property that allowed  Friedenstein to  isolate 
them (3). He found that over 90% of FCFC would adhere to glass within 90 
minutes  in  the  absence  of serum.  The  cells were  few  in  number,  spindle 
shaped  and  dormant  for  2  to  4  days  after  isolation,  after  which  they 
multiplied rapidly.  FCFC had the ability to differentiate into osteocytes when 
placed in diffusion chambers and transplanted  into other sites,  such as the 
kidney in vivo,  but would  not undergo spontaneous osteogenesis while  in 
monolayer  culture.  Castro-Malaspina  et  al  and  Piersma  et  al went  on  to 
characterize  these  cells  further  and  found  them  to  express  bone  marrow 
matrix proteins such as type 1  and 3 collagen and fibronectin (4;5).
Different terms are currently used to describe the  FCFC  population, 
the most common ones being MSC and bone marrow-derived stem cells.
1.1.2  MSC phenotype
The  bone  marrow  houses  a  myriad  of  cells  including  blood  and 
stromal  cells  as  well  as  both  hematopoietic  and  non-hematopoietic  stem 
cells. Specifically: endothelial cells, adipocytes, macrophages, reticular cells, 
fibroblasts, osteoprogentors, various stem cell populations and their progeny 
all  reside  within  the  bone  marrow  stroma  (6).  MSC  are  isolated  from  the 
mononuclear  layer  of  the  bone  marrow,  which  is  considered  the  non- 
hematopoietic compartment (7).  Morphologically MSC  resemble fibroblasts 
and are spindle-shaped when  isolated.  When  kept in  culture for prolonged 
periods however, the cells enlarge and lose their spindle shape.
Determining  the  cell  surface  marker  profile  of  MSC  has  been  a 
common research goal, and a summary of the expression of many cluster of
15differentiation (CD) molecules on MSC is presented in Table 1.1. Unlike the 
haematopoietic stem  cells  (HSC)  isolated from  bone  marrow,  MSC  do  not 
express  haematopoietic  cell  surface  markers  such  CD34,  CD45  or  CD 14 
(although the expression of CD 14 has been detected  by some groups (8;9)) 
or epithelial markers CD 1a, CD31  and CD56 (10). MSC also do not express 
the  epithelial  antigen  ESA  but  do  express  cytokeratins  (10).  MSC  are 
positive for SH2, SH3 and SH4 mesenchymal markers and a-smooth muscle 
actin and also express a large variety of proteins that facilitate cell to cell and 
cell to matrix interactions such as a and (3  integrins (a1/2/3/5/6 and (31/3/4) 
and cell adhesion molecules (ICAM-1  and 2, VCAM-1) on their surface (IQ- 
13). The MSC extracellular matrix (ECM) is rich in collagens 1, 3, 4, 5 and 6, 
fibronectin and laminin, with which the integrins can interact (14). As yet no 
unique marker has been found that is expressed by MSC and no other cell 
type that would aid in their isolation and identification.
Stro-1  binds to about 10% of the bone marrow mononuclear cells and 
is often used as a method for identifying MSC. Stro-1  is not MSC specific as 
it  also  identifies  erythroid  precursors  but  does  not  bind  to  other 
hematopoietic  precursor  cells  (15).  Using  Stro-1,  in  combination  with 
negative selection for glycophorin A expressing cells, isolates a population of 
cells  that  adheres  to  tissue  culture  plastic  and  has  the  potential  to 
differentiate down all MSC lineages (15).
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CD1a
CD14
CD31
CD56
CD29
CD34
CD44
CD45
CD49a
CD49b
CD49c
CD49e
CD49f
CD54
CD61
CD71
CD77
CD90
CD 102 
CD104 
CD 106
CD117
CD 120a 
CD 124a
Other names’
R4; HTA-1 
LPS-R
GPIIa’; endocam; 
PECAM-1 
Leu-19; NKH1; 
NCAM
Platelet GPIIa; VLA- 
beta chain; integrin 
(31
gp105-120; HPCA
ECMRIII; H-CAM;
HUTCH-1; Hermes;
Lu, In-related; Pgp-
1; gp85
B220; CD45R;
CD45RA; CD45RB;
CD45RC; CD45RO;
EC3.1.3.4; LCA;
T200; Ly5
Integrinal
Integrina2
Integrina3
Integrina5
Integrina6
ICAM-1
lntegrin(33
T9; transferrin
receptor
Pk blood group
antigen; BLA; CTH;
Gb3
Thy-1; Theta
antigen
ICAM-2
Integrinp4
INCAM-110;
VCAM-1
c-kit; SCRF
TNFRI; p55 
IL-4R
Remarks
Thymocyte antigen 
Considered a 
hematopoietic marker 
identifying macrophages 
Endothelial cell and 
fibroblast marker 
Expressed on neurons, 
glia and skeletal muscle 
One of the integrins 
expressed by the MSC
Hematopoietic and 
endothelial marker 
Hyaluronic acid receptor, 
interacts with osteopontin 
and collagens
Expressed by all 
hematopoietic cells except 
erythrocytes
Attachment to ECM 
Attachment to ECM 
Attachment to ECM 
Attachment to ECM 
Attachment to ECM 
Adhesion molecule 
Attachment to ECM 
Mediates iron uptake
Mainly expressed on B- 
lymphocytes
Mainly expressed by T- 
cells
Adhesion molecule 
Attachment to ECM 
Mediates monocyte to 
lymphocyte adhesion 
Receptor for stem cell 
factor regulating 
differentiation, in particular 
hematopoietic 
Tumour necrosis factor 
receptor
Interleukin receptor
Expressed by 
MSC
NO
Mixed reports 
(see text)
NO
NO
YES
NO
YES
NO
YES
YES
YES
YES
YES
YES
YES
YES
YES
YES
YES
YES
YES
NO
YES
YES
(Legend on following page)
8  Source of alternative nomenclature: http://www.sciencegateway.org/resources/prow/index.html
17Table  1.1:  Summary of the  expression  of various  cluster of differentiation 
(CD) molecules on MSC (6; 10-13)
MSC are  known to express  high  levels of vimentin,  a  mesenchymal 
marker, identifying cells of mesodermal origin, and have also been found to 
express various neural genes, suggesting that they may have the potential to 
differentiate  into  neural  lineages  (16; 17).  Wagner  et al also  demonstrated 
that altering the media in which MSC are grown has a very significant impact 
on their expression  profile,  adding  another variable  alongside the  isolation 
procedure and yet another factor to be taken into account when comparing 
the results obtained by various groups (16).
1.1.3  MSC culture conditions
Establishing  MSC  in  culture  is  slow,  as they are thought to  be  in  a 
quiescent state when isolated. The rate of proliferation of MSC is related to 
their  density  and  when  cells  are  seeded  too  sparsely  the  doubling  time 
becomes very slow and apoptosis frequent.  It is therefore difficult to culture 
MSC as single cell clones (although work has been published on cells grown 
in this manner as described below) and there is some suggestion that they 
may be programmed to die when single, as cell death naturally occurs during 
development of mesenchymal  tissues  in  processes  such  as  endochondral 
ossification  and  digit  formation  (18).  There  are  also  differences  in  MSC 
growth requirements between different species (19).
Conget and Minguell report that MSC can be passaged up to 25 times 
without displaying dramatic morphological or immunophenotypical changes, 
after which they gradually lose the expression of specific surface antigens 
and  begin  to  display  apoptotic  characteristics  (20).  The  average  doubling 
time was 33 hours and a large proportion (20%) of the cells were found to be 
in the GO phase of the cell cycle which could be seen as an indicator of their 
self-renewal  potential.  Conget and  Minguell  also demonstrate the vast,  but
18not unlimited, expansive potential of MSC, where each cell grown in vitro has 
the capability to give rise to -5.5 x 108  cells (20).
The growth  rates  of MSC vary in vitro depending  on the  donor,  but 
differences can also be  noted with samples taken from the same donor at 
different times  (21 ;22).  Cryopreserving  and thawing  MSC  appears to  have 
no  effect  on  their  growth  and  differentiation  (21;22).  The  donor  variation 
noted  by  Phinney et al could  not  be correlated with  donor age  or gender, 
while Mareschi et al found that MSC from younger donors proliferated more 
rapidly (21 ;23). However, all the donors used by Phinney et al were over 19 
years of age, whereas Mareschi et al investigated the proliferative potential 
from  paediatric  (2-13  year  old)  and  adult  donors  and  found  that  they 
underwent twice as many population doublings as the MSC isolated from the 
adults in the same time period (21;23).
Telomerase  overexpression  can  extend  MSC  lifespan  apparently 
indefinitely (over 260 population doublings) without impairing, and potentially 
even  enhancing  osteogenic  differentiation  (24;25).  Okamoto  et  al 
overexpressed telomerase and E6/E7 papillomavirus genes and claimed that 
the  MSC  continue  to  differentiate  towards  osteocytes,  adipocytes  and 
chondrocytes (26).
The  addition  of  basic  fibroblast  growth  factor  (bFGF)  significantly 
accelerates  the  doubling  time  of  MSC,  without  limiting  the  differentiation 
potential into chondrogenic, adipogenic or osteogenic lineages and so allows 
rapid expansion of MSC, thus making them a more convenient cell type for 
manipulation (27).
1.1.4  Differentiation potential
Two  types  of  assays  are  used  to  determine  MSC  differentiation 
potential: the first are in vitro assays where growth factors are added to cells 
in culture in order to induce differentiation toward a specific lineage and the 
second  are  in  vivo  studies  where  MSC  are  injected  into  a  particular  site
19(usually  in  a  murine  model)  and  then  analysed  microscopically  for 
morphology  and  immunohistochemically  for  expression  of  specific 
molecules.
MSC  can  differentiate  to  cells  of  mesenchymal  origin  including 
chondrocytes,  osteocytes,  and adipocytes in vitro (11;28).  In addition, they 
can  produce marrow stroma and serve as feeder layers for haematopoietic 
stem cell expansion (11 ;29).  As marrow is surrounded by bone, and marrow 
is  often  replaced  with  fat  with  age  -   the  osteogenic,  chondrogenic  and 
adipogenic potential of these cells is not surprising.
MSC  have  also  been  shown  to  differentiate  in  vitro  into  muscle  as 
demonstrated  by  the  presence  of  cells  with  contractile  myotubes  (30). 
Further evidence of myogenesis  was  provided  by bone  marrow cells from 
lacZ expressing transgenic mice contributing to muscle fibres when injected 
into wildtype recipients (30;31). Upon fractionation of the bone marrow cells, 
Ferrari et al concluded that the adherent population (therefore the MSC) has 
myogenic  potential,  but that these cells would  contribute only  minimally to 
actual muscle regeneration normally (31).
According  to some  research,  when  MSC  are  injected  into the  adult 
murine heart they appear to differentiate into cardiomyocytes, as shown  by 
the  expression  all  the  cardiomyocyte genes  (32).  However,  a  more  recent 
investigation  showed  no  evidence  of  differentiation  of  MSC  into 
cardiomyocytes and no restoration of myocardial function when human MSC 
were injected into ischemic rat hearts (33).
There  have  also  been  reports  of  MSC  differentiation  into  non- 
mesodermal  lineages  including  neural  cells  and  hepatocytes.  When  MSC 
were  injected  into  murine  brains,  they  differentiated  into  neurons  and 
astrocytes (34). In vitro, MSC were found to express neural markers (Section
1.1.2  and  ref (17))  and  could  be  induced  to  exhibit  a  neural  morphology 
when cultured in the presence of retinoic acid and brain-derived neurotrophic 
factor (BDNF)  (35).  However, this  study did  not address whether the cells 
generated were functional  neurons. Zhao et al transduced the  BDNF gene
20into human MSC and detected not only the expression of neural markers but 
also  an  electric  current  using  the  patch  clamp technique,  hence  the  cells 
they produced also functionally resembled neurons (36).
Sato et al inoculated various cell populations from bone marrow into 
damaged rat livers and found that only MSC differentiated into hepatocytes 
and  expressed  alpha-fetoprotein,  albumin  and  cytokeratins  (37).  In  vitro 
MSC  differentiation  into  hepatocytes  has  been  achieved  by  3-dimensional 
pellet  cultures  and  supplementation  of  growth  medium  with  bFGF, 
hepatocyte growth factor and oncostatin M (38).
The reported in vivo differentiation experiments seeking to show that 
a  single  cell  has  the  ability  to  differentiate  toward  different  mesenchymal 
lineages  are  somewhat contentious.  This  is  because  it  is  difficult to  prove 
that cell fusion does not occur between the injected cell and an endogenous 
(host) cell,  leading them to express markers of both cell types (39).  In this 
respect,  in  vitro  studies  investigating  the  differentiation  from  a  presumed 
MSC  are  less  problematic  as  fusion  to  another  cell  population  is  not 
possible.  However,  in  contrast  to  in  vivo  experiments,  the  in  vitro 
differentiation conditions are artificial, and it is not clear whether the selected 
cells would behave as they would in vivo. Another contentious issue is how 
differentiation  into  another cell  type  is  defined,  as  it could  be  argued  that 
solely  the  expression  of  genes  associated  with  a  certain  lineage  is  not 
sufficient evidence to confirm differentiation. It is therefore essential to define 
what functionally determines a certain cell type such as the formation of lipid 
droplets in  an  adipocyte or the firing of action  potentials by a  neuron,  and 
apply standardized tests for these.
1.1.5  Sources of MSC-like cells
For the  purposes  of this  thesis,  MSC  are  defined  as  cells  isolated 
from the bone marrow. However cells resembling the MSC, in terms of their 
phenotype and differentiation potential have been isolated from a variety of
21tissues.  Adipose-derived  stem  cells,  termed  processed  lipoaspirate  cells 
(PLA)  have  been  shown  to differentiate  towards  osteogenic,  chondrogenic 
and adipogenic lineages in vitro (40;41). Cells derived from trabecular bone 
and the periosteum also differentiate towards these three lineages (42;43). It 
may seem  more  likely that it is these,  local,  stem  cell  populations that are 
recruited  in  tissue  repair  rather  than  the  pluripotent  bone  marrow 
populations, but their relative contributions are unknown and the relationship 
between MSC and committed  progenitors remains unclear. The isolation of 
MSC-like  cells,  shown  to  differentiate towards  adipogenic,  osteogenic  and 
myogenic  lineages,  has  also  been  reported  from  tendon,  synovial 
membrane, lungs and, recently, the appendix (44-48).
Meirelles et ai attempted a large scale isolation of MSC-like cells from 
a wide variety of tissues including: spleen, muscle, aorta, vena cava, kidney, 
lung, liver, brain and thymus (49). The morphology of the cells isolated from 
all  tissues  resembled  MSC,  but  the  cells  were  more  flattened  and  less 
spindle-shaped  (Section  1.1).  Fluorescence  activated  cell  sorting  (FACS) 
analysis of the  immunophenotype of these cells showed  all  populations to 
express  similar  surface  antigens  and  be  CD29  and  CD44  positive,  with 
variable expression of CD90 and  CD49e,  normally found on  MSC (Section 
1.1.2)  (49).  All  the  cell  lines  showed  some  ability  to  differentiate  into 
adipocytes and osteocytes and could undergo over 50 population doublings 
(49).
Another  point  of  debate  has  been  whether  MSC  are  present  in 
circulating blood. Meirelles et al were unable to establish MSC cultures from 
peripheral  blood,  as were Wexler et al, who also attempted to perform the 
isolation  on  cord  blood  unsuccessfully  (49;50).  However,  others  have 
isolated an MSC population from peripheral  blood and mobilized peripheral 
blood,  and  shown  it  to  display  MSC  characteristics,  such  as  Stro-1 
expression,  as well  as the MSC differentiation  potential  (51). An  additional 
complexity arises from the finding that MSC-like cells can  be cultured from 
blood  vessels.  Hence,  any  damage  caused  to  this  structure  during  the
22collection of a blood sample could result in the release of MSC-like cells that 
would then be assumed to be derived from the peripheral blood itself rather 
than the vessel wall (49). Finally, MSC may be released into peripheral blood 
from the bone marrow as a response to injury, even if they are not normally 
present in the circulation (52).
1.1.6  The uniformity of mesenchymal stem cells
In  1999,  Pittenger et al addressed the question whether MSC were 
truly a multipotent cell population or simply a mixture of committed progenitor 
cells.  This  was  done  by growing  clonal  populations  from  single  cells,  and 
then testing their in vitro differentiation potential (11). Of the 6 clones tested, 
all underwent osteogenesis, of these 5 also differentiated into adipocytes of 
which  3 were also capable of differentiation  into chondrocytes. The finding 
that  not  all  6  colonies  differentiated  into  all  the  lineages  could  either  be 
accounted for by a  loss of multipotentiality due to a  high  passage  number 
(necessary to  obtain  a  sufficient  number of cells)  or  it  could  indicate  that 
MSC are indeed a mixed population of truly multipotent cells and committed 
progenitors.
Muraglia  et  al  performed  a  similar  assay  with  somewhat  different 
results to  Pittenger et al (53).  They analysed  185 clones for differentiation 
into all 3 lineages and conclude that all differentiated into osteocytes, while 
the majority differentiated into chondrocytes and only a third could undergo 
adipogenic  differentiation.  They  did  not  find  any  clones  capable  of 
undergoing adipogenesis and osteogenesis only. This discrepancy with the 
Pittenger  et  al data  may  be  due  to  different  conditions  used  by  the  two 
groups  to  induce  differentiation  as  well  as  different  methods  for  testing 
whether cells  had  undergone differentiation.  Muraglia  et al did  not perform 
staining for calcification to assess for osteogenesis or for proteoglycans to 
test  for  chondrogenesis  as  Pittenger  et  al  did,  instead  they  performed
23immunohistochemistry  for  proteins  expressed  in  cartilage  and  bone 
(Collagen 2 and Osteocalcin respectively).
Beside the experiments on  clonal  populations detailed  above,  many 
researchers  have  identified  subpopulations  of  cells  within  the  MSC 
population, indicating that MSC are a heterogeneous population of cells.
Colter et al identified a morphologically distinct subpopulation of MSC 
that they referred to as: “small, round, rapidly self-renewing cells” (RS1) (54). 
Through continuous passaging of the MSC, the RS1 subpopulation seems to 
be  lost  but  the  RS1-enriched  populations  show  higher  levels  of 
differentiation: the osteoblasts show higher levels of mineralization, a higher 
proportion  of  cells  differentiate  into  adipocytes  and  the  chondrocytes 
produce more matrix (54).
Pochampally  et  al  used  serum  deprivation  to  select  for  a 
subpopulation  of MSC that displayed  longer telomeres  and  expressed  low 
levels of genes  normally attributed to embryonic stem cells,  such as Oct-4 
and  telomerase  (55).  Whether  these  cells  also  have  an  increased 
differentiation capacity remains to be elucidated.
D’lppolito et al isolated a population of bone marrow cells they refer to 
as  marrow-isolated  multilineage  inducible  (MIAMI)  cells.  These  were 
selected without gradient centrifugation in an attempt to replicate the In vivo 
niche  of  the  stem  cells.  MIAMI  cells  were  found  to  express  Oct-4  and 
telomerase  as  well  as  Rex-1,  another  embryonic  stem  cell  gene.  Their 
differentiation  potential  is  reported  to  span  all  three  germ  layers,  although 
differentiation  was  only  evaluated  in  terms  of  marker  expression  and 
morphology but not function (Section 1.1.4) (56).
Multipotent adult  progenitor cells  (MAPC)  are  a  population  of cells, 
similar to the  MSC, that are also purified from the  bone  marrow. They are 
enriched by negative selection with immuno-magnetic beads, which bind all 
CD45  and  Glycophorin  A  positive  cells  (57).  MAPC  are  also  cultured  in 
different conditions to the MSC: they are grown in low serum concentration, 
with  epidermal  growth  factor  (EGF)  and  platelet  derived  growth  factor
24(PDGF) added,  and are  plated on fibronectin-coated  plates.  In vitro human 
MAPC  can  be  induced  to  differentiate  not  only  down  the  osteogenic, 
adipogenic  and  chondrogenic  lineages  but  also  into  skeletal  muscle, 
hepatocytes,  neuroectoderm and endothelium (57-59).  MAPCs can also be 
expanded  for  longer  in  culture  than  MSC  (more  than  80  population 
doublings).  Murine  MAPC  were found  to  express  low  levels  of embryonic 
stem cell  markers Oct-4 and  Rex1.  Single cell cultures of these cells could 
be  induced  to  differentiate  in  vitro  into  tissue  types  from  all  three  germ 
layers, and when a single MAPC was injected into the early blastocyst it was 
capable  of  contributing  to  all  somatic  cell  lines  (58).  While  the  potential 
existence of a pluripotent adult stem cell is an exciting possibility, so far this 
data  has  not  been  reproduced  by  any  researchers  other  than  those 
associated with the  group  responsible for the above  publications  (Verfaille 
and co-workers). Therefore the experiments presented above are somewhat 
contentious and the MAPC are considered by some to be a culture artefact 
rather than an in vivo  population.
As  all  the  above-mentioned  populations  are  isolated  differently  and 
cultured  under different  conditions,  it  is  difficult  to  compare  the  results  of 
studies  analysing  them  and  determine  whether the  RS1  cells,  the  MIAMI 
cells  and  the  MAPC  represent  the  same  subpopulation  of  MSC.  It  also 
remains unknown whether these populations represent an earlier precursor 
of what is commonly defined as an MSC or an entirely unrelated population 
of cells.
251.2 CHONDROGENESIS
During  embryonic  development,  the  generation  of  cartilage  from 
mesoderm  is  an  essential  process  in  the  creation  of the  future  skeleton. 
Insight into chondrogenesis has so far been obtained through the creation of 
knockout mice, analysis of genetic mutations affecting the human skeleton, 
and  in  vitro cultures  of chondroblasts  and  other progenitor cells that  have 
chondrogenic potential, including periosteal cells and MSC.
1.2.1  Skeletogenesis
Skeletogenesis  in  human  embryos  begins  in  the  third  and  fourth 
weeks of development and  in  mouse embryos around  day  10  post coitum 
(60).  The  process of limb formation starts with an outgrowth  referred to as 
the  limb  bud,  at  the  centre  of  which  mesenchymal  cells  condense  into 
cartilaginous anlagen. The close cell to cell contact in these condensations, 
along  with  signalling  molecules  such  as  the  transforming  growth  factor  (3  
family (TGFIi) and the bone morphogenetic protein (BMP) family induce the 
formation of chondroblasts, which further differentiate into chondrocytes and 
start  producing  the  extracellular  matrix  (ECM)  characteristic  of  cartilage. 
Cartilage has a very low cell to matrix ratio, and the few cells embedded in 
the  matrix  appear  spherical  in  shape  (61).  Induced  by  further  signalling 
molecules, such as indian hedgehog (Ihh) and transcription factors, including 
core binding factor alpha  1   (Cbfal), the chondrocytes undergo hypertrophy 
and enlarge five to tenfold. Hypertrophy leads to some chondrocytes lysing, 
which  alters the  pH  of the  matrix,  and  allows calcification to  proceed.  The 
osteoblasts, located in the periosteum, contribute to the mineralisation of the 
cartilage  matrix  and  consequently  the  hypertrophic  cells  die,  while  the 
osteoblasts mature into osteocytes, thereby replacing cartilage by bone (62). 
This  process  of  cartilage  formation  and  subsequent  hypertrophy  and 
replacement by bone  is  referred  to as endochondral  ossification,  and the
26majority of the  bones  develop  in this way  (61).  The  exception  are the flat 
bones of the skull, some of the facial bones and most of the clavicle, which 
form through intramembranous ossification (63).
1.2.2  Formation of mesenchymal condensations
The formation of pre-cartilaginous condensations  is a crucial step in 
skeletal development. Mesenchymal cells express hyaluronan and collagen 
type  I  in  their extracellular matrix,  preventing  close  cell  to  cell  contact.  As 
condensation  starts  hyaluronidase  activity  increases,  facilitating  closer 
contact between cells (61). This change in cell density is accompanied by a 
change  in  expression  levels  of  extracellular  matrix  molecules  as  well  as 
enhanced  cell  to  cell  contact,  leading  to  activation  of signalling  cascades, 
associated with initiation of differentiation (61;64).
Prior to condensation it is important that the cells of the limb bud have 
proliferated sufficiently to form the future limb. The signals required for limb 
bud growth originate  in the apical ectodermal  ridge  (AER),  a  layer of cells 
present at the tip of the outgrowth. The main signalling molecules produced 
by the AER are the fibroblast growth factor (FGF) family proteins, as shown 
by  experiments  in  which  beads  soaked  in  recombinant  FGF  rescued  the 
phenotype of chick limbs where the AER has been  removed  (65).  In  FGF4 
and  FGF8  double  knockout  mice,  hindlimb  development  is  completely 
abolished  and  only  small  cartilaginous  elements  are  observed,  showing 
these molecules to be essential for skeletal development and proliferation of 
the  progenitor  cell  population  prior  to  the  formation  of the  condensations 
(66).
Various other molecules are involved in the specification of the timing 
and  location  of the cartilage formation. A  recently  identified  pair of factors 
involved  in the formation of the proximal elements of the hind  limb are the 
GLI-Kruppel  family  member  3  (GLI3)  and  promyelocytic  leukaemia  zinc 
finger (Plzf).  The  absence  of these  molecules  in  knockout  mice  results  in
27normal  limb bud size but a complete absence of the femur, tibia and fibula 
(67).
The  key  molecule  involved  in  the  adhesion  of  cells  in  the 
mesenchymal condensations is N-cadherin, but N-CAM, fibronectin and their 
respective interacting molecules are also upregulated. The expression of N- 
cadherin first appears in the core of the condensation and only later at the 
periphery, when the expression in the core is lost (61).  N-cadherin  is a cell 
membrane  spanning  protein  that  can  interact  with  N-cadherins  on 
neighbouring cells via  its extracellular domain.  N-cadherin  is dependent on 
Ca2+,  and  adding  exogenous  Ca2+   in  vitro  to  cells  about  to  undergo 
condensation enhances chondrogenesis (68). The presence of N-cadherin is 
essential  for  condensations  to  form  but  it  must  be  downregulated  for 
chondrogenesis  to  proceed.  Therefore,  its  production  is  tightly  regulated 
(69). Retinoic acid, TGFB and Wnt signalling are all involved in modulation of 
N-cadherin levels.
Retinoic  acid  (RA)  is  a  strong  inhibitor  of  early  chondrogenic 
differentiation and activated signalling through the RA receptors is capable of 
overriding  the  chondrogenic  effect  of  the  BMPs.  The  shutdown  of  RA 
signalling, on the other hand, is an equally potent inducer of chondrogenesis 
and  can  bring  about differentiation even  in the  presence of BMP  inhibitors 
such as Noggin (70). One of the ways by which RA signalling acts to inhibit 
chondrogenesis  is  by  sustaining  the  expression  of  N-cadherin  and  so 
preventing  cells  from  undergoing  further  differentiation  after  they  have 
formed the condensations (69).
TGF& family molecules regulate chondrogenesis by inducing mitogen 
activated protein kinase (MAPK) signalling, which in turn also modulates N- 
cadherin levels. When MAPK signalling is inhibited, N-cadherin levels remain 
high  and  chondrogenesis  cannot  proceed,  suggesting  that  MAPKs  play  a 
role  in  downregulating  N-cadherin  (71).  In  addition,  TGFIis  also  affect 
wingless  type  MMTV  integration  site  family  member  (Wnt)  signaling  by
28upregulating Wnt7a, which transiently prolongs N-cadherin stabilization, and 
so suppresses further chondrogenic differentiation (72).
1.2.3  Production of the cartilage ECM
Once mesenchymal cells have condensed they begin to differentiate 
into  chondrocytes  and  produce  the  extracellular  matrix.  Mature  cartilage 
comprises only 5-10% of cells and up to 95% of cartilage matrix, and it is the 
ECM that gives cartilage its functional properties. The primary function of a 
chondrocyte is the synthesis and the maintenance of the matrix (73). Matrix 
maintenance involves a balance of matrix degradation and synthesis, and a 
disruption of this balance leads to degenerative joint disease, osteoarthritis. 
The  cartilage  matrix  comprises  a  network of collagens  and  proteoglycans, 
the former providing tensile strength while the latter’s affinity for water allows 
for cartilage swelling and compression, and thus its load-bearing ability. The 
major collagen  synthesized  by cartilage  is collagen  2  (75-90%  of collagen 
synthesis), and  it forms collagen heterofibrils together with collagens 9 and 
11  (74).  These  ~20nm wide fibrils  are thought to  consist of a  collagen  11 
core  surrounded  by  a  thicker  layer  of  collagen  2  to  which  collagen  9 
molecules  can  bind  (75).  The  most  abundant  proteoglycan  in  cartilage  is 
aggrecan:  others  include  versican,  a  protein  expressed  early  in
chondrogenesis, but downregulated upon aggrecan deposition, perlican and 
link (76).  In  addition,  the  ECM  contains  proteins that are  neither collagens 
nor  proteoglycans.  One  of these  proteins,  the  cartilage  oligomeric  matrix 
protein  (COMP),  binds  collagens,  and  mutations  in  the  gene  encoding 
COMP  cause  chondrodysplasia  in  humans,  characterised  by  short stature 
and  osteoarthritis  (77).  Matrix  proteins  do  not  only  serve  as  structural 
proteins  but  can  also  be  involved  in  signalling.  COMP for example,  when 
overexpressed in chondrogenic cultures in vitro, brings about reduced levels 
of proliferation while inducing differentiation (78).
29The crucial transcription factor in chondrogenesis is SRY-box (Sox) 9, 
as  it  orchestrates  the  production  of  the  cartilage  collagens  as  well  as 
aggrecan (Figure  1.1). Haploinsufficency in Sox9 results in a lethal condition 
called  campomelic dysplasia,  which  involves severe skeletal  malformations 
(79). Bi et al generated Sox9-/- embryonic stem (ES) cells and analyzed their 
behaviour in  mouse chimeras  (80).  None of these  cells ever contributed to 
cartilage,  but  instead  clustered  around  cartilage  nodules  and  retained  a 
spindle  shaped  appearance.  Sox9 -/-  ES  cells do  not express  ECM  genes 
and  when  teratomas  are  derived from  these  cells,  no cartilage forms  (81). 
Sox9 has DNA binding and transcriptional activity, attaching to an enhancer 
element to activate the transcription from its targets (80).
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Figure  1.1:  The  regulators  of  cartilage  differentiation  and  matrix
accumulation. Sox9 is the key transcription factor regulating Sox5, Sox6 and 
matrix  gene  transcription.  BMP,  Wnt  and  PKA-c  signalling  regulate  Sox9 
levels and activity.
Lefebvre  et al found  that  Sox9  is  coexpressed  in  cartilage  with  two 
more  Sox  genes  Sox5  and  Sox6,  and  that these  form  homo-  and  hetero-
30dimers  and  cooperatively  activate  transcription  of  ECM  genes  with  Sox9
(82). Sox5 and Sox6 are essential for cartilage formation. Double Sox5 and 
Sox6 knockout mice are embryonic lethal and single knockout mice of either 
Sox5  or Sox6  develop to  birth  but die  soon  after with  respiratory distress
(83). These mice do not show overt skeletal abnormalities and are the same 
weight and size as wildtype newborns (83). Therefore, Sox5 and Sox6 must 
be at least partially redundant. Sox9 can activate transcription of ECM genes 
alone,  but to a much  lower level than in the presence of L-Sox5 and Sox6 
(83).  Later  experiments  showed  that  Sox9  is  in  fact  necessary  for  the 
expression of Sox5 and Sox6 (84).
Sox9  is  regulated  by  BMP signalling  at the transcriptional  level  and 
cyclic  AMP-dependent  protein  kinase  A  (PKA-Ca)  phosphorylation  at  the 
protein  level  (85;86)  (Figure  1.1).  BMP2  upregulates  Sox9  in  a  dose- 
dependent manner both in cell culture and in chick limbs (85;87). Sox9 also 
interacts with (3-catenin, the target of Wnt signaling, and the two proteins act 
in an antagonistic manner as chondrogenesis proceeds (88).
1.2.4  Regulation of hypertrophic cartilage formation
During  endochondral  ossification  cartilage  does  not  remain  in  the 
Sox9 directed state of homeostasis described above but progresses through 
the next stages of prehypertrophy and hypertrophy, before being superseded 
by bone. Prehypertrophy involves the exit from the cell cycle, and associated 
changes  in  morphology  and  ECM  production.  Hypertrophic  chondrocytes 
reduce  levels  of  collagen  2  production  and  increase  levels  of  alkaline 
phosphatase and collagen 10 (89). This transition is controlled by a variety of 
regulatory molecules including  indian  hedgehog  (Ihh),  parathyroid  hormone 
related  peptide  (PTHrP),  Cbfal  and  the  previously  mentioned  proteins 
involved in BMP, FGF, Wnt and MAPK signalling (Figure 1.2).
Most  experiments  exploring  the  role  of  PTHrP  and  Ihh  in 
chondrogenesis were performed by Vortkamp et al. They found that both of
31these signals suppress hypertrophy and that Ihh upregulates PTHrP, but that 
signaling  from  the  activated  PTHrP  receptor  represses  Ihh  production, 
thereby creating a negative feedback loop (Figure 1.2). The PTHrP receptor 
(PTHrPR)  is  expressed  on  proliferating  chondrocytes  and  its  activation 
prevents hypertrophy (90).  PTHrP acts by signaling to PKA-Ca, which then 
phosphorylates  Sox9,  enhancing  its  DNA  binding  activity,  and  inhibiting 
transition  to  hypertrophy  (81).  PTHrP  is  secreted  by  cells  of  the 
perichondrium and hypertrophic cells (79).
BMP  and  FGF  signaling  act  in  an  antagonistic  manner,  with,  BMP 
signaling upregulating Ihh and thus delaying hypertrophy and FGF signaling 
accelerating chondrocyte terminal differentiation and promoting hypertrophy 
(91). FGF2 treatment of embryos or overexpression of a constitutively active 
FGF  receptor  (such  as  FGFR3)  leads  to  a  shortening  of  limbs  and  to 
disorders characterized  by short stature such as achondroplasia (79).  FGF 
signaling reduces the domain of BMP and  Ihh expression,  but restoring  Ihh 
expression does not rescue the phenotype (92).
Wnt5a  and  Wnt5b  overexpression  leads  to  delayed  and  reduced 
ossification and a delay in the expression of Ihh and  Col 10,  hence both of 
these  have  a  role  in  preventing  premature  hypertrophy.  However,  simply 
overexpressing Ihh does not fully rescue the phenotype of Wnt5a knockouts, 
so the role of Wnt5a must be more complex than just the upregulation of Ihh 
(93).
The intracellular pathway of PTHrP signaling is partially mediated by 
inhibition  of  p38  MAPK  activity.  Inhibition  of  p38  leads  to  a  decrease  in 
collagen  10  production  and  an  increase  in  the  expression  of  some 
prehypertrophic markers such  as cartilage  matrix protein  (CMP).  However, 
PTHrP  also  acts  in  a  p38  independent  manner,  for  example  causing  an 
increase in the expression of link protein, an effect not seen just by inhibiting 
p38 signalling (94).
Cbfal  is the main transcription factor expressed by the  hypertrophic 
chondrocytes. Its expression is regulated negatively by PTHrP and positively
32by  retinoid  signaling  (95).  Mice  deficient  in  Cbfal  also  lack  hypertrophic 
chondrocytes and show no expression of collagen  10, or the later marker of 
calcification osteopontin (95).
3s  Cbfal PTHrP Ihh
PTHrPR Hypertrophy 
genes: 
collagen 10 
Aik. Phos.
BMP signalling
PKA-C
Sox 9
Figure 1.2: Regulation of cartilage prehypertrophy and hypertrophy. The Ihh/
PTHrP  negative  feedback  loop  controls  the  prehypertrophy  to  hypertrophy 
transition and the expression of the hypertrophy transcription factor Cbfal.
1.2.5  TGFIi family member involvement in chondrogenesis
The  TGFfi  superfamily  consists  of  TGFIi  proteins,  BMP  proteins, 
activins,  and growth and differentiation factors (GDF). TGFd family proteins 
bind  to  serine/threonine  kinase  receptors  type  I  and  type  II,  and  the 
interaction  between the 2  receptors  is  required for signal transduction.  The 
binding  of the  ligand  to  the  receptor  can  be  interfered  with  by  a  range  of 
proteins  including  Noggin,  Chordin,  DAN,  Sclerostin  and  Folistatin  (96).  As 
the ligand binds, the  type I receptor is phosphorylated by the type II receptor 
and the type  I  receptor phosphorylates a Smad  protein -  Smad  1, 5 or 8 in 
the  case  of  BMP  proteins  or  in  the  case  of TGFfi  proteins  Smad  2  and  3 
(96). This phosphorylated Smad is now able to form a complex with Smad 4
33and  translocate  into  the  nucleus,  where  it  activates  transcription  of target 
genes,  provided  the  dimerization  is  not  interfered  with  by  the  inhibitory 
Smads  -Smad6  (BMP  signalling  specific)  and  Smad  7  (BMP  and  TGFfc 
signalling) (97) (Figure 1.3).
BMPS 2, 4, 5 and 7 have all been shown to promote bone formation 
in  vivo,  hence  the  name  bone  morphogenetic  proteins  (89).  BMP7  is 
expressed  in  proliferating  chondrocytes  and  the  perichondrium,  BMP4  in 
prehypertrophic  cells  and  BMP2  and  6  in  hypertrophic  chondrocytes  (89). 
Noggin,  the BMP antagonist has an  important role  in skeletal development 
too  and  mice  lacking  it  show  excess  BMP  activity -   resulting  in  cartilage 
hyperplasia  and  lack  of  joints  (98).  In  humans,  dominant  missense 
mutations  in  the  Noggin  gene  lead  to  a  malformation  of  the  joints  (99). 
Noggin  has  also  been  shown  to  inhibit  BMPs  in  vitro,  thereby  delaying 
osteogenesis  in  stromal  cells  (100).  Another inhibitor shown to act in  vitro 
and expressed by chondrocytes at various stages of development in vivo is a 
chordin-like  protein  2  (CHL2).  The  addition  of  CHL2  to  a  chondrogenic 
culture results in a reduction of matrix deposition (101).
BMPs  enhance  chondrogenesis  although  the  precise  effect exerted 
differs from one family member to another. BMP4, for example,  accelerates 
the formation  of the mesenchymal condensations,  induces chondrogenesis 
and  promotes  chondrogenic  maturation  (102).  BMP6,  on  the  other  hand, 
plays  a  more  important  part  in  the  later  stages  of  chondrogenic 
differentiation, inducing hypertrophy (103).
Members of the GDF subfamily have also been reported to play a part 
in  chondrogenesis.  GDF5,  in  particular,  induces  chondrogenesis  and 
mutations in GDF5 cause alterations in the skeleton, especially in the limbs 
(102;104).
The overexpression of constitutively active BMP receptors in culture is 
a sufficiently potent chondrogenic inducer to override the  inhibition caused 
by retinoic acid (Section 1.2.3) (97). The overexpression of the downstream 
proteins Smadl  or Smad5,  however, only has a weak chondrogenic effect,
34whereas the overexpression of the inhibitory Smad6 leads to a reduction of 
levels in BMP7-induced chondrogenesis (97).
BMP signalling  is essential for cartilage formation  and  hence  normal 
skeletal development, but it is also important in the maintenance of cartilage 
after birth when the absence of a  BMP receptor in  mouse joints leads to a 
gradual loss of the cartilage and the development of a condition resembling 
human osteoarthritis in the affected mice (105).
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.3:  BMP  signalling  cascade.  The  blue  lines  represent
phosphorylation  that  begins  with  the  type  2  receptor  phosphorylating  the 
type 1   receptor and continues with the phosphorylation of Smad 1, 5 or 8 by 
the type  1   receptor.  This  second  phosphorylation  step can  be  inhibited  by 
Smad 6 or 7.
351.2.6  In vitro chondrogenesis
From in vivo studies of chondrogenesis,  it is apparent that two main 
criteria must be met in order to generate chondrocytes in culture. The first is 
the dependency of chondrogenesis on cell to cell contact and therefore the 
density at which the cells are cultured and the second is the provision of the 
appropriate signalling molecules.
In  vitro  conditions  for the  culture  of chondrocytes  from  MSC  were 
established  by Johnstone et al in  1998  (106). They cultured  rabbit MSC  in 
aggregate  culture  by spinning  down  105  cells  and  growing them  in  a  high 
glucose medium containing  insulin, transferrin,  selenous acid,  linoleic acid, 
pyruvate  and  ascorbate  2-phosphate  (essential  for  collagen  deposition). 
Dexamethasone,  a  synthetic  glucocorticoid,  was  also  added  and 
chondrogenesis was induced  in about 25%  of the cultures.  Glucocorticoids 
are used in many in vitro differentiation protocols and are required for in vitro 
chondrogenesis.  Grigoriadis  et  al  show  that  dexamethasone  addition 
increases  myogenic  and  osteogenic  differentiation,  while  being 
indispensable  for  adipogenic  and  chondrogenic  differentiation,  in  a  bone 
derived  MSC-like  cell  population  (28).  In  chondrogenesis,  dexamethasone 
acts  to  increase  synthesis  of  ECM  components:  aggrecan,  dermatopontin 
and  collagen  11  (107).  It  also  acts  in  synergy  with  TGFIi  to  upregulate 
collagen 2 (107).
Hence, when TGF(31 was also included in the differentiation media all 
the cultures showed a chondrogenic morphology and  increased  production 
of cartilage ECM molecules such as collagen 2 and  10 while decreasing the 
expression of the MSC ECM  protein,  collagen  1.  Mackay et al adapted the 
Johnstone  protocol  to  human  MSC  and  used  TGF{33  to  add  to  cultures 
instead of TGF|31, with very similar results (108).
Other members  of the TGFB family  have  also  been tested for their 
ability to induce chondrogenesis in vitro. TGF(32, when transfected in human 
MSC,  also  stimulates  the  expression  of  collagen  2  and  aggrecan,  and
36retroviral  overexpression  of  BMP2  in  murine  MSC  has  the  same  effect 
(109;110). Palmer et al expressed TGF|31, BMP2 and IGF1  in MSC with the 
use of an adenoviral vector and found that TGF(31  and BMP2 but not IGF1 
induced chondrogenesis (111).
Majumdar  et al employed  a  different strategy to  the  one  described 
above  for  providing  the  necessary  cell  to  cell  interactions  for 
chondrogenesis. They placed the MSC in a 3-D matrix of alginate beads and 
then  cultured  them  in  the  presence  of  BMP2  and  BMP9  (112).  They 
observed that both of these molecules enhanced the expression of Sox9 and 
matrix  genes,  with  BMP9  causing  greater  upregulation  than  BMP2. 
Therefore,  both  TGFfcs  and  BMPs  are  able  to  induce  the  expression  of 
genes required for chondrogenesis  independently but the  highest levels of 
induction  are  seen  when  the  two  are  combined.  Sekiya  et  al  used  both 
TGF(33  and  BMP6  to  greatly  upregulate  cartilage  matrix  synthesis  in 
differentiating MSC (113).
Another condition that has so far been shown to affect chondrogensis 
in  vitro  is  oxygen  tension.  Cartilage  is  a  non-vascularised  tissue  and  the 
oxygen tension is thought to be as low as  1% in the deepest layers, so the 
atmospheric  levels  of 21%  oxygen,  most commonly used  in tissue  culture 
are quite different to in vivo conditions (114). Domm et al showed that lower 
oxygen tension of 5% is stimulatory to chondrogenesis and  induced  higher 
levels of collagen production in bovine articular chondrocytes (115). The key 
factor involved in the hypoxic response in cells is hypoxia-inducible factor 1  
(HIF1), and, if the a subunit of this factor is lacking in hypoxic chondrocytes, 
results  in  cell  death:  hence  it  appears  to  be  an  essential  factor  for 
chondrogenesis (116).  Furthermore,  HIF1a also has an effect on  levels of 
ECM  synthesis,  and  when  chondrocytes  lacking  this  protein  are  placed  in 
hypoxic conditions levels of collagen 2 and aggrecan decrease significantly, 
whereas they are maintained (and collagen 2 levels are even increased) in 
wildtype cells (117). To date no experiments have been published detailing 
the human MSC response to lower oxygen tension in chondrogenesis.
37The cell populations used for studying chondrogenic differentiation in 
vitro are very diverse and  range from the  pluripotent embryonic stem  (ES) 
cell to the fully committed chondroblasts isolated from mature cartilage.  ES 
cells can differentiate into cartilage when grown as embryonic bodies (EB) 
as seen  by the expression of mRNAs such  as aggrecan  and  Sox9  (118). 
However,  only  a  minority  of  these  cells  undergo  chondrogenesis. 
Dexamethasone addition does not enhance the efficiency of chondrogenesis 
from  ES  cells  whereas  culture  in  micromass  or  pelleted  cultures  after  EB 
dissociation  does  (118).  The  addition  of  the  full  chondrogenic  cocktail 
consisting  of  BMP2,  TGF(31,  insulin  and  ascorbic  acid  induces  a 
chondrogenic  phenotype,  including  the  upregulation  of  all  the  expected 
chondrogenic genes,  albeit at levels  significantly  lower than  those  seen  in 
cultures of MSC (119). From a therapeutic viewpoint, the advantage of using 
ES cells over the more committed mesenchymal or prechondrocyte cells is 
that  they  are  available  in  a  potentially  infinite  supply.  However,  as 
autologous  transplantation  cannot  be  performed,  there  may  be  problems 
with  immunological  rejection,  unless the  ES cells are genetically altered so 
as not to express such  proteins on their cell surface  (120).  It is also clear 
that the  conditions for efficient chondrogenic differentiation of ES cells  are 
still not optimised.
A recently described means of generating chondrocytes from ES cells 
is via an MSC intermediate. Barberi et al used human ES cell lines and co­
cultured them with OP9 cells inducing the ES cells to undergo mesenchymal 
differentiation, prior to exposing them to MSC differentiation protocols, such 
as that needed for chondrogenesis (121).
If  ES  cell  lines  lie  at  one  end  of  the  spectrum,  unipotent 
chondroblasts,  isolated  from  cartilage  lie  at  the  other.  The  advantage  of 
using  MSC  or chondroblasts  over  ES  cells  is  that there  is  a  potential  for 
autologous  transplantation.  This  means  that cells  can  be  isolated  from  a 
patient, expanded in vitro, and then reintroduced back into the patient, in the 
area  where  they  are  required  for  treatment.  This  procedure  has  already
38shown  promising  results  for the  repair of articular cartilage  in  knee joints 
(122).  When  chondrocytes are grown  in  vitro they  lose their chondrogenic 
morphology  and  the  expression  of  ECM  genes.  These  de-differentiated 
chondrocytes can be expanded in monolayer cultures and then re-implanted 
into  sites  of  injury  where  they  potentially  differentiate  back  into  fully 
functional chondrocytes (122). However, whether well formed cartilage forms 
to repair the defect in the treated  patients remains uncertain as these cells 
have a limited proliferative potential. This is particularly problematic in older 
patients  where  treatment  for  degenerative  diseases  is  more  likely  to  be 
required .
1.2.7  Summary
Through the  help of in  vivo studies and in vitro model  systems, the 
regulation  of  chondrogenesis  is  quite  well  understood,  especially  with 
respect to the chondrogenic matrix and the regulation of its production. Less 
well  elucidated  are  the  earlier  stages  of  chondrogenesis,  when  the 
commitment of mesenchymal progenitor cells to the chondrogenic lineage is 
determined.  To  investigate  these  early  chondrogenic  events,  the  MSC 
chondrogenesis  in  vitro  model  system  can  be  used  in  conjunction  with 
microarray  analysis,  thereby  providing  an  overview  of  a  large  part  of the 
transcriptome and identifying the genes involved in this process.
391.3  GENE EXPRESSION MICROARRAYS
Gene  expression  microarrays  (GEM)  are  a  relatively  new  tool, 
enabling the global analysis of expression levels of genes within a population 
of  cells  grown  in  vitro  or from  a  tissue  sample.  This  technique  makes  it 
possible to compare the levels of expression of many genes between two or 
more  populations  within  the  scope  of  a  few  experiments.  The  procedure 
involves first harvesting the RNA from the cells of interest, then labelling it, 
and  finally  hybridizing  it to  an  array  of probes  representative  of genes  of 
interest.  The  probes  can  be  cDNA  derived  100-2000bp  PCR  products 
attached  to  a  glass  or  nylon  matrix  to  produce  the  array,  or  synthesized 
~30mer oligonucleotides printed on ‘gene chips’ such as those manufactured 
by Affymetrix (123).
Experiments can  be performed using one or two-colour microarrays. 
Two-colour  microarray  analysis  allows  the  direct  comparison  of  the 
expression levels between the control state and the state of interest as the 
samples are labelled with different fluorescent tags (for example cyanine 3 
and  cyanine  5)  and  then  allowed  to  hybridize  competitively  to  the  same 
array.  Alternatively,  the  one  colour  procedure  used  for  most  studies 
employing oligonucleotide chips requires hybridization of a single sample per 
chip and comparison of the signal intensities between chips (124). There are 
many possible experimental applications for microarray technology, including 
the investigation of disease and developmental processes and the effects of 
various treatments, for example the exposure to a drug,  on a  population of 
cells (123).
The biggest problem  associated with  GEM  experiments  is also their 
biggest advantage -  the amount of data generated. Some of the more recent 
chips, such as the Affymetrix HGU133+2 chip, contain probes corresponding 
to all the genes in the human genome, culminating  in the analysis of more 
than 47,000 transcripts (http://www.affvmetrix.com).  In order to interpret this 
data and make it comparable between different experiments, a great deal of
40statistical manipulation is necessary  and the methods used by investigators 
are variable (Section 4.1).  Furthermore, the  results obtained for the same 
experiment  by  different  groups  can  vary,  an  issue  not  helped  by  the 
restriction on the number of replicates done for each experiment due to the 
high costs of the procedure (125).
1.3.1  Microarrays in chondrogenesis
The comparison of normal and disease states of a tissue is probably 
the  most  common  use  for  microarrays,  and  has  become  very  popular  in 
cancer biology.  In  the  context of chondrogenesis,  experiments  have  been 
performed comparing normal and osteoarthritic cartilage to investigate which 
genes are differentially expressed  between the two and are therefore likely 
to be implicated in cartilage degeneration seen in osteoarthritis (126). Matrix 
metalloproteinases  (MMPs)  are  known  to  be  involved  in  the  process  of 
cartilage  matrix  turnover.  Aigner  et  al  found  MMP3  to  be  expressed  in 
normal  cartilage  and  early  osteoarthritis  and  therefore  speculated  its 
involvement  in  the  regular turnover  of the  ECM  (126).  In  more  advanced 
osteoarthritic  cartilage,  MMP2  and  MMP13  were  found  to  be  expressed, 
which  may  indicate that they  have  a  role  in  cartilage  degeneration  (126). 
Expression  of MMPs was also  investigated  in the cartilaginous  neoplasms 
chondrosarcomas,  due  to  their  ability  to  invade  bone  (127).  Increased 
expression of MMP13 and  14 was found, with some samples also showing 
elevated levels of MMP1, 7 and 9. These results indicate that MMPs may be 
useful as indicators of more aggressive lesions (127). A more  recent GEM 
study, performed by Rozeman et al compared chondrosarcomas of different 
grades  and  found  differences  in  their  metabolism  (128).  Higher  grade 
tumours upregulated genes involved in glycolysis whilst downregulating the 
expression  of  ECM-associated  genes  (128).  Therefore,  microarrays  can 
provide information about disease states which can lead to the identification 
of genes for use in providing diagnoses.
41Microarray analysis is also well suited as a method for elucidating the 
effects  of  signalling  molecules  on  a  population  of  cells.  Dailey  et  al 
investigated  the  effect  of  FGF  signalling  on  the  proliferation  of  a  rat 
chondrosarcoma cell line by exposing the cells to FGF1  and then harvesting 
the RNA after 3, 6, 9 and 12 hours of exposure (129). GEM analysis allowed 
them  to  look  at a  wide  range  of molecules  involved  in  the  cell  cycle  and 
investigate the stages at which FGF signalling is activated. Gaur et al used 
microarrays  with  probes  specific  to  genes  involved  in  the  Wnt  signalling 
pathway  to  look  at  differences  between  wildtype  osteoblasts  and  those 
where  a  negative  regulator  of  Wnt  signalling  had  been  knocked  out  and 
found  that  the  expression  of  many  Wnt-dependent  genes  was  disrupted 
(130).
The  in  vitro  differentiation  systems  for  cartilage  mentioned  in  the 
previous section can be used in conjunction with microarray experiments to 
provide  information  about  cartilage  development.  Tallheden  et  al  used 
dedifferentiated human articular chondrocytes which they re-differentiated in 
vitro.  They collected  RNA at different time  points for analysis on  cartilage 
chips with over 300  probe sets,  specific to genes  known to  be  involved  in 
cartilage  development  and  homeostasis  (131).  The  results  provide  some 
insight  into  the  temporal  sequence  of the  expression  of genes  previously 
implicated in chondrogenesis.
James  et  al  recently  published  a  detailed  microarray  analysis  of 
various time  points  using  mouse  micromass  chondrogenesis  cultures,  and 
identified  some  general  trends,  such  as  changes  involved  in  signal 
transduction  and  transcriptional  regulation.  However,  their  classifications 
were  generally too  broad  to  be  truly  enlightening  (132).  They finished  by 
focusing  on  a  specific  factor  called  rgs2  shown  to  be  involved  in  the 
hypertrophy  phase  of chondrogenesis.  Rgs2 was  expressed  in  the growth 
plate  and  its  overexpression  was  associated  with  increased  expression  of 
ECM molecules (132).
42Microarray  analysis  has  also  previously  been  performed  on  human 
MSC  undergoing  chondrogenesis  by Sekiya  et al (113).  Even though they 
did not use cartilage-specific chips but instead a general Affymetrix chip for 
expression  analysis  of  a  range  of  human  transcripts,  they  restricted  their 
analysis to genes with  a  previously described  role  in  chondrogenesis  and 
used  their  results  to  support  the  validity  of the  MSC  differentiation  as  a 
model for the study of the development of cartilage in  vitro.  Consequently, 
they concentrated  on  later time  points  in  MSC  chondrogenesis where the 
expression of ECM genes becomes apparent (113).
In  a  recent  study,  mouse  MSC  were  used  by  Robins  et  al  to 
investigate the effect of hypoxia on the expression profile of chondrogenesis 
(133).  Hypoxia induced higher levels of expression of many ECM genes as 
well  as  Sox9.  Robins  et  al  also  took  the  overall  description  of  their 
microarray data a step further than the James et al paper, described above, 
and found that the greatest expressional differences in response to hypoxia 
were  seen  in  metabolic  genes,  along  with  the  expected  increase  in 
angiogenic genes (133).
Therefore,  GEM  experiments  have  previously  been  performed  on 
cells  undergoing  chondrogenesis,  but  the  two  time  course  experiments 
looking  at differentiation  stages  have  not  provided  a  global  transcriptional 
overview of the process nor have they identified novel factors involved in the 
early stages of chondrogenesis.
The  true  power  of  microarray  technology  lies  in  the  ability  to 
investigate the expression levels of thousands of genes at once and obtain a 
global  picture  of the  processes  occurring.  In  chondrogenesis,  the  use  of 
GEM technology in  monitoring the transcriptional changes occurring during 
the early phases could provide insight into the regulatory processes guiding 
mesenchymal  condensation  and  the  commitment  of  MSC  to  the 
chondrogenic lineage.
431.4 CONNECTIVE TISSUE TUMOURS AND CHORDOMAS
1.4.1  A microarray study of connective tissue tumours
A wide spectrum of tumours arise in connective tissue, including bone 
and soft tissue, that are referred to as sarcomas when malignant. All these 
tumours  presumably originate  from  mesenchymal  precursor cells,  and  yet 
show a surprising range of morphologies, which frequently overlap, and the 
lineage  of differentiation  is  not  known  in  a  significant  number.  Bone  and 
cartilage  sarcomas,  for example,  can  both  show  regions  of chondroid  and 
osteoid differentiation as well as dedifferentiated areas with spindle shaped 
cells and myxoid regions (134). Small needle core biopsies are often all the 
material available for a diagnosis and correctly identifying the neoplasm can 
be difficult.
Certain sarcomas, such as pPNET/Ewing’s sarcoma, can be identified 
on the basis of a tumour specific translocation.  However others lack such a 
hallmark and  show a  complex  karyotype,  tending to  have  abnormalities  in 
the commonly affected pathways in cancer -  such as the retinoblastoma or 
p53 pathway (135).
A  GEM  analysis  study  was  recently  published  comparing  the 
expression  profiles  of a  broad  range  of 96  well-defined  connective  tissue 
neoplasms  (134).  These  tumours  were  classified  on  the  basis  of  their 
morphology and immunohistochemistry, as well as with the use of molecular 
genetics, where possible. The aim of this study was to asses the relationship 
between  different  tumour types  and  identify  unique  molecular fingerprints 
that could aid in the diagnosis of particular neoplasms. The results showed 
that  differentiated  tumours  clustered  in  groups  reflecting  common  tissue 
types:  neurofibromas  and  schwannomas  (both  showing  nerve  sheath 
differentiation),  alveolar  and  embryonal  rhabdomyosarcomas  (showing 
myogenic differentiation),  and well-differentiated  liposarcomas  and  lipomas 
(showing adipocytic differentiation) (Figure1.4.1) (134). Similarities were also
44found between the expression profiles of chondrosarcomas and chordomas. 
The  diversity  of  gene  expression  was  greatest  in  osteosarcomas, 
leiomyosarcomas and  pleomorphic sarcomas.  Many of the genes  identified 
as the molecular fingerprints of a  particular tumour type were related to the 
metabolism  or  function  of  its  tissue  of  origin:  adipocytic  tumours  were 
distinguished  by  the  expression  of  perilipin  and  lipoprotein  lipase,  genes 
involved  in  lipid  metabolism  (136; 137).  Similarly,  the  rhabdomyosarcomas 
expressed  cholinergic  receptor  alpha  1,  the  muscle  acetylcholine  receptor 
and  the  neurofibromas  and  the  schwannomas  expressed  Sox10,  a  gene 
involved  in  glial  development  (138; 139).  A  particularly  interesting  finding 
was  that,  brachyury,  a  transcription  factor  known  to  be  involved  in 
notochordal development, was uniquely expressed in chordomas.
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45Figure 1.4: Multi-dimensional scaling of all 96 mesenchymal tumor samples 
representing  how the  GEM  profiles  of the  various  tumours  relate  to  each 
other in a 2-dimensional space. WLS, well-differentiated liposarcoma;  LMA, 
lipoma;  MLS,  myxoid  liposarcoma;  EWS,  Ewing's  sarcoma;  FMT,  desmoid 
fibromatosis;  CHS,  chondrosarcoma;  CHB,  chondroblastoma;  ARMS, 
alveolar rhabdomyosarcoma;  ERMS,  embryonal  rhabdomyosarcoma;  DCS, 
dedifferentiated  chondrosarcoma;  MSS,  monophasic  synovial  sarcoma; 
MPNST,  malignant  peripheral  nerve  sheath  tumors;  CMF,  chondromyxoid 
fibroma;  PMS,  pleomorphic  sarcoma;  LMS,  leiomyosarcoma;  OS, 
osteosarcoma;  CMA,  chordoma;  NFB,  neurofibroma;  SWN,  schwannoma. 
(Figure adapted from (134))
1.4.2 Brachyury
One of the key genes regulating notochord formation is brachyury, a 
T-box  transcription  factor.  Brachyury  homozygous  knockout  embryos  die 
before  birth  and  fail  to  form  a  notochord,  and  brachyury  expression  is 
required  for  the  specification  of  mesodermal  identity  (140).  Brachyury 
expression is induced by FGF and TGFfi signalling and the activation of both 
of these pathways is required for its expression, while the Wnt pathway may 
also  play  a  role  (141 ;142).  In  turn,  brachyury  induces  the  transcription  of 
eFGF, Bix1-4 and Wnt11  (140). There is also some evidence that, at least in 
vitro,  brachyury  may  be  an  important transcription  factor  in  chondrogenic 
development (143).
1.4.3 Notochord
The  notochord  is  an  embryonic  structure,  the  presence  of  which 
defines  the  vertebrate  phylum.  In  the  developing  human  embryo  the 
notochord forms during the third week of development (144). The notochord 
has  2  primary  functions:  the  first  is  to  direct  development  of  surrounding 
tissues  via  production  of  signalling  molecules.  The  second  function  is  to 
provide  the  necessary  structural  support  for  the  developing  embryo,  by 
acting  as  a  turgid  rod  of cells  (145).  The  notochord  secretes  a  variety of
46cytokines, the principal one being Sonic hedgehog (Shh), which is involved 
in fate  specification of various tissues  (146).  The  primary signalling  role of 
the notochord is in specifying the ventral fates in the central nervous system. 
As  the  notochord  is  located  beneath  the  neural  tube  a  gradient  of  Shh 
signalling  is  formed  through  the  developing  nervous  system,  thereby 
initiating  different  transcriptional  responses  in  the  neural  tube  cells 
depending  on their proximity to the  notochord.  In  addition,  the  notochord 
controls  aspects  of  left  right  asymmetry,  induces  the  differentiation  of 
pancreatic  cells  and  controls  the  arterial  versus  venous  identity  of  blood 
vessels (147).
In higher vertebrates, the notochord is a temporary tissue, eventually 
becoming  segmented  and  being  superseded  by  the  vertebrae.  In  lower 
vertebrates  it  can  persist  throughout  life  and  fulfil  a  structural  role.  As  a 
tissue, the notochord most closely resembles cartilage and expresses many 
chondrogenic genes such  as collagen 2 and  9,  aggrecan,  chondromodulin 
and Sox9 (147).  The primary difference between the cells of the notochord 
and  those  of cartilage  is  that  while  the  notochord  produces  many  of the 
cartilaginous  ECM  molecules  it retains them  in  large  vacuoles  rather than 
excreting them into the extracellular matrix (147). Therefore, in the notochord 
cells,  it  is  these  collagen  and  proteoglycan  filled  vacuoles  that  allow  it to 
exert  pressure  and  perform  its  structural  roles.  In  humans,  as  in  most 
vertebrates, the notochord eventually becomes segmented and replaced by 
bone  (vertebral  bodies)  and  by  the  nucleus  pulposus  in  the  intervertebral 
disc  (148).  However,  the  actual  contribution  of  notochordal  cells  to  the 
nucleus pulposus is unclear. The nucleus pulposus is itself composed of two 
types of cells -  one producing an extracellular matrix, small and chondroid in 
appearance and the other, much less abundant cell type, more notochordal 
in appearance with a vacuolated cytoplasm (149).  It is this second cell type 
that is presumed to be notochord derived.
The  persistence  of  small  (from  a  few  mm  to  2cm)  notochordal 
remnants has been documented at the skull base at an incidence of 0.5-2%
47in  autopsies  (144).  More  recent  evidence  supporting  the  existence  of 
notochordal  remnants  within  the  vertebral  column  has  been  presented  by 
Yamaguchi et al, and indicates that these lesions may be far more common 
than  previously  thought  (150;151).  They  examined  vertebral  columns 
microscopically, and found small lesions in 20% of the cases. These lesions 
were  mostly  located  at  either  end  of  the  spine  in  the  clival  and  sacro­
coccygeal vertebrae with a few found in the cervical and lumbar vertebrae.
1.4.4  Chordoma morphology
Chordomas are rare malignant tumours occurring along the spine and 
thought to arise from notochordal remnants.  The distribution of these lesions 
is very similar to that seen  of the  benign  notochordal  remnants  discussed 
above with  52%  occurring  in the sacro-coccygeal  region,  35%  at the  skull 
base and the rest in the cervical and lumbar regions (152). Macroscopically, 
chordomas appear gelatinous and blue-grey in colour (153). Morphologically, 
the tumour cells appear in lobules and are of various sizes and shapes, with 
often prominent vacuoles conferring the typical physalipherous appearance. 
The cells are embedded in a myxoid matrix.
It  is  a  common  finding  for  chordomas  to  exhibit  some  degree  of 
chondroid  differentiation.  In  particular,  skull-base  chordomas  can  appear 
chondroid and therefore be misdiagnosed for chondrosarcomas. Chordomas 
can  also  resemble  epithelial  tumours  as  well  as  exhibit  nuclear 
pleomorphism.  Occasionally,  cases  of  dedifferentiated  chordomas  occur, 
where,  in addition to a typical chordoma component, a sharply demarcated 
region of spindle-shaped ‘dedifferentiated’ cells is also seen (154).
481.4.5  Chordoma immunophenotype
As  chordomas  often  resemble  other  tumours  such  as 
chondrosarcomas,  malignant  melanomas,  carcinomas,  and  in  particular, 
renal cell carcinomas, there has been an effort to identify markers that can 
be used for immunohistochemical classification of the tumour.  Cytokeratins 
(CK) are expressed by chordomas and can be used to distinguish between 
these and chondroid lesions.  O’Hara et al reported that chordomas express 
CK 8 and  19 along with  HBME-1  marker (155).  However,  cytokeratins are 
epithelial  markers  and  are  therefore  also  expressed  by  renal  cell 
carcinomas. HBME-1, on the other hand, was not expressed by the renal cell 
carcinomas but was found to be invariably expressed by chondrosarcomas 
as well as by most extraskeletal  myxoid chondrosarcomas (155).  Similarly, 
S100 and vimentin  were  expressed  by all  the  chondrosarcomas tested as 
well as by a majority of the chordomas (155;156).  CD10  is another marker 
useful for distinguishing between renal cell carcinomas and chordomas as it 
is expressed by the majority of renal cell carcinomas but not by chordomas 
(157).
In  addition  to  the  cytokeratins,  chordomas  express  other  epithelial 
markers such as epithelial membrane antigen (EMA), and in most cases E- 
cadherin, along with variable expression of catenins a,  (3  and y all of which 
interact with E-cadherin (158).  Most chordomas also express the neural cell 
adhesion molecule (N-CAM) (158).
A  combination  of  these  markers  can  be  used  to  distinguish 
chordomas  from  most  other  tumours  but  none  of  them  are  chordoma 
specific. While a positive result for cytokeratin expression will indicate that a 
lesion  is  not  a  chondroid  tumour,  the  differential  diagnosis  of a  renal  cell 
carcinoma must still be taken into account. Conversely,  if the expression of 
S100  excludes  the  diagnosis  of  a  carcinoma,  cytokeratin  expression  still 
needs to be  performed to exclude the  possibility of a  chondroid  lesion. As 
S100  is  not expressed  in  all  chordomas,  the  diagnosis  can  not simply  be
49based upon the combination of S100 and cytokeratin expression, although in 
many cases,  this together with  morphological  analysis and clinical  imaging 
has been enough to diagnose chordomas confidently.
An additional difficulty arises with small  needle core biopsy samples 
as  some  reports  have  shown  that  cytokeratin  expression  is  not  always 
uniform  throughout  the  sample,  particularly  in  the  chondroid  component 
(156;159).  These  samples  may  also  not  be  large  enough  to  make  a 
confident  morphological  diagnosis  as  they  often  contain  a  mixture  of cell 
types.
1.4.6  Extra-axial chordomas
A  small  number of chordomas  arising  outside  the  vertebral  column 
have  been  reported,  some of these within  bones  (chordoma  periphericum) 
and  others  in  soft  tissue  (parachordomas)  (160).  However,  the 
nomenclature  has  been  a  source  of  some  confusion,  and  the  above 
classification  is  not always adhered to.  Nielsen  et al state that,  while  both 
parachordomas  and  chordoma  periphericum  occur  extra-axially, 
parachordomas  are  histologically  and  immunohistochemically  distinct from 
chordomas  whereas  chordoma  periphericum  are  not  (160).  Whether 
parachordomas and chordomas do actually have distinct immunophenotypes 
has been a source of controversy not helped by the difficulties in recognising 
the  extra-axial  lesions  in  the  first  place  and  the  very  small  numbers  of 
samples available for analysis due to the  rare occurrence of these lesions 
(161,162).
501.5  AIMS
The first aim of this project was to isolate MSC and establish a robust 
model  for  their  chondrogenic  differentiation.  Following  this,  the  temporal 
progression of chondrogenic development was to be investigated using GEM 
technology,  with  an  initial  focus  on  providing  a  global  description  of  the 
process.  This  could  aid  in  identifying  novel  factors  involved  in  the  early 
phases  of  chondrogenesis.  This  was  to  be  followed  by  a  more  detailed 
analysis of the role of the factors identified  in cartilage development and  in 
MSC differentiation in general.
The  second  part  of  this  project  followed  on  from  previous  GEM 
studies  of  connective  tissue  tumours  and  aimed  to  examine  further  the 
relationship  between  chordomas  and  chondroid  neoplasms,  particularly  in 
relation to brachyury, a molecule crucial to notochordal development.
512. METHODS
2.1  OPTIMISATION  AND  ESTABLISHMENT  OF  THE  MSC 
CHONDROGENESIS MODEL SYSTEM
2.1.1 MSC isolation
Mesenchymal  stem  cells  were  isolated  from  human  bone  marrow 
aspirates  obtained  after  informed  consent  according  to  local  ethical 
guidelines  (Bone marrow samples provided by Dr Kwee Yong,  Department 
of  Haematology,  Royal  Free  and  University  College  Medical  School,  98 
Chenies Mews,  London WC1E 6HX,  UK).  Donors were healthy individuals 
aged between 24-55 years old. 10ml of bone marrow was strained through a 
40pm cell strainer and an equal volume of phosphate buffered saline (PBS, 
Invitrogen, Paisley, UK) added. 20ml of Ficoll (Ficoll-Paque PLUS, GE, Little 
Chalfront,  UK)  was  dispensed  into  a  50ml  falcon  tube  and  the  bone 
marrow/PBS  mixture  was  layered  carefully  on  top.  After  centrifugation  at 
1800rpm  for  30minutes  the  interface  (containing  the  MSC)  on  top  of the 
Ficoll  layer was  removed  with  a  sterile  disposable  pipette.  The  cells  were 
washed in PBS, centrifuged into a pellet and then resuspended in Mesencult 
media  (StemCell  Technologies,  Vancouver,  Canada)  containing  10% 
supplement (StemCell Technologies, Vancouver, Canada) and 1ng/ml bFGF 
(R&D  systems,  Minneapolis,  MN,  USA)  and  plated  on  two  10cm  dishes. 
10ml of media was used per 10cm diameter dish.
2.1.2 MSC culture
The MSC adhered to the culture dish and the non-adherent cells were 
washed  off in  a  media change 2 days  after isolation. After this, the  media 
was changed every 3 days until the cells began to form colonies on the plate 
after which they were passaged. Generally, the cells were split 1   in 4 every 3
52days,  and  were  not  allowed  to  become  confluent  during  expansion.  The 
procedure  for  splitting  cells  involved  washing  them  with  5ml  phosphate 
buffered saline (PBS, Invitrogen, Paisley, UK), adding 1.5ml of 0.25% trypsin 
(Invitrogen,  Paisley,  UK)  and  allowing  them  to  dissociate  from  the  tissue 
culture  plate  by incubating them  at 37°C for 2-3  min.  The  cells were then 
washed off the plate with growth medium and transferred to a 15ml falcon to 
be centrifuged in order to remove any residual trypsin. Cell counts were not 
performed  with  every  expansion,  but  when  they  were,  this  split 
approximately equated to 3 x  105  cells  being  seeded  per 10cm  dish.  After 
expansion, the MSC were frozen down using  1   ml of supplement with  10% 
v/v dimethyl sulfoxide and stored in liquid nitrogen.
2.1.3 Growth curves
The growth curve assays were performed using an amended version 
of the 3T3 protocol (163). The experiments were performed in 6-well plates, 
35mm in diameter. Initially 6 x 105  cells were seeded and allowed to grow for 
3 days, when they were detached from the well using 300pl of 0.25% trypsin, 
resuspended with  1ml of media and counted using a haemocytometer. After 
the counts, 6 x 105  cells were seeded again. The cell counts were performed 
in  triplicate  per  culture  condition  or  cell  sample  by  seeding  3  wells  per 
sample.  In  order to  calculate  the  population  doubling  time  the  cell  counts 
obtained after 3 days  in  culture were divided  by the  initial  number of cells 
seeded (6 x 105) and these values were Log2 transformed.
2.1.4 Osteogenic differentiation
MSC  were  grown  to  confluence  at  which  point  the  osteogenic 
medium,  comprising  Mesencult  and  100nM  dexamethasone,  10|jM  (3- 
glycerol  phosphate  and  50|jg/ml  ascorbate-2-phosphate  was  added.  The
53medium  was  changed  every  3  days  and  differentiation  was  allowed  to 
proceed for 14 to 21 days (All reagents obtained from: Sigma, Poole, UK).
A  kit was  used  to  detect the  presence  of alkaline  phosphatase  (all 
reagents obtained from: Sigma, Poole, UK). This involved exposing the cells 
to a 2% citrate/60% acetate solution for 30 seconds, and then rinsing twice 
with  dH20.  The  stain  (1  dye  capsule  dissolved  in  49ml  dH20  with  2ml 
Naphthol  AS-MX) was  applied  for 30  seconds,  after which  the  cells  were 
rinsed with dH20 for 2 min.  Mayer’s Haematoxylin solution was applied for 
10 minutes, when it was removed by  2 washes with dH20.
Calcium  deposition  during  osteogenic  differentiation  was  assessed 
with Alizarin Red staining. Cells were fixed with ice-cold  100% methanol for 
15 minutes, and then washed 3 times with dH20 and stained for 10 minutes 
with  1.5% w/v Alizarin red (pH 4.2 with ammonium hydroxide). Excess stain 
was removed with further dH20 washes and cells were left to air-dry before 
being visualized (all reagents obtained from: Sigma, Poole, UK).
2.1.5  Adipogenic differentiation
MSC were grown to confluence at which point the adipogenic medium 
comprising Mesencult with  1pM dexamethasone (Sigma,  Pool,  UK), 500pM 
IBMX  (Sigma,  Pool,  UK),  2pM  indomethacin  (Sigma,  Pool,  UK),  10pg/ml 
insulin  (Roche,  Indianapolis,  IN,  USA)  was  added.  The  medium  was 
changed every 3 days and differentiation was allowed to proceed for 7 to 14 
days.
Adipocytes were identified using the oil red O lipid stain (all reagents 
obtained from: Sigma, Poole, UK).  This entailed removing the medium from 
the plates, rinsing the cells with PBS, and fixing the cells by applying 8ml of 
4%  formaldehyde,  75mM  sodium  phosphate  buffer,  3%  methanol  for  30 
minutes. The fixative was then removed and the plate washed 3 times with 
PBS,  before  applying  8ml  of  oil  red  dye  (600[jg/ml  oil  red  dissolved  in
54isopropanol; diluted 60:40 in water and filtered) and incubating in the dark for 
1  to 4 hours. Plates were rinsed with 50% ethanol and covered with PBS.
2.1.6 Chondrogenic culture
Chondrocyte  differentiation  media  was  comprised  of  high  glucose 
DMEM  (Invitrogen,  Paisley,  UK) with  1%  penicillin/streptomycin  (Invitrogen, 
Paisley,  UK),  10'7M  Dexamethasone  (Sigma,  Poole,  UK),  50pg/ml 
ascorbate-2-phosphate (Sigma, Poole, UK), 40pg/ml l-proline (Sigma, Poole, 
UK), lOOpg/ml sodium pyruvate (Sigma, Poole, UK),  50 mg/ml ITS + Premix 
(6.25pg/ml  insulin,  6.25pg/ml  transferrin,  6.25ng/ml  selenious  acid, 
1.25mg/ml  BSA,  5.25mg/ml  linoleic acid) (BD  Biosciences,  Franklin  Lakes, 
NJ, USA), 500ng/ml BMP6 (R&D systems, Minneapolis, MN, USA),  10ng/ml 
TGF33  (R&D  systems,  Minneapolis,  MN,  USA).  2.5  x  105   MSC  were 
suspended  in  500pl  of chondrocyte  differentiation  media,  placed  in  a  15ml 
falcon tube and centrifuged at 600g for 5 minutes so the cells formed a loose 
pellet at the  bottom.  These  pellets  were  incubated  in  the  falcon  tubes  at 
37°C,  5%  CO2  for 4  days  before  the  first  media  change  after  which  the 
differentiation  media  was  changed  every  3  days  and  differentiation  was 
allowed to proceed for 14 to 21 days.
Experiments that were performed under hypoxic (3% [O2]) conditions 
were  carried  out  within  a  humidified  anaerobic  chamber  (Coy  Laboratory 
Products,  Grass  Lake,  Ml,  USA).  The  chamber  was  digitally  set  at  the 
required O2  concentration  and  was  maintained  at  37°C  by  a  thermostatic 
controller.
2.1.7 Wax embedding of pellets and sectioning
Pellet  measurements  were  taken  using  a  graticule  eye-piece.  For 
histology,  chondrocyte  pellets were fixed  in 4%  paraformaldehyde  (Sigma,
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then placed in ‘Cellsafe’ biopsy capsules (Raymond Lamb, Eastbourne, UK) 
and  put through the following dehydration steps:  30% ethanol,  10  minutes; 
80%  ethanol,  10  minutes;  95%  ethanol,  10  minutes;  100%  ethanol,  30 
minutes;  xylene,  20  minutes.  Pellets  were  then  embedded  in  paraffin 
(Raymond  Lamb,  Eastbourne,  UK)  and  left  overnight  to  set  at 4°C.  Wax 
sections were cut 5pm thick and floated in a water bath at 40°C before being 
applied to polysine coated slides, and allowed to dry on a hotplate overnight.
Slides were de-waxed  in xylene for 10  minutes,  rehydrated  in  100% 
ethanol  5  minutes,  90%  ethanol  5  minutes,  70%  ethanol  5  minutes  and 
washed  in  distilled  water.  The toluidine  blue  stain  (0.1%w/v toluidine  blue 
dissolved  in 0.1M sodium  phosphate buffer -  188ml of 0.1 M  NaH2PC> 4 and 
12ml  0.1M  Na2HP04) (Sigma,  Poole,  UK) was applied for 45 seconds and 
washed with distilled water. The slides were then dehydrated by consecutive 
ethanol  washes  (70%,  90%,  100%),  and  dipped  in  xylene  for  5  minutes. 
Slides were air dried and mounted with DPX (BDH, Poole, UK).
2.1.8 Culture of normal human articular chondrocytes (NHAC)
NHAC cells were obtained from Cambrex (Cambrex, Nottingham, UK) 
and cultured according to the manufacturer’s instructions. The cells were first 
expanded  using the Chondrocyte Growth  Medium  Bullet kit (Basal  medium 
with R3-IGF-1, bFGF, insulin, transferrin, fetal bovine serum 5%, gentamicin/ 
amphotericin) (Cambrex,  Nottingham,  UK) and then differentiated using the 
protocols detailed under 2.1.4, 2.1.5 and 2.1.6.
2.1.9 RNA isolation
RNA was isolated from cells using the RNAeasy kit (Qiagen, Crawley, 
UK). 600pl of RLT buffer were applied directly to a  10cm dish or 350pl per 
well  of a  6-well  plate.  The  cells were then  disrupted  by  centrifuging  them
56through  a  QIAshredder  column  (Qiagen)  and  the  RNA  isolated  using  the 
RNAeasy  mini  kit  (Qiagen,  Crawley.  UK)  according  to  the  manufacturer’s 
instructions.
2.1.10 RNA isolation from pellets
For RNA isolation, pellets grown in chondrogenic differentiation media 
for  longer  then  5  days  were  first  incubated  with  3mg/ml  collagenase  IV 
(Invitrogen,  Paisley,  UK),  1  mg/ml  hyaluronidase  (Sigma,  Poole,  UK)  and 
0.25% trypsin (Invitrogen, Paisley, UK) for 3h at 37°C. The pellets were then 
dissociated  with  repeat  pipetting  before  being  placed  in  350pl  RLT  buffer 
(Qiagen,  Crawley,  UK)  and  centrifuged  through  a  QIAshredder  (Qiagen, 
Crawley,  UK) column to disrupt the cells.  RNA was then  isolated  using the 
RNAeasy  mini  kit  (Qiagen,  Crawley,  UK)  according  to  the  manufacturer’s 
instructions. MSC or cells grown in chondrogenic culture for less then 5 days 
were  placed  in  RLT  buffer  and  disrupted  by  rapid  pipetting  and  passing 
through a QIAshredder column before RNA isolation with the RNA easy mini 
kit  according  to  the  manufacturer’s  instructions.  The  isolated  RNA  was 
stored at -80°C.
2.1.11  RNA isolation from MSC differentiated into adipocytes
RNA from  MSC exposed to adipogenic media for more then  7 days 
was isolated using the RNAeasy lipid mini kit (Qiagen, Crawley, UK).  1ml of 
Qiazol  reagent (Qiagen,  Crawley,  UK) was  applied  to the  cells  in  a  10cm 
dish and left on the cells for 2 to 3 minutes. The cells were scraped off using 
a  cell-scraper  and  spun  through  a  QIAshredder  (Qiagen,  Crawley,  UK) 
column  before  proceeding  with  the  RNA  isolation  according  to  the 
manufacturer’s instructions.
572.1.12  RT-PCR
Reverse transcription  PCRs were performed  using the Superscript II 
enzyme kit (Invitrogen, Paisley, UK) according to manufacturer’s instructions 
and with 100ng starting RNA. Briefly, 1pl OligodTie (500pg/Ml)  and 1pl dNTP 
mix (Promega,  Madison, Wl,  USA) was added to 100ng total RNA, and the 
volume  made  up to  12pl  with  RNAse free water (Invitrogen,  Paisley,  UK). 
This mixture was incubated for 5 minutes at 65°C and briefly chilled on  ice 
before the addition of 4pl of 5X First Strand Buffer (Invitrogen,  Paisley,  UK) 
and 2pl 0.1M DTT (Invitrogen, Paisley, UK). This mixture was then incubated 
at 42°C for 2 minutes, before the addition of 1pl of the Superscript II reverse 
transcriptase  (Invitrogen,  Paisley,  UK)  The  subsequent  PCRs  were 
performed  in  25pl  reaction  volumes  with  2.5pl  of  10X  reaction  buffer with 
50mM MgCb, 0.5pl of 10mM dNTP, 0.5pl of 10uM of each primer,  0.2pl of 
5U/pl Taq  polymerase,  1pl  cDNA (from  the  reverse transcription  reaction). 
For GAPDH,  Sox5,  osteocalcin,  Col1a1,  aP2  and  PTHrPR  primers,  1.25pl 
DMSO was added to a reaction mix containing 2.5pl of 10X reaction buffer 
with 50mM MgCh, 1  M l of 10mM dNTP, 2.5pl of 10pM of each primer, 0.3pl of 
5U/ul  Taq  polymerase  and  1pl  cDNA.  The  cycling  times were,  94°C for 2 
minutes; and then 30 cycles of 94°C for 30 seconds, 55°C for 1   minute, 72°C 
for 45 seconds; 72°C for 10 minutes. The reactions were then run on a 2% 
agarose gel, in  1X TAE buffer (National Diagnostics, Hessle Hull, UK).  The 
following primers were used:
OSTEOCALCIN (forward)  TGAGAGCCCTCACACTCCTC 
OSTEOCALCIN (reverse)  CTGGAGAGGAGCAGAACTGG
COL1A1  (forward) 
COL1A1  (reverse) 
COL2A1 (forward) 
COL2A1 (reverse) 
COL10A1  (forward) 
COL10A1  (reverse) 
COMP (forward)
CACT  GGT  GCTAAGGGAGAGC 
CT  CCAGCCT  CT  CC  AT  CTTT  G 
TTC  AGCTAT  GGAGAT  GAC  AAT  C 
AGAGTCCTAGAGTGACTGAG 
C  ACC  AGGCATT  CCAGGATT  CC 
AGGTTT  GTTGGTCT  GATAGCTC 
T  GGGCCCGCAGAT  GCTT  C
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LINK (forward)
LINK (reverse)
SOX5 (forward)
SOX5 (reverse)
SOX6 (forward)
SOX6 (reverse)
SOX9 (forward)
SOX9 (reverse)
PTHrP (forward) 
PTHrP (reverse) 
PTHrP-R (forward) 
PTHrP-R (reverse) 
BMP-2 (forward) 
BMP-2 (reverse) 
BMP-6 (forward) 
BMP-6( reverse) 
AGGRECAN (forward) 
AGGRECAN (reverse) 
GAPDH (forward) 
GAPDH (reverse)
AGGTTT  GTT  GGTCT  GATAGCT  C 
CCTATGATGAAGCGGTGC 
TTGTGCTTGTGGAACCTG 
AGCC  AGAGTTAGC  AC  AATAGG 
CATGATTGCCTTGTATTC 
ACT  GTGGCT  GAAGCACGAGT  C 
TCCGCC  AT  CT  GT  CTT  CATACC 
GAACGCACAT  CAAGACGGAG 
TCTCGTTGATTTCGCTGCTC 
CT  CGGAGCGT  GT  G  AACATT  CC 
CTT  CCGG  AAAGTT  GATT  CC  AC 
AGGAACAGAT  CTT  CCT  GCT  GCA 
T  GCAT  GT  GGAT  GTAGTT  GCGCGT 
CAGAGACCCACCCCCAGCA 
CT  GTTT  GT  GTTT  GGCTT  GAC 
CTCGGGGTT  CATAAGGT  GAA 
ACAGCAT  AACAT  GGGGCTT  C 
GAAGGAGGTAGT  GCT  GCT  GG 
ACGT  CCT  CACACCAGGAAAC 
GAT  CAT  CAGC  AAT  GCCT  CCT 
TGTGGT  CAT  G  AGT  CCTTCCA
592.2 MICROARRAY ANALYSIS OF CHONDROGENESIS
2.2.1  Preparation of RNA for microarrays
RNA  isolated  from  the  differentiations  was  quantified  using  a 
nanodrop machine and quality tested using RNA 6000 Nano chips on Agilent 
2100  Bioanalyser  according  to  the  manufacturer’s  instructions  (Agilent 
Technologies, Cheshire, UK). RNA quality-control threshold was 28s/18s<2. 
2pg  of total  RNA from  each  sample  was  then  processed  using  the  One- 
Cycle cDNA Synthesis Kit (Affymetrix,  Santa Clara, CA,  USA) according to 
manufacturer’s  instructions.  Briefly,  2pg  RNA was  reverse-transcribed  into 
cDNA  and  then the  second  strand  was  synthesized.  The  resulting  double 
stranded  cDNA  was  in  vitro  transcribed  to  obtain  biotinylated  cRNA, 
quantified using the nanodrop and 20pg were fragmented for hybridization. 
The  cRNA was  hybridized  to  HG-U133A  Human  Chips  (Affymetrix,  Santa 
Clara,  CA,  USA),  according  to  the  manufacturer’s  recommendations. 
Hybridization  of the  synthesised  probes  and  scanning  of the  images were 
performed  by  the  scientific  services  team  (Scientific  Services,  Wolfson 
Institute  for  Biomedical  research,  The  Cruciform  Building,  Gower  Street, 
University College London, London, WC1E 6BT) who also produced the CEL 
data files for further analysis.
2.2.2 Analysis of microarray data
Most of the  initial  data  analysis was  performed  by  Dr Stephen  Henderson 
(Wolfson  Institute for Biomedical  research,  The  Cruciform  Building,  Gower 
Street,  University  College  London,  London,  WC1E  6BT)  using  the  R 
statistical software and programming language with the packages ‘affy’ and 
‘limma’. Robust multi-array average (RMA) was used to background correct, 
to normalize the data and then to calculate expression values for each probe 
set  (164).  The  levels  of differential  expression  between  arrays  were  then
60calculated using moderated standard deviation and the P-value adjusted for 
multiple  testing  using  the  false  discovery  rate  model  (165).  Cluster  and 
Treeview (http://rana.lbl.gov/EisenSoftware.htm) were then used to organize 
genes, showing a significant amount of change, by behavioural patterns with 
hierarchical clustering. The steps of analysis listed above were performed by 
Dr Stephen  Henderson and are described  in  more detail  in the  microarray 
results chapter 4.
The  lists obtained from the  statistical  analysis  above were  used for 
further  analysis  with  other  tools  such  as  the  WebGestalt  ontology  tool, 
GeneCard and Pubmed (Section 4.1.2).
612.3 NOTCH SIGNALLING IN CHONDROGENESIS
2.3.1  DMSO treatment of MSC
DMSO  concentration  was  optimized  for  the  chondrogenic  in  vitro 
model  system  (Sigma,  Poole,  UK).  MSC  were  exposed  to  various 
concentrations  of  DMSO  (1pl/ml,  2pl/ml  and  5pl/ml)  16  hours  prior  to 
induction  of  differentiation  and  alongside  the  differentiation  inducers 
throughout  the  differentiation  (as  detailed  under  2.6).  Differentiation  was 
allowed  to  proceed  for  21  days  and  the  pellets  were  measured  with  a 
graticule eye-piece at days 7,  14 and 21  before being fixed and stained as 
detailed in Section 2.1.7.
2.3.2 DAPT treatment of MSC
DAPT  (Merck  Biosciences,  Darmstadt,  Germany)  was  dissolved  in 
DMSO (Sigma, Pool, UK) to make 20mM and 10mM stocks which were then 
added to the MSC cultures at 1:1000 dilution producing a final concentration 
of  10pM  DAPT and 20pM  DAPT.  In  all  cases where  DAPT treatment was 
used in conjunction with differentiation medium, DAPT or DMSO was applied 
16 hours prior to induction of differentiation and alongside the differentiation 
inducers  throughout  the  differentiation.  MSC  were  allowed  to  reach 
confluence before DAPT or DAPT and 100nM dexamethasone treatment.
2.3.3 DAPT treatment in chondrogenesis
Chondrogenesis was  performed  as detailed  under 2.1.6.  Six  pellets 
were grown per condition, and the experiment was performed in duplicate. In 
the case of DAPT treatment, the MSC were exposed to 1  pl/ml DMSO,  10pM 
DAPT or 20pM  DAPT for  16  hours  prior to  growing  in  pellet cultures  and 
throughout  the  differentiation  process  (Section  2.1.6).  Differentiation  was
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graticule eye-piece at days 7,  14 and 21  before being fixed and stained as 
detailed under 2.1.7.
2.3.4  RNA isolation and RT-PCR
The  RNA  isolation  was  performed  as  detailed  under 2.1.11,  2.1.12 
and  2.1.13.  Reverse  transcription  PCRs  were  performed  using  the 
Superscript  II  enzyme  kit  (Invitrogen,  paisley,  UK)  according  to  the 
manufacturer’s  instructions  and  with  100ng  starting  RNA.  The  subsequent 
PCRs were performed using DyNAzyme kits (Finnzymes, Espoo, Finland) in 
25pl  reaction volumes  using 2.5pl of  10X  reaction  buffer containing  50mM 
MgCb,  1pl of 10mM dNTP (Promega, Madison, Wl,  USA), 2.5pl of 10pM of 
each  primer (Thermo),  0.25pl of 5U/pl  Taq  polymerase,  1.25pl  DMSO and 
1  pi cDNA. The cycling times were, 94°C for 2 minutes; and then 28 cycles of 
94°C for 30 seconds, 55°C for 1   minute, 72°C for 45 seconds;  72°C for 10 
minutes.  The  reactions were then  run  on  a  1.5%  agarose  gel,  in  1X TAE 
buffer (National  Diagnostics,  Hessle Hull,  UK).  The following  primers were 
used:
HES1 (forward) 
HES1 (reverse) 
HEY1  (forward) 
HEY1  (reverse) 
Col2a1 (forward) 
Col2a1 (reverse) 
GAPDH (forward) 
GAPDH (reverse)
CTACCCCAGCCAGT  GTCAAC 
CATT  GAT  CT  GGGT  CAT  GCAG 
AACT  GTT  GGT  GGCCT  GAAT  C 
CCAGTT  CAGT  GGAGGT  CGTT 
TT  C  AGCTAT  GG  AGAT  GAC  AAT  C 
AGAGTCCTAGAGTGACTGAG 
GAT  CAT  CAGCAAT  GCCT  CCT 
TGTGGT  CAT  GAGT  CCTT  CCA
632.3.5  DAPT treatment in osteogenesis and adipogenesis
Adipogenesis was carried out as detailed under 2.4. The media was 
changed  every  3  days.  In  the  case  of  DAPT  treatment  the  hMSC  were 
exposed to either 1  pl/ml DMSO,  10pM DAPT or 20pM DAPT 16 hours prior 
to  exposing  to  differentiation  media  and  thereafter.  Adipogenesis  was 
allowed to proceed for 14 days before the cells were stained with oil red O 
(as detailed in Section 2.1.4).
Osteogenesis was carried out as detailed under 2.1.5. The media was 
changed  every  3  days.  In  the  case  of  DAPT  treatment,  the  hMSC  were 
exposed to either 1  pl/ml DMSO,  10pM DAPT or 20pM DAPT 16 hours prior 
to  exposing  to  differentiation  media  and  thereafter.  Osteogenesis  was 
allowed to proceed for 21 days before the cells were stained with alizarin red 
or  for  alkaline  phosphatase  activity  as  described  in  section  2.1.5.  When 
osteogenic  and  adipogenic  staining  were  combined  the  cells  were  first 
stained  for  alkaline  phosphatase  activity  before  staining  for  oil  red  O  (as 
detailed in Section 2.1.4 and 21.5 respectively).
2.3.6  In situ hybridizations
2.3.6.1  Fixing of mouse embryos for in situ hybridizations
Pregnant female wildtype mice were culled at day 11.5 (E11.5), 13.5 (E13.5) 
and  15.5  (E15.5)  gestation.  The  bodies  of  E11.5,  E13.5  and  the  limbs  of 
E15.5 were fixed overnight in 4%  paraformaldehyde at 4°C (Sigma,  Poole, 
UK),  and  then  placed  in  20%  w/v  sucrose  (Sigma,  Poole,  UK)  in 
diethylpyrocarbonate  (DEPC)  (Sigma,  Poole,  UK) treated  PBS  (Invitrogen, 
Paisley,  UK)  overnight  at  4°C.  The  embryo  bodies  and  limbs  were  then 
embedded  in  OTC  compound  (Raymond  Lamb,  Eastbourne,  UK),  snap 
frozen  on  dry  ice  and  kept  at -80°C.  Sections  10pm  thick were  cut  on  a 
cryostat and placed on Superfrost slides (VWR, Leuven, Belgium).
642.3.6.2  Cloning the collagen 2 template for probes
RNA was isolated from an E13.5 mouse embryo using the TRIzol LS 
reagent  (Invitrogen,  Paisley,  UK)  according  to  the  manufacturer’s 
instructions. 750pl of TRIzol LS reagent was added to the embryo tissue and 
the tissue was homogenized using a power homogenizer. The samples were 
incubated for 5  minutes at room temperature and 200pl of chloroform was 
added. Tubes were then shaken for 15 seconds, left to stand for 5 minutes at 
room  temperature  and  centrifuged  at  12,000g  for  15  minutes  at  4°C. 
Following centrifugation, the aqueous phase was transferred to a new tube 
and the  RNA  precipitated  using  500pl  isopropanol  and  incubating at room 
temperature for 10 minutes. The mixture was then centrifuged at 12,000g for 
10  minutes  at 4°C and the supernatant discarded.  The  pellet was washed 
with 1ml of 75% ethanol, vortexed and centrifuged at 7,500g for 5 minutes at 
4°C. The supernatant was then discarded, the RNA pellet air-dried for 5-10 
minutes and re-dissolved in 100pl DEPC-treated water.
The RNA was reverse transcribed as detailed in section 2.1.12
In order to amplify the mouse collagen 2a1  gene, a PCR was set up 
using the E13.5 cDNA and DyNAzyme kits (Finnzymes, Espoo, Finland) in a 
50(jI  reaction.  2.5pl  DMSO was added to a  reaction  mix containing  5pl  of 
10X reaction  buffer with 50mM  MgCh, 2pl of 10mM dNTP,  5pl  of 10pM  of 
each primer, 0.6pl of 5U/ul Taq polymerase and 1  pi cDNA. The cycling times 
were, 94°C for 2 minutes; and then 30 cycles of 94°C for 30 seconds, 55°C 
for 1   minute,  72°C for 45 seconds;  72°C for  10  minutes. The reaction was 
run  on  an  0.8%  gel,  in  1X TAE  buffer (National  Diagnostics,  Hessle  Hull, 
UK). The following primers were used:
mCOL2A1  (forward) CTGGAGCCAAAGGATCCGCT 
mCOL2A1  (reverse) CGGAATTCTTCTCCTTGATCACCCTTGG
65After PCR amplifying the sequence and  running  it on a  1% agarose 
gel in TAE buffer (National Diagnostics, Hessle Hull, UK), the DNA fragment 
was  cut  out  and  purified  using  a  QIAquick  gel  extraction  kit  (Qiagen, 
Crawley,  UK). As the primers used to amplify collagen 2 were designed to 
include  the  BamHI  and  EcoRI  sequence,  a  restriction  digest  was  set  up 
using these two enzymes  (Promega,  Madison,  Wl,  USA)  and the  reaction 
incubated  at  37°C  for  1   hour.  The  same  digest  was  performed  on  the 
pSPT18 (Roche,  Indiannapolis,  IN,  USA).  Both of these reactions were run 
on  a  1%  agarose  gel  and  purified  using  the  QIAquick  gel  extraction  kit 
(Qiagen,  Crawley,  UK).  A  ligation  was  set  up  using  1pl  of  the  purified 
linearised plasmid DNA and 3pl of the purified collagen 2 sequence with T4 
DNA ligase (Promega, Madison, Wl, USA) and incubated at 16°C overnight. 
The ligated plasmid was transformed into TOP10 chemically competent cells 
(Invitrogen,  Paisley,  UK).  Colonies  were  checked  for  presence  of plasmid 
and insert and a positive clone inoculated into 500ml Luria-Bertani (LB) broth 
(Sigma, Poole, UK). The plasmid was then purified using The QiaPrep Maxi 
kit (Qiagen, Crawley, UK).
2.3.6.3  Cloning the Sox9 template for probes
A pCMV-mmSox9  plasmid was obtained from  Prof Michael  Wegner 
(Lehrstuhl  fur  Biochemie  und  Pathobiochemie,  Universitat  Erlangen- 
Numberg,  Fahrstralie  17,  91054  Erlangen,  Germany).  The  Sox9 fragment 
was isolated  using the BamHI and Xbal enzymes (Promega,  Madison,  Wl, 
USA) and incubating at 37°C for 1   hour. The same digest was performed on 
the pSPT18 (Roche,  Indiannapolis,  IN,  USA).  Both of these reactions were 
run on a  1% agarose gel and purified  using the QIAquick gel extraction kit 
(Qiagen,  Crawley,  UK).  A  ligation  was  set  up  using  2pl  of  the  purified 
linearised plasmid DNA and 3pl of the purified Sox9 sequence, with T4 DNA 
ligase (Promega,  Madison, Wl,  USA) and incubated at 16°C overnight. The 
ligated  plasmid  was  transformed  into  TQP10  chemically  competent  cells
66(Invitrogen,  Paisley,  UK).  Colonies  were  checked  for  presence  of plasmid 
and insert and a positive one inoculated into 500ml Luria-Bertani (LB) broth. 
The plasmid was then purified using The QiaPrep Maxi kit (Qiagen).
2.3.6.4 Cloning the HES1 and HEY1 template for probes
IMAGE  clones  were  purchased  of  HES1  and  HEY1  sequences 
(IMAGE  numbers:  6478994  and  374164,  NCBI  accession  numbers: 
BQ938563  and  AI414254  respectively).  The  HES1  sequence  was  cloned 
within the pCMV-SPORT6 vector that already contained a T7 promoter in the 
appropriate orientation with  respect to the insert. The HEY1  sequence was 
within  pT7T3D  but not in the correct orientation for the T7  promoter to  be 
used and therefore needed to be inserted into a different vector. The HEY1 
sequence  was  isolated  using  a  Notl  and  EcoRI  digest  (enzymes  from 
Promega,  Madison,  Wl,  USA)  and  a  pCR2.1-TOPO  vector  (Invitrogen, 
Paisley, UK) was linearised using the same enzymes. A ligation was set up 
using 2pl of the purified linearised pCR2.1-TOPO DNA and 3pl of the purified 
HEY1  sequence  with  T4  DNA  ligase  (Promega,  Madison,  Wl,  USA)  and 
incubated  at  16°C  overnight.  The  ligated  plasmid  was  transformed  into 
TOP10 chemically competent cells (Invitrogen,  Paisley,  UK). Colonies were 
checked for presence of plasmid and insert and a positive clone inoculated 
into  500ml  LB  broth  (Sigma,  Poole,  UK).  The  pCMV-SPORT6-HES1  was 
also inoculated into 500ml LB broth (Sigma, Poole, UK). The plasmids were 
then purified using the QiaPrep Maxi kit (Qiagen, Crawley, UK).
2.3.6.5 In vitro transcription of probes
10pg of each plasmid DNA (pSPT18-mCol2, pSPT18-mSox9, pCMV- 
SPORT6-HES1, pSPT18-HEY1) was linearised using 5pl of an enzyme that 
cuts  at the  beginning  of the  insert sequence  and  incubated  at 37°C for 2 
hours.  The enzyme was  inactivated  by adding 5pl  of 10% sodium dodecyl
67sulphate  (Sigma,  Poole,  UK)  and  1pl  of  20mg/ml  Proteinase  K  (Roche, 
Indiannapolis, IN, USA) to the restriction digest and incubating at 55°C for 15 
min.  The  linearised  plasmids  were  then  purified  using  the  QIAquick  gel 
extraction kit (Qiagen, Crawley, UK).
For  the  in  vitro  transcription  reaction  the  DIG  RNA  Labelling  Kit 
(Roche,  Indiannapolis,  IN,  USA) was used according to the  manufacturer’s 
instructions. Briefly, RNAse-free water was added to 1  pg of purified template 
DNA to a final volume of 13pl and then 2 jjI of 10 x NTP labeling mixture, 2pl 
transcription  buffer,  1pl  RNase  inhibitor and  2pl  RNA  polymerase  T7  was 
added. This mixture was incubated at 37°C for 2 hours, then 80pl of RNase- 
free water was added and 5pl ran on a 1% gel for quantification. The probe 
was kept at -80°C until used.
Ready made PDGFRA probe were a kind gift from Dr Nikoletta Tekki- 
Kessaris (Wolfson Institute for Biomedical research, The Cruciform Building, 
Gower Street, University College London, London, WC1E 6BT).
2.3.6.6  In situ hybridization
Probes  were  diluted  in  in  situ  hybridisation  buffer  1:1000  and 
denatured  by  incubating  at  70°C  for  10  min.  200pl  of  diluted  probe  was 
added  to  each  slide  and  the  slides  were  covered  with  22mm  x  50mm 
coverslips  (previously  incubated  overnight  at  220°C).  The  probes  were 
hybridised  to  the  cut sections  overnight at 65°C  in  a  sealed  Perspex  box 
lined with Whatman paper soaked in in situ wash buffer. The following day, 
the slides were transferred into coplin jars and washed in in situ wash buffer 
at 65°C for 15 minutes to allow the coverslips to fall off. This was followed by 
2 more washes in in situ wash buffer at 65°C for 30 minutes each. The slides 
were  then  incubated  in  MABT  at  room  temperature  twice for 30  minutes. 
Slides  were  then  transferred  to  a  humidifying  chamber,  400pl  of  blocking 
buffer  was  applied  to  each  slide  and  incubated  for  1   hour  at  room 
temperature.  The  anti-DIG-AP,  Fab  fragments  (Roche,  Indiannapolis,  IN,
68USA) antibody was diluted  in  blocking  buffer 1:1500, 400|jl was applied to 
each slide and incubated overnight at 4°C. The next day, the sections were 
washed  in  room temperature MABT 4 times for 20  min  and then  rinsed  in 
staining buffer without nitro blue tetrazolium (NBT) and 5-bromo-4-chloro-3- 
indolyl  phosphate,  p-toluidine  salt  (BCIP).  Slides  were  then  transferred  to 
staining buffer and incubated at 37°C for 3 hours for those stained with the 
col2 probe and overnight for the sox9,  HES1  and HEY1  probes. Finally, the 
slides were rinsed in dH20, dehydrated (with consecutive 5 minutes ethanol 
washes  in  50%,  80%  and  95%  ethanol,  and  immersed  in  xylene  for  5 
minutes) and mounted with DPX (BDH, Poole, UK).
2.3.6.7  Composition of reagents for in situ hybridization
In situ hybridization buffer
For 10 ml:  1ml of 10X salts (2M NaCI, 50mM EDTA,  100mM Tris-HCI 
pH 7.5, 50mM NaH2P04.2H20 , 50mM Na2HP04), 5ml deionised formamide, 
2ml of 50% w/v dextran sulphate, 1ml of 10mg/ml baker’s yeast rRNA, 10Opil 
of  100X  Denhardt’s  Solution  (2% w/v BSA,  2% w/v  Ficoll,  2% w/v  PVP  in 
DEPC-treated water) and  900pl  DEPC-treated  distilled water.  This  mixture 
was  aliquoted  and  stored  at  -20°C  until  used  (all  reagents  from  Sigma, 
Poole, UK).
MABT -  maleic acid buffer
100mM maleic acid,  150mM NaCI -  pH to 7.5 with NaOH. Finally, 0.1% v/v 
Tween 20 was added and the mixture was stored at room temperature (all 
reagents from Sigma, Poole, UK).
Blocking buffer
Boehringer blocking reagent (Roche,  Indiannapolis,  IN,  USA) was made up 
in  MABT as  a  10%  stock.  This was  heated  to  65°C  and  autoclaved.  The
69solution applied to the slides was further diluted to 2%  boehringer blocking 
reagent and 10% sheep serum (Sigma, Poole, UK).
Staining buffer without NBT and BCIP
For 200ml: 4ml 5M NaCI, 10ml 1M MgCI2, 20ml 1M Tris pH9.5, 200pl Tween 
20 (all reagents from Sigma, Poole, UK).
Staining buffer
To 20ml staining  buffer without NBT and  BCIP,  1ml  1M  MgCfe,  87pl  NBT, 
67pl  BCIP and 20ml  poly-vinyl  alcohol  (10% w/v) was added  (all  reagents 
from Sigma, Poole, UK).
702.4 IDENTIFICATION OF BRACHYURY AS A CHORDOMA MARKER
The  work  presented  in  this  chapter  is  based  upon  previously 
published work by the group (134).
2.4.1 Microarray analysis
Microarray  analysis for this  study was  performed  as  detailed  under
2.2.2 using the R statistical environment in Bioconductor. The ‘affy’ package 
was  used  to  perform  the  normalization  steps  using  the  RMA  algorithm 
(chapter 4  offers  a  more  detailed  description).  The  ‘limma’  package  was 
used  to  select  statistically  significant  differences  in  expression  between 
tumour groups.  The  heatmaps were  produced  using  Cluster and  Treeview 
software.  This analysis was performed by Dr Stephen  Henderson (Wolfson 
Institute  for  Biomedical  research,  The  Cruciform  Building,  Gower  Street, 
University College London, London, WC1E 6BT).
2.4.2 RT-PCR analysis
RNA was extracted using the TRIzol reagent (Invitrogen, Paisley, UK) 
followed  by  purification  with  RNeasy  columns  (Qiagen,  Crawley,  UK) 
according to the manufacturer’s instructions. Tumour RNA was converted to 
cDNA  using  the  Superscript  II  RT-PCR  kit  (Invitrogen,  Paisley,  UK) 
according to the  manufacturer’s instructions using  200ng  of total  RNA and 
OligodT primers (Thermo, Ulm, Germany). PCR was performed using 1pl of 
the cDNA reaction and 30 cycles of 94°C for 30 seconds, 55° for 1   minute, 
72° for 1  minute using PCR DyNAzyme kit (Finnzymes, Espoo, Finland). The 
products were resolved by electrophoresis on a 1.5% agarose gel in 1X TAE 
buffer (National Diagnostics, Hessle Hull, UK)
Brachyury (forward)  GCCAGACTGGAGAGTTGAGG
71Brachyury (reverse)  CAGGTGGTCCACTCGGTACT
GAPDH (forward)  GAT  CAT  CAGC  AAT  GCCT  CCT
GAPDH (reverse)  TGTGGTCATGAGTCCTTCCA
2.4.3 Tissue retrieval
Cases of chordomas, other tumors and normal tissue were retrieved 
from  the  archives  of the  Royal  National  Orthopaedic  Hospital  NHS  Trust, 
University College NHS Trust, the Institute of Neurology, UCL and Guy’s and 
St.Thomas’ Hospitals, and this study was approved by the ethics committees 
of these hospitals. The selection was restricted to paraffin-embedded tissue, 
resected within the last 6 years.
2.4.4 Immunohistochemistry
3pm  thick  sections  were  cut  from  paraffin-embedded  samples, 
dewaxed  in xylene,  rehydrated  and then  pressure-cooked for 2  minutes  in 
antigen-unmasking  solution  (Vector  Laboratories,  Peterborough,  UK).  The 
iVIEW™  DAB  Detection  Kit  and  NexES  immunohistochemistry  system 
(Ventana  Medical  Systems,  Inc.  Tucson, AR,  USA) was used according to 
the manufacturer’s instructions.  Briefly, the endogenous peroxidase activity 
was inhibited and the sections incubated with the primary brachyury antibody 
(Santa Cruz, Santa Cruz, CA, USA) for 30minutes, followed by a biotinylated 
Ig secondary antibody (Ventana Medical Systems, Tucson, AR, USA) and a 
streptavidin -  horseradish peroxidase conjugate (Ventana Medical Systems, 
Tucson,  AR,  USA).  Finally,  a  copper  DAB  enhancer  (Ventana  Medical 
Systems, Tucson, AR, USA) was applied. Sections were counterstained with 
Harris’  Haematoxylin  (HD  supplies,  Aylesbury,  UK),  dehydrated  and 
mounted with a glass coverslip. The other antibodies used were S100 (Dako, 
Glostrup,  Denmark),  AE1/AE3  (Dako,  Glostrup,  Denmark)  and  MNF116 
(Dako, Glostrup, Denmark). The S100 antibody was used at a dilution of 1   in 
1600 and the slides were pretreated with protease for 6 minutes. AE1/AE3
72antibody was diluted 1   in 50 and the slides were pretreated with protease for 
12 minutes. MNF116 was used at a dilution of 1   in  100 and the slides were 
pretreated with protease for 14 minutes.
Most  S100  and  cytokeratin  immunohistochemistry  was  performed 
following  tumour  resection  for diagnostic  purposes  and  therefore  was  not 
repeated for the purposes of this project.
733.  MESENCHYMAL  STEM  CELL  ISOLATION, 
CULTURE AND DIFFERENTIATION
3.1  INTRODUCTION
Mesenchymal stem cells (MSC) are isolated from adult bone marrow 
and have the capacity to differentiate into various connective tissue lineages 
(Section  1.1). The proliferative potential of these cells is very high and can 
be further enhanced  by culturing them  in  media  containing  bFGF  (Section
1.1.3).
The interest in optimising protocols for MSC growth and differentiation 
primarily stems from the  potential application  of these cells for therapeutic 
purposes. MSC have a higher replicative potential than the more committed 
local progenitor cell populations and therefore a higher potential for repair of 
damaged  tissues.  MSC  have  been  used  or  proposed  as  treatment for  a 
variety  of  conditions,  ranging  from  osteogenesis  imperfecta  and 
intervertebral disc degeneration to myocardial ischemia (166-168). The use 
of MSC to repair damaged cartilage has also been a therapeutic aim, due to 
the prevalence of cartilage injuries and diseases such as osteoarthritis (169).
Besides the therapeutic potential presented by MSC, they are also a 
valuable  tool  for  modelling  developmental  processes  such  as 
chondrogenesis, as they represent an earlier developmental stage than the 
committed chondrocytes used in other model systems. Chondrogenesis is a 
complex process involving a multitude of signalling and transcription factors 
leading to the formation of an extracellular matrix that is crucial for cartilage 
strength  and  durability  (Section  1.2).  Insight  into  the  process  of cartilage 
development has been obtained through the studies of mutations in humans 
and mice and through various model systems.
The composition and function of the cartilage extracellular matrix as 
well as the signalling processes involved in cartilage growth, maturation and 
hypertrophy are  well  elucidated.  However,  much  less  is  known  about the
74transcriptional  events  involved  in the commitment of mesenchymal cells to 
the  chondrogenic  lineage  and  guiding  the  formation  of  mesenchymal 
condensations.
3.1.1  Aims
The  first  aim  of this  project was  to  optimise  the  conditions  for the 
isolation  and  expansion  of  MSC  and  to  determine  the  variability  in  MSC 
proliferation  and  differentiation  between  bone  marrow  donors.  Next,  the 
procedure for differentiating MSC was optimised, with a  particular focus on 
establishing  the  in  vitro chondrogenic differentiation  system.  An  additional 
area  of  interest  was  the  comparison  between  chondrogenesis  of  the 
multipotent MSC and the unipotent normal human articular chondrocyte cells 
(NHAC). The final aim for this section was to monitor chondrogenesis at the 
molecular level using RT-PCR analysis of chondrogenic markers, in order to 
determine  the  temporal  time  frame  of  events  as  MSC  undergo 
chondrogenesis.
753.2 MSC ISOLATION AND ESTABLISHMENT OF CULTURES
Ficoll  gradient centrifugation  of filtered  bone  marrow  resulted  in  the 
separation  of erythrocytes  and  granulocytes  in the  pellet and  mononuclear 
cells,  including the MSC,  in the interphase  (Methods:  Section 2.1.1). When 
the bone marrow mononuclear cells from the interphase were seeded on a 
culture  dish,  the  MSC  adhered  to the  plates  while  the  non-adherent  cells 
were subsequently lost during media changes (Methods: Section 2.1.1). The 
population of adherent cells was confirmed to uniformly express SH2,  SH4 
and  Stro-1  by  FACS  analysis,  as  in  previous  publications  (Section  1.1.2) 
(experiments performed by Stephen Elliman and Claire Westwood, personal 
communication, manuscript submitted).
Two to three  days after isolation,  small  groups,  consisting  of 2  or 3 
MSC,  were  visible  on  the  plate  (Figure  3.1)  (Methods:  Section  2.1.2).  The 
cells  continued  to  proliferate,  forming  colonies,  and  were  ready  to  be 
passaged after 7 days in culture. The MSC had a spindle-shaped, elongated 
morphology  and  grew  in  small  clusters.  During  expansion,  MSC  were  not 
allowed to become confluent and were passaged when the cells covered 70- 
75% of the culture dish.  If the cells were allowed to reach confluency, they 
formed a swirling pattern on the plate (Figure 3.2).
Figure 3.1: Emerging MSC, 3 days after isolation (A, arrow) and 5 days after 
isolation (B) with Ficoll gradient centrifugation.
762 0 0  -jjm '
Figure  3.2:  MSC  that  have  reached  confluence,  9  days  after  isolation, 
forming a swirling pattern on the plate.
MSC were routinely grown  in a  basal  media supplemented with  10% 
serum  and  1ng/ml  bFGF.  The  addition  of  bFGF  has  been  reported  to 
enhance  the  proliferative  capacity  of  MSC  by  increasing  the  doubling  rate 
and  allowing  the  MSC  population  to  be  expanded  for  more  population 
doublings (27) (Section 1.1.3).
In order to test the effect of bFGF, growth curve assays, similar to the 
3T3  assay  were  set  up  (Methods:  Section  2.1.3)  (Figure  3.3  -  assay 
performed  by Claire Westwood).  During the assay, the  MSC  cultured  in the 
presence of bFGF were passaged every 3 days while the cells grown in the 
absence of bFGF could only be passaged every 6 days due to their slow rate 
of proliferation. The growth curve assay was carried out for 30 days and both 
populations were still proliferating when it was terminated,  by which time the 
cells cultured with bFGF had undergone -14 population doublings and those 
cultured without bFGF had undergone -5. These results correlated well with 
the  published  results  of  Tsutsumi  et  al  (27).  MSC  ability  to  undergo 
differentiation  was  unimpaired  by  addition  of  bFGF  (Claire  Westwood, 
personal  communication,  (27))  therefore,  bFGF  was  added  to  all  MSC 
cultures unless stated otherwise.
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Figure 3.3: The  effect of bFGF  addition  on  MSC  proliferation  as assessed 
by the  3T3  assay.  MSC were  grown  in triplicate with  1ng/ml  bFGF  added. 
Cell  numbers  were  counted  every  3  days  for  cells  grown  with  bFGF  and 
every 6 days for the cells grown without bFGF.
As MSC from different donors are reported to vary in their proliferative 
potential, growth curve assays were performed on MSC isolated from donors 
of  both  genders  and  a  variety  of  ages  (Figure  3.4)  (Methods:  Section:
2.1.3)(21;23). The donors included: two 24 year old males (labelled 24M and 
n24M), a 38 year old male (38M), a 46 year old female (46F) and a 55 year 
old female  (55F).  Considerable variability was  noted  between  MSC  growth 
rates from  different donors.  In  particular,  the  MSC  isolated  from the  eldest 
donor, 55F, showed very slow rates of growth and the cells growth arrested 
after  the  6th   passage.  The  other  populations  continued  to  proliferate 
throughout the 9 passages until the assay was terminated on day 27. While 
some differences were  noted  in the growth  rates  of the  other donors’  MSC 
these  did  not  seem  to  correlate  with  donor age.  Using  a  paired  t-test,  the 
doubling rates of the 38M and the n24M MSC were shown to be significantly 
different  (p<0.05),  with  the  older donor MSC  multiplying  more  rapidly.  The 
reasons for this variability are unclear.
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Figure 3.4: Proliferation of MSC isolated from different donors as assessed 
by the  3T3  assay.  Different  donors’  MSC  were  grown  in  triplicate  and  cell 
numbers counted every 3 days.
793.3 POTENTIAL OF MSC TO DIFFERENTIATE TOWARDS OSTEOGENIC
AND ADIPOGENIC CELL FATES
In  order  to  induce  differentiation  into  osteogenic  and  adipogenic 
lineages,  MSC  were  first  allowed  to  reach  confluency  during  monolayer 
culture  and  then  a  cocktail  of  differentiation  inducers  particular  to  each 
lineage was added to the cells.
For osteogenesis,  the  differentiation  media  was  supplemented  with 
ascorbic  acid,  (3-glycerophosphate  and  dexamethasone  (Methods:  Section
2.1.4).  The  extent  of  MSC  differentiation  to  osteocytes  was  assessed  by 
alizarin  red  staining  for  calcium  deposition  and  staining  for  alkaline 
phosphatase  activity.  These  histological  stains  were  best viewed  with  the 
naked  eye  and  images  of the  whole  wells  are  presented  in  Figure  3.5.A. 
Alizarin  red  staining  indicated  that  only  MSC  exposed  to  the  osteogenic 
differentiation-inducing  reagents  deposited  significant  amounts  of calcium. 
Alkaline phosphatase activity showed a characteristic deep purple staining, 
which was seen in the differentiated cells, while the cells kept in the regular 
MSC  media  remained  unstained.  When  observed  under  the  microscope, 
morphological changes were also obvious in the cells that have undergone 
osteogenesis  (Figure 3.5.B).  While the  undifferentiated  MSC were spindle- 
shaped  and  formed  swirling  patterns  on  the  culture  dish,  the  osteoblasts 
appeared more rounded (Figure 3.5.B inset).
Adipogenesis was induced by the addition of isobutyl methyl xanthine 
(IBMX),  indomethacin,  insulin  and  dexamethasone  (used  at  a  higher 
concentration than for osteogenesis) (Methods: Section 2.1.5). Adipogenesis 
was assessed using oil red O that stains lipids red (Figure 3.5.B). By day 2 
of adipogenic differentiation, the MSC changed morphology from a spindled 
to a more rounded appearance and began to acquire the characteristic lipid 
droplets in the cytoplasm that were stained with oil red O (data not shown). 
The cells continued to accumulate lipid throughout culture with the size and 
the number of the droplets increasing, culminating in an overall increase in 
the size of the individual adipocytes (Figure 3.5.B inset).
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Figure 3.5: Osteogenic and adipogenic differentiation of MSC. A)  Scanned 
images  of  12-well  plates  with  MSC  undergoing  osteogenesis.  B) 
Photomicrographs  of undifferentiated  MSC  and  those  that  have  undergone 
osteogenesis and adipogenesis, with higher magnifications inset.
813.4 POTENTIAL OF MSC TO DIFFERENTIATE TOWARDS
CHONDROGENIC CELL FATES
MSC  require  two factors  in  order to  differentiate  into  chondrocytes: 
the first is very close cell to cell contact and the second is the differentiation 
inducing chemical signals. The close contact between cells was achieved by 
centrifuging  the  cells  into  a  pellet,  so  that  they  grew  in  a  3-dimensional 
structure  rather  than  a  monolayer.  The  differentiation  media  was 
supplemented  with  ascorbic  acid,  dexamethasone  and  the  chondrogenic 
cytokines  BMP6  and  TGFp3  (170)  (Methods:  Section  2.1.6).  By  day  1   of 
chondrogenic  culture  the  pelleted  cells formed  a  flat  disc  and  adhered  to 
each  other  but  not  the  sides  of  the  tube  they  were  cultured  in.  As 
chondrogenesis proceeded, the discs became more spherical in shape until 
becoming  fully  rounded.  From  day  6  onwards  the  chondrocyte  spheres 
began  to  increase  in  size,  tripling  their  diameter  by  day  21  in  culture. 
Regardless of the media composition, the MSC adhered to each other and 
formed  spheres,  but  the  size  increase  was  only  seen  in  those  cultures 
supplemented  with  differentiation  media.  The  chondrogenic  pellets  also 
changed  appearance  and  became  slightly  clear  and  hard  to  the  touch 
(Figure 3.6.A).  Chondrogenesis was normally allowed to  proceed for 14 to 
21  days  after which  the  pellets  were  dehydrated,  embedded  in  wax  and 
sectioned  (Methods:  Section  2.1.7).  The  10pm  sections were  stained  with 
the  toluidine  blue  dye  that  stains  nucleic  acids  blue  and  proteoglycans 
purple.
At  the  microscopic  level  the  changes  taking  place  during 
chondrogenesis could be observed more closely. The previously mentioned 
increase  in  pellet  size  was  found  to  be  due  to  the  production  and 
accumulation  of  the  chondrogenic  matrix  that  was  visualized  by  purple 
toluidine blue staining (Figure 3.6.B). By day 8 of the chondrogenic culture, 
some  matrix  accumulation  was  apparent  and  this  coincided  with  the 
observed  size  increase  of  the  pellets  at  this  time.  Matrix  production
82continued  and  much  greater proteoglycan  deposition  could  be  observed  by 
day  12.  There  were  areas  within  the  pellet  that  showed  increased  matrix 
accumulation  as  chondrogenesis  appeared  to  begin  at  multiple  sites.  In 
addition,  by day 12, changes in the cell morphology could be observed: as a 
typical  chondrogenic  ‘rounding’  of  previously  spindle  shaped  cells  and  a 
development of lacunae around the main body of the cells was observed.  In 
many cultures there was  also a  layer of flattened  cells  around the  edge  of 
the  pellet which  remained  spindle  shaped,  and  it has  been  speculated that 
these cells may be an in vitro version of the perichondrium (18).  Palmer et al 
found these cells to express collagen 1   at higher levels than the remainder of 
the pellet (111). Finally, by day 15 the sections resembled true cartilage with 
a  high  ratio of matrix to cells, and a large number of rounded cells  present, 
some beginning to enlarge and appear hypertrophic.
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83Figure  3.6:  Chondrogenic  differentiation  of  MSC.  A)  Photomicrographs  of 
pelleted  MSC  in  media without any cytokines added  (undifferentiated) and 
with  cytokines  (differentiated).  B)  Toluidine  blue-stained  sections  of 
differentiating pellets. Cells within lacunae are marked with an arrow.
3.4.1  Donor variation of chondrogenic potential
Of  all  the  MSC  in  vitro  differentiation  model  systems,  MSC 
differentiation into cartilage is the most sensitive to passage number with the 
chondrogenic  potential,  as  measured  by  matrix  accumulation,  already 
diminishing after passage 6 (27).  As MSC rates of proliferation were found 
to vary between different donors’ MSC (Section 3.2), the variability between 
their  chondrogenic  potentials  was  also  tested.  The  MSC  derived  from 
different donors were ail induced to differentiate at the 5th passage (p5). The 
extent  of  chondrogenesis  was  assessed  by  graticule  eye-piece 
measurements of pellet diameters between days 7 and 14 of the culture, as 
well as by toluidine blue staining of sections of the final  14 day pellets. The 
effect of BMP6 addition to cultures was also tested on a range of MSC lines. 
This is the first time that a detailed examination of MSC donor variability in 
chondrogenesis has been reported.
Significant  differences  were  observed  in  pellet  diameters  between 
different  donors  (Figure  3.7).  MSC  derived  from  the  46F  and  55F  donor 
showed  no  size  increase  and  may  have  required  longer  exposure  to  the 
chondrogenic media. The 24M and 38M MSC showed the highest levels of 
differentiation,  with  the  diameters  of the  pellets  increasing  by  -35%  and 
-55% respectively by day 14. The results for chondrogenesis correlate with 
the results for the growth curves presented above  (Section  3.2) with the 2 
MSC  lines  that  proliferate  the  fastest  also  producing  the  most  cartilage 
matrix.
A size  increase was still observed for the 24M  and the 38M  pellets 
even in the absence of BMP6 but this was much less dramatic, being -15% 
for  both  by  day  14.  The  omission  of  BMP6  from  the  media  produced  no
84effect on the cells that did not respond to the chondrogenic stimulus such as 
the  46F  and  55F.  Therefore,  BMP6  addition  significantly  enhanced 
chondrogenesis,  but  only  in  those  MSC  that  respond  positively  to  the 
chondrogenic stimulus in the first place.
A
□   d a y   7
□ day  11 
■ day 14 0.8
0.6
0.4
0.2
n24M 38 M 24 M 46 F 55F
B
1.8
2 4 M   n24M  38M  46F  55F
Figure  3.7:  Pellet  size  increase  during  chondrogenesis.  Chondrogenesis 
was performed on 5 different MSC lines and the pellet diameters measured. 
A)  Pellets grown under regular chondrogenic conditions.  B) Pellets grown  in 
the absence of BMP6.
85Histological  examination  of the  day  14  pellets  further  illustrates  the 
differences in chondrogenic potential (Figure 3.8). The size of the pellets in 
this figure was not necessarily representative of the actual diameter size as it 
was very difficult to section the spheres at their equator, so the images are 
useful  as  comparisons  of the  cell  morphology  between  pellets.  Areas  of 
matrix accumulation and cell rounding were seen in all pellets. The 24M and 
38M pellets cultured in the presence of BMP6, showed typical chondrogenic 
morphology throughout the pellet, with large amounts of the purple stained 
chondrogenic matrix and rounded cells set within lacunae. The n24M  pellet 
grown  with  BMP6  showed  some  matrix  accumulation  but  also  an  area  of 
undifferentiated  cells  in  the  middle  of the  pellet.  The 46F  and  55F  pellets 
showed some matrix staining but this is much paler with only the occasional 
cell that appeared  rounded.  In accordance with the pellet diameter results, 
the  pellets  grown  in  the  absence  of BMP6  showed  less  matrix  production 
and  an  area  of undifferentiated  cells  was  often  seen  in  the  centre  of the 
pellets.
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87Figure 3.8: Toluidine blue-stained sections of chondrogenic pellets,  14 days 
after the  start of the  differentiation.  The  pellets were  grown  from  different 
donors’  MSC  under regular chondrogenic  conditions  or  in  the  absence  of 
BMP6. Inset are higher magnifications of cartilaginous areas.
3.4.2 The effect of lower oxygen tension on chondrogenic differentiation
As  lower oxygen  levels are  known to  induce  higher levels of matrix 
production  in  other  model  systems  (Section  1.2.6),  the  effect  of  inducing 
chondrogenesis in MSC at 3% oxygen was tested (Methods: Section 2.1.6). 
Pellets grown  in a  hypoxic chamber at 3% oxygen were larger in size and 
showed  more  matrix  deposition  than  those  grown  at  21%  (Figure  3.9.A). 
While a small area of undifferentiated cells was seen at 21% oxygen, all the 
areas of the pellet grown at 3% oxygen appeared differentiated and showed 
matrix production,  however, the  morphology of the chondrocytes produced 
did not change (Figure 3.9.A inset).  In addition, the layer of spindle-shaped 
cells surrounding the pellet, seen in the cultures grown at 21% oxygen, was 
absent in the hypoxic cultures. This might suggest that the external layer is 
actually  inhibited  from  undergoing  chondrogenesis  by  the  high  oxygen 
tension and only the cells further inside the pellet, where the oxygen levels 
may be somewhat lower, undergo differentiation.
Because of its strong chondrogenic effect, the ability of lower oxygen 
tension  to  compensate  for the  removal  of TGF(33  and  BMP6  was  tested 
(Figure 3.9). The removal of both TGF{33 and BMP6 from the media led to a 
complete  lack  of  matrix  deposition  regardless  of  oxygen  concentration. 
When only BMP6 but no TGF(33 was added, some staining for proteoglycans 
was  seen,  but  it  was  more  intense  in  the  pellet  grown  at  3%  oxygen. 
Cultures where only TGFp3 but no BMP6 was added, showed considerable 
matrix production, which was enhanced  by lower oxygen levels. Therefore, 
lower oxygen tension did not compensate for the lack of BMP6 and TGF(53 
cytokines but the two seemed to act in synergy to enhance the production of 
the cartilage matrix.A [02] 21% [02]  3%
B [ 02 ]  21% [02]  3%
\
Figure 3.9: Toluidine blue-stained sections of cartilage pellets. A) The effect 
of varying [O2] on chondrogenic differentiation.  B) The effect of varying [O2] 
and removal of cytokines on chondrogenic differentiation.
893.5  RT-PCR  ANALYSIS  OF  MOLECULAR  EVENTS  DURING  MSC 
DIFFERENTIATION
Besides  the  histological  stains  used  to  determine  the  extent  of 
differentiation  above,  RT-PCR  analysis  was  also  performed  to  check  if 
appropriate  markers  for each  lineage  were  expressed  (Methods:  Sections 
2.1.9  -  2.1.12).  Collagen  1   and  osteocalcin  were  chosen  as  genes 
representative of the osteogenic lineage, aP2 as a marker of the adipogenic 
lineage,  collagen  2  as  a  marker  of  chondrogenesis  and  GAPDH  as  the 
control.  RNA  was  isolated  from  undifferentiated  MSC,  MSC  differentiated 
towards each  of the  3 lineages and embryoid  bodies  made from  ES cells, 
that were used as a positive control. The RNA was reverse transcribed into 
cDNA and used as a template for the PCR reactions.
The GAPDH control was expressed equally in all the samples (Figure 
3.10).  Collagen 2 was detected  in the  RNA from MSC that had  undergone 
chondrogenic differentiation  and  in the  embryoid  body  RNA,  where  it was 
expressed at a lower level.  The adipogenic marker aP2 was expressed  by 
MSC that had undergone adipogenic differentiation and at lower levels in the 
MSC  that  had  undergone  chondrogenic  differentiation.  The  expression  of 
osteogenic  markers  was  found  to  be  less  specific  and  collagen  1   was 
detected  in  all  samples.  Collagen  1   was  expressed  at  lower  levels  by 
undifferentiated MSC, embryoid bodies and adipocytes and at comparatively 
higher levels in the osteogenic and chondrogenic cells. Similarly, osteocalcin 
expression  was  seen  in  all  the  samples  tested,  except  the  MSC-derived 
adipocytes.
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Figure  3.10:  Gel  electrophoresis  showing  RT-PCR  analysis  of  the 
expression  of osteogenic,  chondrogenic and  adipogenic lineage  markers in 
undifferentiated  MSC  (1),  embryoid  body  (2),  osteogenic  MSC  (3), 
chondrogenic MSC (4) and adipogenic MSC (5) cDNA.
To  examine  the  molecular  progression  of  MSC  chondrogenesis,  a 
selection  of chondrogenic genes was tested  for expression  using  RT-PCR 
analysis  (Methods:  Section  2.1.9  -   2.1.12).  RNA  was  isolated  from 
differentiating MSC every day for the first week of differentiation and then at 
the 2 and 3 week time points. The genes tested for expression included the 
matrix  proteins:  collagens  2  and  10,  aggrecan  and  link,  the  transcription 
factors: Sox 5, 6 and 9 and the BMPs (Figure 3.11).
The  expression  of  many  regulatory  molecules  involved  in 
chondrogenesis, when assessed using RT-PCR analysis, remained constant 
throughout the  differentiation.  BMP2  and  6,  as  well  as  Sox9  were  already 
expressed  by  the  undifferentiated  MSC,  and  their  expression  continued 
throughout the differentiation. This was  in contrast to the  matrix molecules, 
which  were  upregulated  as  chondrogenesis  proceeded.  All  the  ECM 
molecules tested showed the highest levels of expression at the 14 day time 
point.  The  14  day  time  point  was  the  only  time  when  the  expression  of 
aggrecan was detected. Collagen 10 and link transcript showed low levels of 
expression  up  to  7  days,  upregulated  at  14  days  and  then  somewhat
91downregulated again by the 21 day time point. Collagen 2, the main cartilage 
collagen, showed low levels of expression at 2 days, but was downregulated 
at days 3 and 4. Day 5 showed another increase in collagen 2 levels, which 
persisted through days 6 and 7 and reached a peak at day  14.  Collagen 2 
expression was still  high at day 21  when the time course was terminated. 
COMP was the earliest ECM gene to be detected,  and was upregulated at 
day 1, with its expression levels increasing throughout the time course until 
day  14.  The  Sox6  transcription  factor  was  upregulated  at  day  5,  the 
expression  peaked  at day  14,  but was  no  longer detected  in  the  day  21 
sample.  Sox5  was  upregulated  earlier,  at  day  2,  although  a  low  level  of 
expression  may  have  been  present  at  day  1   as  well,  after  which  it  was 
expressed  throughout  the  time  course.  PTHrP  was  present  in  the 
undifferentiated  MSC  and throughout the time  course  but its  receptor was 
expressed at low levels at day 2 and  higher levels after day 7,  reaching a 
peak at 14 days.
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Figure  3.11:  Gel  electrophoresis  showing  RT-PCR  analysis  of  the 
expression  of  genes  reported  to  be  involved  in  cartilage  development 
throughout the chondrogenic differentiation of MSC.
933.6  COMPARISON  OF  THE  CHONDROGENIC  POTENITIAL  OF  NHAC 
AND MSC
Cells labelled as ‘normal human articular chondrocytes’ (NHAC) were 
purchased from Cambrex. These cells had been isolated from human knee 
cartilage  and  were  differentiated  chondrocytes  when  placed  into  culture. 
When  grown  in  the  absence  of  chondrogenic  stimuli,  the  cells 
dedifferentiated  and  lost  their  chondrogenic  phenotype,  such  as  the 
expression  of  matrix  molecules,  within  2  or  3  passages.  It  is  in  this 
undifferentiated state that the cells were received. These cells were sold on 
the  premise  that  they  could  be  expanded  and  redifferentiated  under  the 
appropriate conditions (171).
When  cultured  in  a  monolayer  the  NHAC  were  similar  to  MSC  in 
appearance.  The  NHAC  were  spindle-shaped  when  they  were  seeded 
sparsely on  a  plate,  but  as the  cell  cultures  approached  confluency,  they 
adopted  a  more  polygonal  shape  (Figure  3.12)(Methods:  Section  2.1.8). 
NHAC have a shorter proliferative lifespan than the MSC and could only be 
passaged 4 times, equating to about 15 population doublings, before growth 
arrest (171). The culture procedure is very similar to the MSC and the cells 
were split before reaching confluence, which is usually every 4 days.
Following expansion in culture, the p5 NHAC were placed under the 
same conditions for chondrogenesis as the MSC (Methods:  Section 2.1.6). 
Compared to the MSC pellets, the NHAC pellets were larger after 14 days in 
chondrogenic  media  (Figure  3.13).  The  differentiated  NHAC  also  showed 
matrix  production  throughout  the  pellet  without  displaying  any 
undifferentiated areas, and in contrast to the MSC, the cells at the outer rim 
were  chondrogenic  in  morphology.  Unlike  the  MSC  chondrocytes,  the 
differentiated  NHAC  did  not  appear  hypertrophic  or  produce  the  lacunae 
seen in the differentiating MSC.
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Figure 3.12: Photomicrographs showing MSC and NHAC morphology when 
undifferentiated  and  after  adipogenic  and  osteogenic  differentiation. 
Undifferentiated  NHAC  cultures  consist  of  a  spindle-shaped  (a)  and  a 
polygonal (b) subpopulation. Adipogenic differentiation was assessed by Oil 
red  O  staining  and  osteogenic  differentiation  by  staining  for  alkaline 
phosphatase activity.
The ability of NHAC to differentiate  in culture to other mesenchymal 
lineages  was  also  tested  (Figure  3.12).  When  grown  under  adipogenic 
conditions,  p5  NHAC  did  not  change  their  morphology  as  MSC  did  and
95showed  no lipid accumulation as assessed  by oil  red O staining (Methods: 
Section  2.1.5).  When  p5  NHAC were  placed  under osteogenic conditions, 
some changes  in the cell  morphology were seen  but only low amounts  of 
alkaline  phosphatase  activity  could  be  detected.  Therefore,  while 
undifferentiated MSC and NHAC resemble each other, the NHAC appear to 
be a more committed progenitor cell than the MSC, that is, they are capable 
of  undergoing  chondrogenesis  but  not  differentiating  into  adipocytes  or 
osteocytes.
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Figure  3.13:  Toluidine  blue-stained  sections  of  day  21  MSC  and  NHAC 
chondrogenic pellets at various magnifications. Both the MSC and the NHAC 
were at p5 at the start of the differentiation.
973.7 CONCLUSIONS AND DISCUSSION
The  main  purpose  of  these  initial  experiments  was  to  optimise 
conditions for the growth and differentiation of MSC, as well as to establish a 
chondrogenic model system in preparation for a  microarray study (Chapter 
4).  The  MSC  were  isolated  from  donor  bone  marrows  by  gradient 
centrifugation.  Bone marrow samples were available from a range of donor 
ages (24-55 years) and both genders. While the addition of bFGF affected 
MSC proliferation as in previously published data (27), the proliferation rates 
between  different donors’  MSC were found to vary  greatly.  This variability 
has  been  documented  in  previously  published  studies  (21;23).  Donor age 
has  been  suggested  as  one  of  the  potential  variables  affecting  MSC 
proliferation -  although not all studies agree on this (21 ;23). The sample size 
used in the growth curve assays presented here (section 3.2) was too small 
to  draw  any  conclusions  with  respect  to  age  or  gender  affecting  MSC 
proliferation,  but  was  a  good  representation  of  the  variability  observed 
between samples.
Following  the  successful  establishment  of  MSC  cultures,  the  next 
focus  was  on  optimising  the  conditions  for  MSC  differentiation.  Using 
previously  published  methods,  MSC  were  differentiated  into  adipocytes, 
osteocytes and chondrocytes, but were found to undergo chondrogenesis at 
various  rates  of  efficacy.  MSC  from  all  donors  could  produce  some 
chondrogenic matrix and showed changes in cell morphology but the amount 
of matrix accumulated was very variable as quantified by the size increase of 
the pellets. The same cell lines that showed the highest rates of proliferation 
also showed the  highest levels  of chondrogenic  matrix  accumulation.  This 
correlation is interesting as it indicates that there may be a link between the 
ability  of  cells  to  proliferate  and  the  extent  of  differentiation  they  can 
undergo.
In agreement with previously published data, the addition of BMP6 to 
chondrogenic cultures was found to enhance matrix accumulation (170) but
98only in those  MSC lines that were able to produce high amounts of matrix 
even  in the absence of this factor. The MSC that showed  limited ability to 
differentiate  into chondrocytes also showed  no response to the addition  of 
BMP6.  These  cells  may  have  had  a  better  response  to  stimulation  with 
higher  concentrations  of  these  cytokines,  or  may  need  a  different 
chondrogenic cocktail. A recent study suggest that a combination of TGF{32 
and IGF-I promotes chondrogenesis in MSC derived from older adults (>50 
years old) but does not attempt to compare how cells from younger donors 
respond  to the  same  stimuli  (172).  Most combinations  of TGFB and  BMP 
molecules stimulate chondrogenesis  (106;108-110;170),  but it has  recently 
been suggested by Sekiya et al that the most potent is a mix of TGFJ33 and 
BMP2 (173).  It would be of interest to know if TGF(33 and  BMP2 would  be 
effective in stimulating chondrogenesis of the less responsive MSC lines.  In 
an attempt to imitate the in vivo chondrogenic conditions, the most effective 
way  to  induce  chondrogensis  may  be  to  expose  the  cultures  to  different 
growth factors at the start of the differentiation, to induce the formation of the 
condensations, and later, to enhance matrix accumulation.
Another factor which was found to enhance chondrogenesis was the 
culture of the pellets under lower oxygen tension. Growing the pellets at 3% 
oxygen  rather  than  the  atmospheric  21%  normally  used  in  tissue  culture 
produced  larger pellets with greater extracellular matrix accumulation.  This 
inductive  effect  of  lowering  oxygen  concentration  on  chondrogenesis  has 
been  documented  previously  on  other  cell  lines,  such  as  bovine  articular 
chondrocytes but not MSC (115). As cartilage is a non-vascularised tissue, 
the  hypoxic  growth  conditions  are  in  fact  more  representative  of the  true 
environment that the in vivo chondroblasts would be exposed to. Due to the 
potent  chondrogenic  effect  of  the  lower  oxygen  conditions,  the  ability  of 
hypoxia to substitute for TGF(33 and BMP6 addition was tested.  However it 
was shown that lowering the oxygen tension could  not compensate for the 
removal of these cytokines from the differentiation media. This finding shows
99that the addition of cytokines and a hypoxic environment are not redundant, 
but instead the optimal chondrogenic differentiation conditions require both.
To  monitor  the  progress  of  MSC  chondrogenesis  and  help  in  the 
selection of time points appropriate for microarray analysis,  RT-PCRs were 
performed that examined the levels of various genes known to be involved in 
chondrogenesis.  The  RT-PCRs  validated  the  MSC  chondrogenesis  model 
system, showing that all the cartilage markers expected were expressed. By 
day  14  of the  differentiation  all  extracellular matrix  markers  expressed  by 
mature  cartilage  are  present.  MSC-derived  chondrocytes  expressed  a 
mixture of mature cartilage markers (such as collagen 2 and aggrecan) as 
well  as  markers  of  hypertrophic  cartilage  (such  as  collagen  10), 
corresponding  to the slightly  hypertrophic  morphology seen.  Chondrogenic 
markers  could  be  detected  as  early  as  day  2  of the  differentiation  even 
though morphological changes, such as the accumulation of the matrix were 
not obvious till later.
In order to investigate chondrogenesis in vitro,  models using already 
committed  chondrocytic  cells  are  more  commonly  used  than  ones  using 
multipotent progenitors such as MSC.  However, a comparison between the 
two model systems has not previously been described.  The NHAC could be 
induced to undergo chondrogenesis with the same stimuli as the MSC,  but 
the  resulting  pellets  produced  more  matrix  and  fewer  hypertrophic  cells. 
Unlike  the  MSC,  the  NHAC  did  not  differentiate  into  osteocytes  or 
adipocytes,  indicating  that  they  are  committed  to  the  chondrogenic  fate. 
Despite  their  morphological  similarity  to  the  MSC,  the  NHAC  must  have 
differences at the molecular level restricting their ability to differentiate into 
adipogenic  and  osteogenic  lineages  and  enhancing  their  chondrogenic 
ability. One way of pinpointing these changes at the transcriptional level is to 
perform  microarray  profile  comparisons  between  the  two  cell  populations. 
Therefore, microarrays can be used to address questions about differences 
between  undifferentiated  MSC  and  NHAC  as  well  as  between  the 
chondrocytes that they produce when differentiated.
100While  the  later  events  in  chondrogenic  development  are  well 
documented,  the  molecules  involved  in the early stages of commitment to 
the chondrogenic lineage  remain  unclear.  In an  attempt to elucidate these 
early  processes,  microarray  analysis  was  performed,  investigating  the 
transcriptional progression of MSC chondrogenesis and this is presented in 
the following chapter.
1014.  MICROARRAY  ANALYSIS  OF  MESENCHYMAL 
STEM CELLS UNDERGOING CHONDROGENESIS
4.1  INTRODUCTION
The  exposure  of  a  progenitor  cell  to  the  signals  inductive  of 
differentiation,  triggers  a  response  involving  transcription  factors  and 
signalling molecules that activate the expression of their downstream targets 
and lead to the cell assuming a differentiated phenotype.
In  vivo  chondrogenesis  is  known  to  be  a  dynamic  process, 
commencing with mesenchymal cells that form cartilaginous condensations 
and  then  begin  to  produce  the  chondrogenic  ECM  and  other  molecules 
associated with cartilage (Section 1.2). MSC can differentiate in vitro to form 
chondrocytes,  amongst other lineages  such  as  adipocytes and  osteocytes 
(Chapter 3).  While the  regulatory processes involved  in the formation and 
maintenance of the cartilage matrix and the consequent hypertrophy of the 
chondrogenic  cells  have  been  investigated  in  detail,  less  is  known  of the 
early  processes  involved  in  the  commitment  of the  mesenchymal  cells  to 
cartilage,  and  in  particular  the  transcription  factors  involved  in  such  a 
process.
The MSC in vitro chondrogenesis model system is well suited for the 
investigation  into  the  early  chondrogenic  events  as  it  involves  the 
differentiation of a multipotent progenitor into a cell that morphologically and 
functionally  resembles  mature  chondrocytes.  The  resulting  cartilage  from 
MSC  differentiation  is  very  similar  to  that  obtained  by  differentiating 
committed chondrocytes isolated from adult cartilage (Section 3.5).
4.1.1  Previous GEM studies into chondrogenesis
Gene expression microarray (GEM) analysis is a method appropriate 
for  examining  the  global  expression  profiles  of  cells  and  tissues  and
102comparing  normal  and  disease  states  as well  as  the  response  of cells  to 
different culture conditions, such as exposure to growth factors (Section 1.3).
A  number  of  GEM  studies  have  already  been  performed  on  MSC 
chondrogenic differentiation (Section 1.3.2). The first GEM study, performed 
by Sekiya et al validated the use of MSC as a chondrogenic model system, 
by  showing  that  MSC  that  had  undergone  chondrogenesis  expressed  all 
chondrogenic  markers  including  high  levels  of  matrix  collagens  and 
proteoglycans (113).
A more  recent study  by  James  et al attempted to  provide  a  global 
overview  of chondrogenesis  of  mouse  MSC  (132).  They  isolated  RNA  at 
different time points during the differentiation but began at day 3, thereby not 
capturing  any  earlier  events.  The  genes  that  changed  expression  levels 
during  chondrogenesis  were  also  classified  using  broad  gene  ontology 
categories,  revealing  that  many  upregulated  genes  had  roles  in  signal 
transduction, while a high proportion of the downregulated genes had roles 
related to molecular transport or transcription.
Another recent study on the chondrogenic differentiation of a mouse 
stromal cell line  investigated the effect of hypoxic growth conditions on the 
expression  profile  (133).  Hypoxic  growth  conditions  increased  the  level  of 
HIF1a in the nucleus and activated the Sox9 promoter but also induced the 
expression of metabolic and signal transducing genes.
Therefore  neither  of  these  recent  studies  described  the  global 
transcriptional  profile  in  detail.  Furthermore,  both  of  these  studies  were 
performed on mouse cell lines rather than human MSC.
4.1.2  Affymetrix HGU133A chips and data analysis
For  the  analysis  presented  here,  commercially  available 
oligonucleotide gene chips were employed.  The Affymetrix HGU133A chips 
used  contained  22,000  probe  sets  representing  14,500 genes.  Probe  sets 
comprised  11  pairs  of  sequence  probes  and  each  probe  was  25
103oligonucleotides  in  length.  The  probes  were  selected  so  that  they  are 
sequence  specific  to  their  target  gene  and  tended  to  be  located  more 
towards the 3’ end as this was likely to be better transcribed and represented 
in the biotinylated cDNA. Each probe pair consisted of a perfect match and a 
mismatch  sequence.  The  mismatch  sequence  differed  from  the  perfect 
match  by  one  base  located  in  the  middle  of the  25-mer  sequence.  The 
results from the hybridizations were obtained in the form of a signal intensity 
for each probe.
When  a  GEM  experiment  is  conducted,  a  large  amount  of data  is 
generated  and  statistical  analysis  needs  to  be  performed  to  extract 
meaningful information from this data. In order to make datasets comparable 
between different chips, a process of normalization is required and different 
algorithms are available for this. The first step is to combine the information 
from the 11  probe pair sets into an expression value for that transcript. The 
algorithm provided with the Affymetrix software and entitled microarray suite 
(MAS),  calculates  the  robust  average  (Tukey  biweight)  of the  differences 
between the perfect match and the mismatch probe.  The usefulness of the 
mismatch probe has been disputed because, in almost one third of the probe 
sets,  the  mismatch  signal  is actually  higher than  the  one  obtained  for the 
perfect match  (164). Another algorithm often  used  is the robust multi-array 
average  (RMA).  RMA  does  not  include  the  mismatch  probe  into  its 
calculation  but  instead  takes  the  robust  average  of  the  log  transformed 
difference between the perfect match and the background (164). There are 
other,  slightly different algorithms also available for data  analysis,  such  as 
dChip  but a  recent study confirmed  that of all  the  normalization  methods, 
RMA gave the  most reproducible  results when  compared  with  quantitative 
PCR (174;175).
To analyse lists of differentially expressed genes obtained from GEM 
profiling,  a  variety  of  tools  are  available.  The  data-mining  programme 
WebGestalt can  be  used for data  retrieval  of a  large  number of genes  at 
once (176). WebGestalt retrieves information including: gene ontology (177),
104tissue  expression  pattern,  chromosome  distribution,  metabolic  pathways, 
signaling pathways and protein domain information. There is also a statistics 
module  available  that  can  perform  statistical  tests,  comparing  the  list  of 
genes  of interest to  a  control  gene  list  (such  as  the  whole  of the  human 
genome,  or the  genes  present on  a  particular gene  chip)  and  suggesting 
biological  areas  that are  important  in  the  gene  set  of interest which  may 
warrant further investigation.
The WebGestalt tool  also  has  a feature that searches for the  over­
represented KEGG pathways for the group of genes of interest. KEGG is a 
manually annotated database integrating knowledge on molecular interaction 
networks, responsible for various cellular processes. KEGG provides a list of 
proteins involved  in any particular pathway as well as  maps describing the 
interaction between these proteins (www.keqq.com).
In  addition  to  using  the  WebGestalt  tool,  manual  analysis  can  be 
performed  using the following  databases:  GeneCard  (www.qenecards.org). 
OMIM (http://www.ncbi.nlm.nih.gov/Omim) and PubMed (www.pubmed.gov). 
These  databases  can  only  be  searched  for  information  on  single  genes 
rather  than  whole  gene  lists.  GeneCard  provides  information  on  gene 
expression,  orthologies,  alternative  nomenclature  and  a  brief  synopsis  of 
gene  function.  OMIM  describes  the  human  diseases  associated  with  the 
gene, and the mutations responsible for the disease phenotype.
4.1.3  Aims
Using the insight obtained from the optimisation of the chondrogenic 
model system and the RT-PCR analysis of the expression of chondrogenic 
genes (Chapter 3), a GEM experiment was set up and performed.  The aim 
of this GEM experiment was to generate reproducible data representing the 
changes in the expression profile of MSC undergoing chondrogenesis with a 
particular emphasis on the early events. This data was then analysed with
105the  objective  of  providing  a  global  overview  of  chondrogenesis  and 
identifying novel factors involved in this process.
1064.2 STATISTICAL MANIPULATION OF DATA
4.2.1  Sample preparation, hybridization and visualization of data
RNA  isolated  from  undifferentiated  MSC  and  MSC  undergoing 
chondrogenesis  was  reverse  transcribed  into  cDNA,  put  through  second 
strand  synthesis  and  then  in  vitro  transcribed  into  biotinylated  cRNA 
(Methods:  Section  2.2).  The  labelled  cRNA  was  hybridized  onto  the 
HGU133A gene chips. Due to the variability in chondrogenic potential noted 
between  the  MSC  isolated  from  different  donors  (Section  3.4.1),  this 
experiment  was  performed  in  triplicate  using  cells  isolated  from  the  24M 
donor only.  The  MSC  derived from this  donor were shown to differentiate 
well into chondrocytes (Section 3.4.1)
Microarray results were, in the first instance, obtained in the form of a 
scanned image (Figure 4.1.A). It was important to perform quality control on 
this image and check that it was free of irregularities,  such as shadows or 
scratches. As the biotinylated cRNA bound to the probes in the chip, each 
probe  appeared  as  a  spot on  this  image,  and  the  brightness  of the  spot 
varied  according  to  how  much  cRNA  has  bound.  The  intensities  of  the 
hybridized  spots  on  the  gene  chips  were  then  converted  into  numerical 
values representing the signal intensity for each probe.
Prior to normalization, the signal intensities were checked, to ensure 
that  background  signal  intensities  were  comparable  between  the  different 
chips.  This  was  done  by  producing  a  boxplot  of  log  transformed  signal 
intensities (Figure 4.1.B). The log transformation is necessary to convert the 
otherwise skewed distribution into a normal one that is easier to handle with 
statistical tools. The box plot indicates the median and the 25% boundaries 
on  either side;  hence  50%  of the  data  are  included  in  the  box  while  the 
remainder are represented by the dashed lines. Minor variation between the 
microarrays is inevitable and was corrected by normalization, but for others
107(such as sample  17 in  Figure 4.1.B) the background intensity was too high 
and such samples could not be used in the analysis.
Following the quality control, normalization was performed. The RMA 
algorithm  was  used  that  normalizes  each  probe  intensity  using  rank 
normalization (164)(Section 4.1.2). This process levels all the median signal 
intensities  as  well  as  achieving  the  same  spread  for  all  arrays,  thereby 
making them comparable.
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109Figure 4.1: Microarray data. A) A scanned image of a microarray gene chip, 
showing the signal from the biotinylated cRNA that has bound to the probes. 
The signal is visible as areas of white on the chip. A brighter signal indicates 
higher levels of expression of the mRNA specific to this probe. B) Box plots 
of all GEM analyses performed showing the distribution of signal intensities 
on the chips.  The  boxes  represent the  median  50%  of expression  values, 
with  the  dashed  lines  representing  the  rest.  The  central  line  in  the  boxes 
represents the median expression value. Sample 17 had an abnormally high 
signal  intensity  and  was  therefore  excluded  from  analysis  (Figure  4.1.B 
produced by Dr Stephen Henderson).
4.2.2  Overview of data
The  initial  aim  was  to  perform  microarrays  of  5  time  points  during 
chondrogenic differentiation of MSC, each in triplicate, to obtain statistically 
significant  results.  The  first  time  point  included  was  0  hours  (OH), 
representing  undifferentiated  MSC.  In  order to  investigate the transcription 
factors  upregulated  early  and  directly  induced  by  the  change  in  culture 
conditions,  the  next  time  point  used  was  3  hours  (3H).  From  the  results 
obtained with the  RT-PCR analysis of chondrogenesis  (Section  3.5),  the 2 
day  (2D)  time  point  was  included,  as  the  earliest  time  point  when 
chondrogenic markers could be detected. The  14 day (14D) time point was 
also included as the RT-PCR analysis  indicated that this was when all the 
matrix molecules reached their peak of expression;  hence this defined the 
transcriptional  profile  of  MSC  fully  differentiated  into  chondrocytes.  To 
decide on the best 5th sample, a single cRNA sample of a 6 hour (6H) and a 
12 hour (12H) time point were hybridized onto a chip in the first instance.
The cluster dendrogram in Figure 4.2.A shows how closely related the 
expression profiles of all time points were to one another other. As expected 
all replicates for a time point clustered together.  In addition, the 6H sample 
was found to resemble the 3H  samples very closely, tightly clustering with 
these on the dendrogram. The 3H and 6H time point are on the same branch 
as the OH MSC. The 12H sample clustered with the 2D time point, but these 
did not cluster as closely to one another as the earlier time points, as seen
110by  the  height  of the  respective  nodes.  Therefore,  the  12H  time  point  was 
more representative of an intermediate between 3H and 2D than the 6H time 
point and was repeated  in triplicate. The fully differentiated chondrocytes of 
the 14D time point are on a separate branch to the other samples, indicating 
that their expression  profile  is  most divergent to the  earlier timepoints.  The 
single  6H  sample  is  present  both  in  the  dendrogram  and  the  heatmaps 
(Figure 4.2) but was not used for any of the later statistical analysis.
Figure  4.2:  Microarray  data  analysis.  A)  Cluster  dendrogram  showing  the 
relationship  between  the  expression  profiles  of different  samples  and  time 
points. The height of the nodes is representative of the degree of difference 
between  the  two  connected  samples.  B)  Heatmap  showing  all  1,394 
significantly  changing  probe  sets  as  ordered  by  hierarchical  clustering 
(Figure produced by Dr Stephen Henderson).
Multi-dimensional  scaling  (MDS)  is  another  way  to  demonstrate 
graphically  the  overall  similarities  and  differences  seen  between  different 
arrays.  MDS  summarizes  the  data  obtained,  and  rearranges  it  in  a  given
111number  of  dimensions.  For  microarray  data  this  involves  combining  the 
values for the 22,000 probe sets present on a chip into 2 or 3 values that can 
be  mapped  onto  a  plot.  The  MDS  plot  in  Figure  4.3  shows  the  same 
distribution  of  phases  of  chondrogenesis  as  seen  with  the  dendrogram. 
Again,  the  replicates  from  the  same  time  point  cluster  together.  The  OH 
(MSC) and 3H samples cluster closely together with the 12H and 2D sample 
forming a separate group. The final time point (14D) forms a distinct group 
that is most divergent from any of the others and therefore further away on 
the MDS plot.
Overall,  3  phases  of  chondrogenic  differentiation  were  seen.  The 
earliest  phase  was  represented  by  the  3H  samples  as  these  formed  a 
distinct,  but  closely  related,  group  to  the  OH  samples.  The  next  phase 
included the 12H and 2D samples. At these time points the expression levels 
of many genes were different from the 0H/3H group  but were also distinct 
from the final 14D profile, which was in itself a distinct phase.
112Figure 4.3: Multi-dimensional scaling  plot showing the relationship between 
the  different  time  points  of  MSC  undergoing  chondrogenesis  (figure 
produced by Dr Matthew Trotter).
4.2.3  Identifying differentially expressed genes
The  relevance  of  the  different  time  points  lay  in  the  particular 
transcripts  that  change  from  one  time  point  to  the  next.  A  moderated 
standard deviation test was performed on the normalized data to obtain lists 
of most significantly changing genes from  OH  to 3H,  3H to  12H,  12H to 2D 
and 2D to 14D. The p-value obtained was adjusted for multiple testing using 
the false discovery rate thus producing the q value (178).  It was particularly 
important  to  take  the  false  discovery  rate  into  account  due  to  the  large 
amounts  of  data  obtained  from  microarray  analysis  and  the  multiple 
hypotheses  being  tested,  as  opposed  to  testing  the  expression  levels  for
113each  gene separately  (178).  In  such  cases the  p-values were  likely to  be 
inaccurate and produce many false positives, hence the tests used needed 
to be adjusted.
An  initial  significance  cut-off  was  placed  at  q<0.01.  This  cut-off 
generated  a  list  of  375  probe  sets  with  expression  values  that  change 
significantly  between  OH  and  3H.  However,  using  this  cut-off,  probe  lists 
generated for the later time  points were too long for further analysis to  be 
performed  on  them.  Therefore,  only  the  top  500  most  significantly 
differentially  expressed  genes  were  chosen  for  analysis  of  the  changes 
between the later timepoints.  Between the 3H  and  12H time point,  the top 
500 most significantly changing genes had a q value < 0.0003. The top 500 
genes were also chosen for the  12H to 2D step and 2D to  14D step giving 
q<0.0005  and  q  <  0.0000015,  respectively.  As  some  of these  probe  sets 
changed significantly in more then one of the steps, when combined, the q- 
value test generated  a  list of  1,394  probe  sets,  equalling  1,109  genes  as 
some genes were represented by more than one  probe set. The full list of 
the  1,394  probe  sets  is  provided  in  a  digital  format  on  a  CD-ROM  in 
supplementary data (Section 9).
To  get  an  overall  visual  impression  of  the  expressional  changes 
occurring  to  these  probe  sets  during  the  time  course,  a  heatmap  was 
produced  (Figure  4.2.B).  Hierarchical  clustering  was  used  to  group  these 
probe sets according to their behaviour (i.e. their expression values) across 
all  the  chips  examined.  Hierarchical  clustering  orders  the  expression 
patterns by similarity. The process works by first picking out the two probe 
sets  showing the  greatest similarity in terms  of gene  expression  and then 
grouping them  together to  make  a  node,  which  consequently operates  as 
one unit. This search for most similar nodes continues, until all the genes are 
connected into one node and the nodes are numbered in the order in which 
they are created. The results from the clustering are visualized in the form of 
a heat map. The mean expression value for each gene is calculated, and the 
deviation from this mean  is what is displayed on the heat map rather than
114the actual expression values. If the expression value is higher than the mean 
the field is represented by red on the heat map. If it is equal to the mean the 
field is black and if it is lower than the mean, the field is green. The more an 
expression  value  deviates  from  the  mean  the  stronger the  colour  that  is 
displayed.
1154.3 VALIDATION OF GEM DATA
The  microarray data was validated  in  a variety of ways.  Firstly,  the 
data was shown to be reproducible between the samples for the same time 
point.  The  Pearson  correlation  coefficient  is  a  measure  of  the  similarity 
between replicates; this takes into account how well the values obtained for 
each probe set correlate with one another. A Pearson correlation value of 1  
would signify that the two datasets are identical whereas a value of -1 would 
mean that the datasets are exact opposites of each other. In this dataset the 
correlation values were as follows: 0.99 for the OH time points, 0.99 for the 
3H time points, 0.99 for the 12H time points and 0.98 for the 14D time points. 
For  comparison,  previously  published  microarray  data  have  obtained 
Pearson correlation coefficients as low as 0.73 for replicates, showing that 
the data presented here is robust (179).
The  dendrogram  and  the  MDS  plot  (Figure  4.1.A  and  4.2)  also 
validated  the  microarray  data  as  all  the  timepoint  replicates  were  more 
similar to each other than to the profile at any other time point.  In addition, 
the time points cluster in a temporal order.
To see if the expression profiles obtained through the microarray data 
could be replicated by another technique, RT-PCR analysis was used. Nine 
genes  exhibiting  different  patterns  of expression  were  chosen  -   including 
genes upregulated early (HES1), upregulated late (Col2) and downregulated 
(ADAMTS1). The gene expression patterns seen using RT-PCR analysis are 
similar to those obtained with microarray analysis.  Furthermore, even some 
subtle  changes  seen  in  the  heatmaps  are  reproduced  with  the  RT-PCR 
technique (Figure 4.4).
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Figure 4.4. A) Gel electrophoresis showing  RT-PCR analysis of a selection 
of  genes  with  significantly  altered  levels  of  expression  during  MSC 
chondrogenic  differentiation.  B)  Heatmap  showing  the  GEM  expression 
patterns  for  the  genes  in  A,  selected  from  the  overall  heatmap  in  figure 
4.2.B.
As  the  microarray  analysis  replicates  were  performed  on  MSC 
isolated  from  only one  donor,  the  next step  in  the  validation  was to  check 
whether  the  same  expression  patterns  could  be  seen  in  MSC  samples 
derived from other donors. These results were confirmed using RNA isolated 
from  MSC  undergoing  chondrogenesis  of 2 further bone  marrow donors  (a 
31  year old  male  -  31M,  and  a  second  24  year old  male  sample  -  n24M) 
(Figure  4.5).  The  expression  of  6  genes  (col2,  fos,  HES1,  HEY1,  dec1, 
CTGF) was the same between different MSC lines.  D!x2 was upregulated at 
3H in all samples but the second upregulation at 2D noted in the 24M, could 
only be seen at very low levels in the 31M and not at all in the n24M. TXNIP 
was upregulated in all samples but much less dramatically in n24M and 31M
117than  in 24M.  Finally, ADAMTS1  was downregulated  in the 24M sample but, 
in the 31M sample, it was downregulated and then upregulated again, which 
produced a different expression pattern.
Overall,  the  expression  patterns  seen  between  MSC  isolated  from 
different donors were very similar and any differences noted were minor, and 
to  be  expected  due  to  the  known  variability  seen  in  MSC  growth  and 
differentiation  when  cells  are  obtained  from  different  donors  (Sections  3.2 
and 3.4.1).
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Figure  4.5:  Gel  electrophoresis  showing  RT-PCR  analysis  comparing  the 
transcript  levels  of  a  selection  of  genes  expressed  by  MSC  undergoing 
chondrogenic differentiation. The MSC were isolated from 3 different donors: 
24M (that the GEM experiments were performed on), 31M and n24M.
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1184.4  SIMILARITY  OF  GEM  DATA  TO  IN  VIVO  CARTILAGE 
DEVELOPMENT
Microarray  data  was  reproducible  between  replicates  and  robust 
when  validated  by  a  different  technique  to  measure  changes  in  gene 
expression.  Therefore the  next  issue  addressed  was whether the  MSC  in 
vitro  chondrogenesis  model  system  is  a  good  representation  of  cartilage 
development.
The  most striking confirmation that MSC form  cartilage in  vitro is in 
the  expression  of  ECM  genes.  The  change  in  expression  levels  of  ECM 
genes  during  the  time  course  are  displayed  as  a  heatmap  (Figure  4.6). 
Chitinase 3, decorin and COMP are upregulated already at 2D, showing that 
by this time point, the MSC could already be considered chondroblastic. This 
finding  confirms  the  RT-PCR  results  obtained  during  the  optimisation 
procedure  (Section  3.6).  Matrix  genes  expressed  during  the  time  course 
included  the  main  cartilage  collagens  2,  9  and  11  that form  the  cartilage 
collagen fibres, giving it its tensile strength, as well as proteoglycans such as 
aggrecan  and  cartilage  linking  protein,  responsible  for  allowing  cartilage 
compression.  Some of the upregulated matrix proteins are associated with 
mature cartilage (such as collagen 2, collagen  11  and aggrecan) but others 
are involved in the later hypertrophic stages (collagenlO and osteopontin).
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Figure 4.6:  Heatmap showing changes  in expression  levels of ECM genes 
selected from the overall heatmap in figure 4.2.B.
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2972Besides the cartilage  ECM  genes,  the  levels of expression  of other 
genes involved in the regulation of chondrogenic development also changed 
significantly  during  MSC  differentiation  (Figure  4.7)  (Section  1.2).  The 
expression  level  of Sox9,  the  main  chondrogenic transcription  factor,  was 
strongly  elevated  by  the  12  hour  time  point.  Differentially  expressed  in 
chondrogenesis (Dec1), also referred to as bHLH2, is another transcriptional 
regulator  of  chondrogenesis,  the  expression  of  which  is  significantly 
upregulated during the time course (180).
Genes which inhibit mesenchymal condensation, such as hyaluronan 
synthase, were downregulated at 3 hours,  but N-cadherin and  retinoic acid 
receptor  responder,  necessary  for  condensation  but  inhibitory  of  further 
differentiation  were  downregulated  later,  at the  2  day  time  point  (Section 
1.2.2). Fibronectin was already strongly expressed by MSC, but its receptor, 
integrin alpha 5 was upregulated at 3H and subsequently downregulated by 
14D.  Wnt5a  was  upregulated  transiently at 2D.  Consistent with  its  role  in 
delaying  hypertrophy,  Wnt5a  was  downregulated  again  before  the 
hypertrophy markers were expressed at the final time point. Prehypertrophic 
and  hypertrophic genes such as  FGFR3 and  PTHR1  were  upregulated  by 
the final 14D time point (Section 1.2.4).
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Figure 4.7:  Heatmap  showing  changes  in  expression  levels  of genes  with 
known roles in chondrogenic development selected from the overall heatmap 
in figure 4.2.B.
To study further the similarity of the gene expression  profile between 
the  final  time  point  (14D)  and  normal  cartilage,  the  expression  profiles 
obtained at OH and  14D were compared, and the  100 probe sets, where the 
expression  levels  were  most  significantly  altered,  identified  (q<0.0001).  Of 
these probe sets, 76 were expressed 4 fold or more higher in the 14D than in 
the  OH  time  point  (representing  58  genes,  as,  in  some  cases,  2  or  more 
probe  sets  represented  the  same  gene).  The  gene  list  obtained  was 
analyzed  by  the  WebGestalt  gene  ontology  tool
(http://bioinfo.vanderbilt.edu/webgestalt/ (176)). As may be expected,  genes 
encoding  proteins  located  in  the  extracellular  region  (24  genes,  p<0.0001) 
and their subset,  the extracellular matrix genes  (17 genes,  p<0.0001) were
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^enriched  when  compared  to  a  reference  set  of  all  the  genes  on  the 
HGU133A  chip.  Table  4.1  shows  the  over-represented  biological  process 
categories.  The  most  significantly  upregulated  categories  were 
developmental genes, especially those involved in skeletal development.  In 
addition,  cell  adhesion,  phosphate  transport  and  extracellular  matrix 
organization  and  biogenesis  categories were  also enriched.  When  KEGG 
pathways  were  analysed,  genes  involved  in  cell  communication,  focal 
adhesion,  and  ECM-receptor  interaction,  were  all  over-represented
(p<0.0001).
The  authors  of the  WebGestalt  tool  also  offered  their  own  lists  of 
genes for various tissue types,  comprising the enriched transcripts in each 
tissue  (176).  The  list for transcripts enriched  in  cartilage  consisted  of  101 
genes, and showed the same cellular localizations, biological processes and 
KEGG pathways over-represented as in the  14D microarray sample. These 
findings validated both the microarray findings and the MSC chondrogenesis 
model  system  in  terms  of providing  an  accurate  representation  of in  vivo 
cartilage development.
0H-14D COMPARISON
GO  CATEGORY N P value GENES
Cell Adhesion 8 0.00030 DPTOMD COMP COL11A1  COL11A2AGC1  SPP1  IBSP
Extracellular matrix organization 
and biogenesis
3 0.00060 MATN3 COL11A1  COL11A2
Phosphate transport 7 <0.0001 C1QTNF3 COL10A1  COL11A1  COL11A2 COL9A2 COL9A3 COL2A1
Development 25 <0.0001 MEF2C MATN3 KLF4 HEY1  SCRG1  PRELP COL11A1  FGFR3 COMP PTHR1 
COL10A1  IBSP PTCH SPP1  IGFBP5 COL2A1  COL9A2 COL11A2 PMP22 
ANGPTL2 IGF1  FOS PAPSS2 GPL4 PTGS2
- Organ development 16 <0.0001 MEF2C MATN3 HEY1  PRELP COL11A1  FGFR3 COMP PTHR1  COL10A1 
IBSP SPP1 COL2A1  COL9A2 COL11A2 IGF1  PAPSS2
- - Skeletal development 14 <0,D001 MATN3 PRELP COL11A1 FGFR3 COMP PTHR1 COL10A1  IBSPSPP1 
COL2A1  COL9A2 COL11A2 IGF1 SPP1
- Tissue development 4 0.00973 IBSP SPP1  KLF4 COL11A1
Sensory perception 7 0.00233 RBP4  AOC2 COL11A1  COL11A2 COL2A1  IGF1  PMP22
Table  4.1:  The  WebGestalt  results  of  significantly  over-represented 
biological  processes.  The  analysis  was  performed  on  the  gene  list 
comprising  the  most significantly  upregulated  genes  between  the  OH  and 
14D  time  points.  As  many  of  these  genes  have  multiple  names,  their 
recognized gene symbols are used.  Indented gene ontology categories are 
subsets of the category above.
1234.5  GENE  ONTOLOGY  ANALYSIS  OF  PROBE  SETS  WITH 
SIGNIFICANTLY  CHANGING  EXPRESSION  LEVELS  BETWEEN  TIME 
POINTS
To provide an overview of the transcriptional changes that occur as 
MSC  undergo chondrogenesis,  the genes  identified  as  having  significantly 
altered expression levels above could not be considered individually (Section 
4.2.4).  Instead,  a  tool  needed  to  be  used  that  could  group  these  genes 
according  to  their  characteristics.  Gene  ontology  analysis  provided  such 
groupings,  according  to the  biological  processes that the  protein  products 
are  involved  in,  their  cellular  localization  and  molecular  function.  The 
advantage of using WebGestalt over other gene ontology programmes is in 
the statistical features of WebGestalt. WebGestalt is not only able to group 
the  input  genes  by  gene  ontology  but  also  provides  statistical  values  for 
over-representation  of  genes  in  a  particular  category  as  compared  to  a 
reference set.
To perform the WebGestalt gene ontology analysis, the lists obtained 
for  the  probe  sets  with  most  significantly  changing  levels  of  expression 
between  consecutive  time  points  (Section  4.2.4)  was  further  divided  into 
those  that were  upregulated  and  those  that were  downregulated.  The full 
gene lists are provided in the supplementary data (Section 9). The number of 
probe sets and the number of genes that these represent for each time point 
is presented in Table 4.2. Gene ontology analysis was performed using the 
WebGestalt programme and the  HGU133A gene list as a  reference  list for 
comparison. The HGU133A gene chips, used for the GEM experiments, did 
not contain all the genes of the human genome, it was therefore important to 
only  include  the  subset  of  human  genes  present  on  these  chips  as  the 
reference list.
The  analysis  presented  here  focuses  on  biological  processes  and 
cellular localization as molecular function was not found to be informative for 
the  purposes  of this  study.  Significantly over-represented  categories  were 
chosen using the hypergeometric test and a cut-off of 2.5% of genes from
124the gene list was set in order to exclude categories with only 2 or 3 genes. 
The cut-off p-value chosen was p<0.01.
Category Number of probe sets Number of genes
0H-3H Upregulated 246 164
0H-3H Downregulated 129 87
3H-12H Upregulated 229 146
3H-12H Downregulated 271 205
12H-2D Upregulated 292 203
12H-2D Downregulated 208 136
2D-14D Upregulated 215 152
2D-14D Downregulated 285 182
Total 1394 1109
Table 4.2:  Numbers of significantly upregulated  and  downregulated  probe 
sets  between time  points and  the  number of genes that these  probe  sets 
correspond to.
4.5.1  Gene ontology analysis for biological processes
Changes in gene expression occurring between the OH and 3H time points
In order to induce MSC to undergo chondrogenesis they were placed 
in differentiation media and grown in pellet cultures. The cytokines added to 
the media as well as the close cell to cell  contact induced  changes at the 
transcriptional  level  that  eventually  led  to  the  MSC  differentiating  into 
cartilage.
Between  OH  and  3H,  246  probe  sets  were  upregulated  and  these 
represent  164  genes  (Table  4.2).  A  surprising  number  of  gene  ontology 
categories were enriched within this group (Table 4.3).  However, the  most 
significantly over-represented categories were those related to transcription 
and development. As this is the first step of MSC towards chondrogenesis, 
the  over-representation  of  these  categories  was  not  surprising.  The 
upregulated  transcription  factors  may  well  be  the  key  players  in  initiating 
chondrogenesis.  Among  the  upregulated  transcription  factors  are  genes
125already implicated in chondrogenesis such as BHLH2 (also known as DEC1) 
(180),  Runxl  (181),  Dlx5  (182)  and  Gli2  (183).  Id1,  3  and  4  are  all  also 
upregulated at this time point. Their expression has previously been noted in 
cartilage but their roles in chondrogenesis have  not been elucidated (184). 
The function of Id  proteins is generally to prevent premature differentiation 
and  it  is  probable  that  they  play  such  a  role  in  chondrogenesis  through 
inhibiting  the  action  of subsets  of transcription  factors  upregulated  at this 
stage (185).
The main targets of Notch signalling, HES1  and HEY1 were also both 
upregulated at this early stage. Notch signalling is known to play a part in the 
cell  fate  commitment  and  differentiation  in  many  tissues  and  has  been 
implicated in chondrogenesis (186). In addition, Notch signalling is reliant on 
cell to cell  interaction that is also a necessary factor for the progression of 
chondrogenesis (187) (Section 5.1). As this is a pathway chosen for further 
analysis, it will be discussed in more detail in Chapter 5.
Nineteen  of  the  genes  present  in  the  group  of  transcriptional 
regulators are also known to have a role in development, so there is overlap 
between  these  two  categories.  Signal  transduction  is  another  enriched 
category and includes members of the MAPK cascade, known to be involved 
in the early stages of chondrogenesis (188).
The  enriched  categories  among  the  87  downregulated  genes  also 
included  transcription  and  development  (Table  4.4).  Many  of  the 
downregulated  transcription  factors  are  known  to  be  involved  in 
differentiation  into  other lineages  such  as  neural  (e.g.  BDNF,  HoxA1  and 
ENC), adipogenic (NR2F2) and myogenic (MEOX2).
1260H-3H UPREGULATED
GO  CATEGORY N P value GENES
Response to stress 26 0.00110 ADORA2B ANGPTL4 BCL6 CD9 CEBPB DUSP1  EGFR ELN F2RL1  F3 
GADD45B HRH1  IFNGR1  IL11  IL1R1  INHBA MAP3K4 NFKBIA NR4A2 POLS 
PTGS2 REV3L SERPINE1  SMAD7 SNN VEGF
- Response to wounding 12 0.00950 ADORA2B BCL6 CD9 CEBPB F2RL1  F3 HRH1  IL11  IL1R1  INHBA PTGS2 
SERPINE1
Response to external stimulus 19 0.00560 ADORA2B ANGPTL4 BCL6 CD9 CEBPB F2RL1  F3 HRH1  IFNGR1  IL11 IL1R1 
INHBA NFKBIA NR4A2 PTGS2 SERPINE1  STC1  STC2 VEGF
Transcription 48 <0.0001 BCL6 BCOR BHLHB2 BTAF1  BTG1  CEBPB DLX2 DLX5 ELF1 EPAS1 ERF 
FOSB FOX03A GABPB2 GLI2 HES1  HEY1  ID1  ID3 ID4 JARID2 JUNB KLF13 
KLF4 KLF9 MAFF MEF2A NFATC1  NFIL3 NR4A1  NR4A2 NR4A3 PER1  PER2 
RORA RUNX1  RYBP SAP30 SEC14L2 SMAD7 SNAI2 SPEN TBX2 THRAP1 
TLE3 TSC22D3 VGLL4 2NF189
Cell communication 59 0.00722 ADORA2B ANGPTL4 BMPR2 CD9 CRYAB DNMBP DUSP4 EDNRA EGFR 
EPAS1  F2RL1  GADD45B GEM GLI2 HMOX1  HRH1  IFNGR1  111 1   IL1R1 
INHBA ITGA5 JAG1  JAK1  MAP3K2 MAP3K4 MTSS1  MYO10 NEDD9 NFKBIA 
NMB NR4A1  NR4A2 PBEF1  PER1  PER2 PGF PIK3R3 RAB20 RAB31  RGS2 
RGS3 RHOB RORA RRAD SHB SMAD7 SNF1LK SOCS2 SPEN SPRY4 STC1 
STC2 STK24 THRAP1 TLE3 TNFAIP3 TRAF3IP2 TRIO VEGF
- Signal transduction 56 0.00011 ADORA2B BMPR2 CRYAB DNMBP DUSP4 EDNRA EGFR EPAS1  F2RL1 
GADD45B GEM GLI2HMOX1  HRH1  IFNGR1  IL1R1 INHBA ITGA5 JAG1  JAK1 
MAP3K2 MAP3K4 MTSS1  MYO10 NEDD9 NFKBIA NMB NR4A1  NR4A2 
PBEF1  PER1  PER2 PGF PIK3R3 RAB20 RAB31 RGS2 RGS3 RHOB RORA 
RRAD SHB SMAD7 SNF1LK SOCS2 SPEN SPRY4 STC1 STC2 STK24 
THRAP1 TLE3 TNFAIP3 TRAF3IP2 TRIO VEGF
- - Intracellular signalling cascade 25 0.00277 ADORA2B DNMBP DUSP4 EDNRA EGFR GADD45B GEM HMOX1  HRH1 
JAK1  MAP3K2 MAP3K4 NFKBIA PIK3R3 RAB20 RAB31  RGS3 RHOB RRAD 
SHB SNF1LK SOCS2 THRAP1 TNFAIP3 TRAF3IP2
—  Protein kinase cascade 12 0.00403 ADORA2B DUSP4 GADD45B HMOX1 MAP3K2 MAP3K4 NFKBIA RGS3 
SNF1 LK SOCS2 TNFAIP3 TRAF3IP2
------MAPKKK cascade 6 0.00179 ADORA2B DUSP4 GADD45B MAP3K2 MAP3K4 RGS3
Positive regulation of enzyme 
activity
6 0.00336 ADORA2B BTG1 GADD45B  MAP3K2 MAP3K4 EDNRA
Apoptosis 14 0.00854 ANGPTL4 BAG3 BTG1  FOX03A GADD45B INHBA MCL1  NFKBIA NOL3 
RHOB RYBP SOCS2 TNFAIP3 VEGF
- Negative regulation of apoptosis 7 0.00153 ANGPTL4 BAG3 MCL1 NOL3 SOCS2TNFAIP3 VEGF
Development 45 <0.0001 ADARB1  ANGPTL4 BMPR2 BTG1  CD9 DLX2 DLX5 EGFR ELN EMP1 EPAS1 
FABP5 FOSB GADD45B GLI2 HES1 HEY1  ID1  ID3 IL11  INHBA JAG1 JARID2 
KLF MCL1  MEF2 MTSS1 NDRG1  NEDD9 PGF PTDSR PTGS2 RHOB RUNX1 
SEMA4C SLC3A2 SNAI1  SNAI2 SNF1 LK SOCS2 SPRY4 SYNE1 TBX2 TLE3 
VEGF
- Cell differentiation 20 <0.0001 ANGPTL4 BTG1  CD9 EPAS1  GADD45B IL11   INHBA JAG1  KLF4MCL1 
NDRG1  PGF PTDSR PTGS2 RHOB SEMA4C  SNF1LK SOCS2 SYNE1 VEGF
- Nervous system development 14 0.00460 ADARB1  CD9 DLX2 DLX5 HES1  HEY1  INHBA JAG1  JARID2 MTSS1  SEMA4C 
SNAI1  SOCS2 VEGF
- Morphogenesis 18 0.00112 ANGPTL4 BTG1  ELN EMP1  EPAS1  GLI2 HEY1  INHBA JAG1  KLF4 MTSS1 
NEDD9 PGF RHOB SLC3A2 SOCS2TLE3 VEGF
- Organ development 20 0.00018 ANGPTL4 BMPR2 BTG1  DLX2 DLX5 EGFR ELN EPAS1  GLI2 HEY1  IL11 
INHBA JAG1  MEF2A MTSS1  PGF RHOB SNAI1 TLE3 VEGF
Table  4.3:  The  WebGestalt  results  of  significantly  over-represented 
biological  processes.  The  analysis  was  performed  on  the  gene  list 
comprising the most significantly upregulated genes between the OH and 3H 
time points. As many of these genes have multiple names, their recognized 
gene symbols are used.  Indented gene ontology categories are subsets of 
the category above.
1270H-3H DOWNREGULATED
GO  CATEGORY N P value GENES
Protein kinase cascade 7 0.00474 BCL3 CCL2 EDG2 FGF2 PLK2 RGS4 SOCS5
Cell homeostasis 6 0.00052 7XNRD1 CXCL12 EDG2TFRC BDKRB1  CCL2
Development 26 0.00081 BDNF CCL2 CDC42EP3 CYR61  DKK1  DLC1  DSCR1  ENC1  FGF2 FGF5 FZD2 
GATA6 HMGA2 HOXA1  HOXA5 HOXA9 HOXB2 ID2 KRT10 MCAM MEOX2 
PITX2 SOCS5 TNFRSF11B TWIST1  UGCG
Transcription 25 0.00101 AHR ARID5B BCL3 CEBPD CITED2 CRSP9 EGR1 GATA6 HMGA2 HOXA1 
HOXA5 HOXA9 HOXB2 ID2 IRX5 LM04 MEOX2 NR2F2 NRIP1  PITX2 RFP 
SOX4 TRFP TWIST1 ZNF238
Table  4.4:  The  WebGestalt  results  of  significantly  over-represented 
biological  processes.  The  analysis  was  performed  on  the  gene  list 
comprising the most significantly downregulated genes between the OH and 
3H  time  points.  As  many  of  these  genes  have  multiple  names,  their 
recognized gene symbols are used.
Changes in gene expression occurring between the 3H and 12H time points
Between  3  and  12  hours,  146  genes  were  upregulated  and  205 
downregulated  within  the  500  probe  sets  that  changed  expression  levels 
most significantly (Table 4.2). Genes involved in cell proliferation were over­
represented  in  both  the  upregulated  and  downregulated  category,  with 
negative regulators of proliferation being upregulated and genes involved in 
mitosis being downregulated (Table 4.5 and 4.6). Some of these genes were 
already  known  to  be  expressed  by  cartilage  -   for  example  MXI1,  which 
regulates cell  cycle through  its involvement with the Myc proteins.  MXI1  is 
expressed  in  both  mesenchymal  condensations  and  mature  chondrocytes 
(189; 190). GAS1  protein inhibits the GO to G1 transition and has been found 
to  be  expressed  in  limb  bud  chondrocytes  that  have  begun  differentiating 
(191).
Another enriched category within  the genes  upregulated  between  3 
and  12  hours  was  glycolysis.  As  chondrocytes  are  located  within  an 
anaerobic environment,  it has been reported that they are mostly glycolytic 
and  have  few  mitochondria.  Therefore,  chondrocytes  upregulate  glycolytic 
genes including the main glycolytic enzyme PGK1 (192).
Among the downregulated categories,  genes involved  in cell  motility 
were  significantly  over-represented.  Mesenchymal  stem  cells  are  mobile
128and it has been proposed that they ‘home into’ sites of injury (193). However 
as they begin to differentiate into chondrocytes, they become locked into the 
cartilaginous  matrix  and  therefore  this  could  explain  why  they  lose 
expression of the genes required for cell motility.
3H-12H UPREGULATED
GO  CATEGORY N P value GENES
G-Protein signalling 4 0.00925 EDNRA AGTR1  HRH1  PPAP2A
Cell proliferation 17 0.00703 BTG1 ZPF36L2 MXI1 MYC MADREL BCL6 GAS1  EDNRA IFI16 CDKN1B 
PPAP2A TGFB3 PMP22 MTCPI GRN IFITM1  SESN1
- Regulation of cell proliferation 10 0.00443 BTG1 MXI1  BCL6GAS1 CDKN1B PPAP2A PMP22GRN IFITM1  SESN1
- - Negative regulation of oell 
proliferation
8 0.00082 BTG1  MXI1  GAS1  CDKN1B PPAP2A PMP22 IFITM1  SESN1
Glycolysis 4 0.00440 PGK1  EN02 PGM1 ALDOC
Cell homeostasis 6 0.00710 MYC EDNRA STC1AGTR1 GLRX GPR24
- Di/ tri valent inorganic cation 
homeostasis
5 0.00775 MYC EDNRA STC1AGTR1  GPR24
Table  4.5:  The  WebGestalt  results  of  significantly  over-represented 
biological  processes.  The  analysis  was  performed  on  the  gene  list 
comprising  the  most significantly  upregulated  genes  between  the  3H  and 
12H  time  points.  As  many  of  these  genes  have  multiple  names,  their 
recognized gene symbols are used.  Indented gene ontology categories are 
subsets of the category above.
3H-12H DOWNREGULATED
GO  CATEGORY N P value GENES
Behaviour 12 0.00642 ACTR3 ANXA1 THBS1  ACSL4 TPBG HAS1 JAG1  CTGF ARPCS PPAP2B 
NRP1 TNFRSF12A
- Cell motility 11 0.00168 ACTR3 ANXA1 THBS1 TPBG HAS1  JAG1  CTGF ARPCS PPAP2B NRP1 
TNFRSF12A
Cell cycle 24 0.00074 BCAR3 C10orf7 CCND1  CCT2 DKC1  DUSP4 DUSP6 EML4 EXT1  FGF2 
GAS2L1  KPNA2 MACF1  MAPRE1  MCM5 NEDD9 PCNA PNN POLS RAN 
SNF1LK STAT1 TARDBP TUBG1
- Mitotic cell cycle 10 0.00244 CCND1 EML4 KPNA2 MAPRE1  NEDD9 POLS RAN SNF1 LK TARDBP TUBG1
RNA splicing 8 0.00464 TARDBP SFRS2 SFRS1 SFRS5 SFRS6 SFRS7 SFPQ RBM25
Positive regualtion of enzyme 
activity
6 0.00950 FGF2 CYCS CARD10 MAP2K3 NALP1  STAT1
Table  4.6:  The  WebGestalt  results  of  significantly  over-represented 
biological  processes.  The  analysis  was  performed  on  the  gene  list 
comprising the most significantly downregulated genes between the 3H and 
12H  time  points.  As  many  of  these  genes  have  multiple  names,  their 
recognized gene symbols are used.  Indented gene ontology categories are 
subsets of the category above.
129Changes in gene expression occurring between the 12H and 2D time points
Between 12 hours and 2 days, 203 genes were upregulated and 136 
downregulated  within  the  500  probe  sets  that  changed  expression  levels 
most significantly (Table 4.2). Similarly to the changes occurring between 3H 
and 12H, categories involved in cellular proliferation were over-represented, 
with many genes with roles in cell cycle arrest upregulated and mitotic genes 
downregulated.  In addition,  genes implicated  in  regulation  of differentiation 
towards other lineages, in particular muscle, were downregulated.
There were also changes in cell surface proteins, with a large number 
of  cell  communication  and  cell  adhesion  molecules  downregulated.  N- 
cadherin  (CDH2),  a  marker  of  mesenchymal  condensations,  was 
downregulated.  There was also a group of genes the expression  of which 
was downregulated at 2D and then upregulated again at the final  14D time 
point, such as CTGF and HAPLN1, which are necessary for the late phase 
of chondrogenic development.
12H-2D UPREGULATED
GO  CATEGORY N P value GENES
Cell cycle arrest 5 0 00447 CUL3 IL8 GADD45A CDKN1C KHDRBSI
Amine metabolism 14 0.00098 GNPDA1 GUSB DI02 ARG2 KYNU MAOA AOC3 ASNS PSPH UST CTH 
CHST7 CHI3L2 GLUL
Table  4.7:  The  WebGestalt  results  of  significantly  over-represented
biological  processes.  The  analysis  was  performed  on  the  gene  list 
comprising the most significantly upregulated  genes  between the  12H  and 
2D  time  points.  As  many  of  these  genes  have  multiple  names,  their 
recognized gene symbols are used.
13012H-2D DOWNREGULATED
GO  CATEGORY N P value GENES
Cell communication 49 0.00838 AD  AM 12 ADAM9 ALCAM ANGPT2 CD59 CDH2 CFL1  CIB1 COL1A2 COL8A1 
CRSP2 CSPG2 CTGF CXCL12 DIRAS3 EDNRA ENPP1  EPAS1  EPHB2 GAS6 
GEM GPR24 HAPLN1  HRH1  INHBA ITGB5 MTSS1  NGFB NID2 PLAU 
PPAP2A PRKCA PTN RGS2 SEMA3C SFRP1  SOCS2 SSX2IP STC2 STK6 
TGFB3TGM2 THBS2 TNFRSF12A TOP2A TPM1 TYMS UBE2C
- Cell adhesion 16 0.00028 ADAM12 ALCAM CDH2 CIB1  COL8A1 CSPG2 CTGF CXCL12 HAPLN1  ITGB5 
MTSS1  NID2 SSX2IP TGM2 THBS2 TNFRSF12A
- Phosphoinositide mediated 
signalling
7 <0.0001 TOP2A TYMS UBE2C EDNRA HRH1  STK6 PPAP2A
Cell cycle 23 <0.0001 ASPM BIRC5 CCNB1  CCNB2 CDC2 CENPF DIRAS3 HGF INHBA KIF2C 
MTSS1 MYC PRC1  PRKCA PSMD1  PSMD2 PTN PTTG1  RGS2 STK6 TGFB3 
TPX2 UBE2C
- Mitosis 12 <0.0001 ASPM  CCNB1 CCNB2 CDC2 CENPF HGF KIF2C PRC1  PTTG1  STK6 TPX2 
UBE2C
Organ development 14 0.00635 EPAS1  ACTA2 CALD1  COL1A2 SOX9 ADAM 12 TAGLN ANGPT2 TPM1 
MEF2C TGFB3 MTSS1  INHBA TNFRSF12A
- Muscle development 7 0.00228 ACTA2 CALD1 ADAM 12 TAGLN TPM1  MEF2C MTSS
Table  4.8:  The  WebGestalt  results  of  significantly  over-represented 
biological  processes.  The  analysis  was  performed  on  the  gene  list 
comprising the most significantly downregulated genes between the 12H and 
2D  time  points.  As  many  of  these  genes  have  multiple  names,  their 
recognized gene symbols are used.  Indented gene ontology categories are 
subsets of the category above.
Changes in gene expression occurring between the 2D and 14D time points
Between 2 days and  14 days,  152 genes were upregulated and  182 
downregulated  within  the  500  probe  sets  that  changed  expression  levels 
most significantly (Table 4.2).  Most of the  upregulated categories  involved 
genes  characteristic  of  cartilage  (Table  4.9).  As  expected,  the  most 
significantly  over-represented  category  were  genes  involved  in  skeletal 
development,  including  matrix  proteins  such  as  collagens,  matrillin  3, 
osteopontin, FGF and IGF receptors. Another upregulated category included 
genes involved in cell adhesion which are characteristic of cartilage such as 
COMP, CTGF and OMD.
Downregulated  categories  included  genes  involved  in  cell 
communication  as well  as  those  involved  in  the  immune  response  (Table 
4.10).
1312D-14D UPREGULATED
GO  CATEGORY N P value GENES
Cell adhesion 19 0.00012 ADAM22 AGC1 ALCAM CD36 COL11A1  COL11A2 COL9A1 COMP CTGF 
DPT DSG2 HAPLN1  IBSP NINJ2 OMD SPON2 SPP1 THBS1 THBS2
Amine metabolism 10 0.00713 AOC2 ASNS CHST3 IARS MARS ODC1  PSAT1  PTS SLC7A1 WARS
Development 41 <0.0001 ACTC ADAM22 ALPL ANGPTL2 CHAD COL10A1 COL11A1  COL11A2 
COL1A2 COL2A1  COL9A1  COL9A2 COMP CSPG4 CTGF FGFR2 FGFR3 
FOS GPC4 HEY1IBSP IER3 IGF1  KRT14 LECT1 MATN3 MEF2C NINJ2 
PAPSS2 PRELP PTCH PTHR1  PTS S100A1 SMPD3 SPON2 SPP1 THBS1 
VIL2 WNT11
- Morphogenesis 15 0.00626 CHAD COL9A1  COMP CSPG4 CTGF FGFR2 FGFR3 GPC4 HEY1  IER3 NINJ2 
PTCH SPON2 VIL2 WNT11
- Organ development 22 <0.0001 ACTC ALPL COL10A1  COL11A1  COL1A2 COL2A1  COL9A1  COL9A2 COMP 
CSPG4 FGFR3 HEY1  IBSP IGF1 LECT1 MATN3 MEF2C PAPSS2 PRELP 
PTHR1 SPP1
- - Skeletal development 17 <0.0001 ALPL COL10A1  COL11A1  COL11A2 COL1A2 COL2A1 COL9A2 COMP 
FGFR3 IBSP IGF1 LECT1  MATN3 PAPSS2 PRELP PTHR1  SPP1
- Tissue development 9 0.00050 ALPL COL11A1 CSPG4 CTGF IBSP KRT14 LECT1 NINJ2 SPP1
Organic acid metabolism 13 0 00225 ASNS CD36 HADHSC IARS IGF1  LPL MARS PLA2G4A PSAT1  PTS SLC27A2 
SLC7A1 WARS
Amino acid and derivative 
metabolism
9 0.00522 WARS ODC1 IARS ASNS AOC2 PTS SLC7A1  MARS PSAT1
Phosphate transport e <0.0001 C1QTNF3 COL10A1  COL11A1  COL11A2 COL1A2 COL2A1  COL9A1 COL9A2 
COL9A3
Table  4.9:  The  WebGestalt  results  of  significantly  over-represented 
biological  processes.  The  analysis  was  performed  on  the  gene  list 
comprising  the  most significantly  upregulated  genes  between  the  2D  and 
14D  time  points.  As  many  of  these  genes  have  multiple  names,  their 
recognized gene symbols are used.  Indented gene ontology categories are 
subsets of the category above.
2D-14D DOWNREGULATED
GO  CATEGORY N P value GENES
Cell communication 65 0.00909 RAB11A SDCBP PLP2 TIMP3 TXNRD1  ITGA5 MGST3 NQ01  LAMB1  IFITM1 
IGBP1  DKK3 ARL4C COPS2 IL8 ADM IL1R1 STMN2 MTSS1  GPRC5A MME 
MET HMOX1  ITPR1 MAP3K5 IGFBP6 F2R MAOA GEM CD44 STC1  LTBP2 
SRPX LAMA2 NMB AGTR1  ITGBL1  CCL20 PCSK1  ING2 MAP4K4 HMGB2 
GABARAPL1  GADD45B PGF CXCL12 RIT1  RORA AKAP12  POSTN IGFBP3 
GNG12 NRP1  SPRY1  RND3 RAC2 KHDRBS1  GLUL DIRAS3  PBEF1 JAM2 
TREM1  RAB20 ANGPTL4 RAB9A
- Small GTPase mediated signal 
transduction
9 0.00913 RAB11AARL4C GEM RIT1  RND3 RAC2 DIRAS3 RAB20 RAB9A
Response to stimulus 49 0.00012 ADM AKR1C1 ANGPTL4  APEX1  C1R C1S CCL20 CLEC2B CXCL12 DDIT3 
EFEMP1  F2R FTH1  GADD45B GBP2 GEM HLA DPA1 HLA DPB1 HLA DRA 
HLADRB1 HLAEHMGB2 IF IFI16IFITM1  IGBP1  IL1R1  IL8 KIAA1199 LTA4H 
MAP3K5 MAP4K4 MGP MGST3 NDRG1  NFIL3 NQ01  PLP2 PSMB8 PTX3 
SERPING1  SOD2STC1 TAP1 TFPI TFPI2 TIMP3 TREM1
Immune response 28 <0.0001 C1R C1S CCL20 CLEC2B CXCL12 FTH1  GBP2 GEM HLA DPA1 HLA DPB1 
HLA DRA HLADRB1 HLA E IF IFI16 IFITM1  IGBP1  IL1R1  IL8 LTA4H MGST3 
NFIL3 PSMB8 PTX3 SERPING1  SOD2TAP1 TREM1
Table  4.10:  The  WebGestalt  results  of  significantly  over-represented 
biological  processes.  The  analysis  was  performed  on  the  gene  list 
comprising the most significantly downregulated genes between the 2D and 
14D  time  points.  As  many  of  these  genes  have  multiple  names,  their 
recognized gene symbols are used.  Indented gene ontology categories are 
subsets of the category above.
1324.5.2  Gene ontology analysis for cellular localization
The  gene  ontology  categories  for  cellular  localization  were  first 
subdivided into proteins located inside and outside the cell. Within the cell, 
there were further subcategories  including the different organelles and the 
cytoplasm (Table 3.11).
Transcriptional  regulation,  signalling  and  development  were  the 
biological process categories, which were over-represented in the genes that 
changed  expression  between  0  and  3  hours  (Section  4.5.1).  When  the 
cellular localization of the protein products of these genes was considered, 
there was a significantly higher number of proteins expressed in the nucleus 
than what would be expected by chance. As the function of many of these 
proteins  is transcriptional, the over-representation  of those  localized  in the 
nucleus is not surprising.
Between the 3H and  12H time points, genes involved  in cell  motility 
were downregulated, in terms of cellular localization, this was demonstrated 
as an over-representation of cytoskeletal genes.
The changes which occurred between  12H and 2D time points were 
more  difficult  to  interpret,  but  involved  the  downregulation  of  many  cell 
communication  genes  and  consequently  extracellular  genes  were  over­
represented.
Between the 2D and  14D time  points,  the  most significant changes 
involved  the  expression  of  cartilage  matrix  molecules  and  this  was  also 
apparent  when  the  cellular  localization  of  the  upregulated  proteins  was 
examined.  In  both  the  upregulated  and  the  downregulated  gene  sets, 
extracellular genes were over-represented, and in the upregulated gene set, 
these generally consisted of extracellular matrix molecules.
133TIMEPOINT 0h-3h up 0h-3h down 3h-12h up 3h-12h down 12h-2d up 12h-2d down 2d-14d up 2d-14d down
INTRA­
CELLULAR
Nucleus 76
(p=1.695*e-0)
35
(p=0.00086)
Cytoskeleton 25
(p=0.00042)
16
(p=0.00858)
Vacuole 7
(p=0.00468)
EXTRA­
CELLULAR
25
(p=0.0024B)
42
(p<0.D001 )
30
(p=0.00213)
Matrix 12
(p=0.0Q155)
27
(p<0.0001  )
Table  4.11:  WebGestalt  results  for  over-represented  gene  ontology 
categories  for  cellular  localization  throughout  the  time  course.  For  each 
category, the number of genes is shown, as well as the significance value for 
the over-representation.
4.5.3 KEGG pathways
The  WebGestalt  programme  can  also  identify  over-represented 
KEGG  pathways  of  molecular  interactions.  A  summary  of  the  pathways 
significantly over-represented (p<0.01) in this microarray study is presented 
in Table 3.12.
The TGFIi pathway was activated by 3 hours and further upregulated 
by 12 hours. This is likely to be a response to the addition of TGF(33 to the 
chondrogenic  media.  A  consequence  of  the  upregulation  of  the  TGFIi 
pathway was the activation of the MAPK pathway by 12 hours.
A range of metabolic pathways and those involved in glycolysis were 
upregulated  by  12  hours.  Wnt  signalling,  which  is  known  to  be  an  active 
player in chondrogenesis, was upregulated by 2 days.
Finally,  by  14  days,  the  large  number  of  upregulated  extracellular 
molecules  led to  pathways such  as cellular communication,  ECM  receptor 
interaction and focal adhesion being over-represented. These are the same
134KEGG  pathways  that  are  over-represented  in  the  WebGestalt  cartilage 
expression set mentioned previously in Section 4.4.
Timepoint KEGG pathway N P value Genes
0H-3H up TGF-beta signalling 7 0 00031 SMAD7 BMPR2 RHOB INHBA ID1  ID3 ID4
Adherens junction 5 0 00732 SNAI1 SNAI2 EGFR BAIAP2 RHOB
0H-3H down No significantly overrepresented categones
3H-12H up MAPK signalling 9 0.00595 PLA2G4A MEF2C DDIT3 JUN TGFB3 IL1R1  GADD45B 
MYC FOS
Glycolysis 5 0,00152 EN02 PGK1  PGM1 ALDH2 ALDOC
TGF-beta signalling 5 0.00596 BMP2 DCN TGFB3 MYC ID2
Valine, leucine and isoleucine degradation 4 0 00399 HMGCL AUH SH3GLB1 ALDH2
Starch and sucrose metabolism 4 0.00588 PGM1  ENPP2 UGP2 GBE1
Arganine and proline metabolism 4 0.00547 SAT ARG2 ALDH2 P4HA2
Butanoate metabolism 4 0.00308 HMGCL AKR1B10SH3GLB1 ALDH2
3H-12H down Axon guidance 7 0 00970 SEMA4C MET CXCL12 EFNB2 RRAS2 NFATC1 NRP1
Proteasone 5 0 00409 PSMD6 PSMD14 PSMC2 PSMD11 PSMA3
12H-2D up Wnt signalling 9 0 00131 MMP7 DKK1 WNT5A SMAD2 F2D1  ROCK2 CCND1 
TBL1X CSNK2A1
Glycine, serine and threonine metabolism 4 0 00683 AOC3 MAOA CTH PSPH
12H-2D down Cell adhesion molecules (CAMs) 6 0.00514 CDH2 SDC1  CSPG2 ALCAM JAM3 NFASC
2D-14D up Cell communication 12 <0.0001 DSG2 KRT14 THBS2 THBS1  COMP COL11A1 COL11A2 
COL1A2 COL2A1 CHAD SPP1  IBSP
Focal adhesion 12 0.00011 CAPN6 THBS2 THBS1  COMP COL11A1  COL11A2 
COL1A2 IGF1  COL2A1 CHAD SPP1  IBSP
ECM receptor interaction 10 <0.0001 CD36THBS1 THBS2 COL11A1  COL11A2 COL1A2 
COL2A1 CHAD SPP1  IBSP
Arginine and proline metabolism 5 0 00083 ODC1 AOC2 ALDH1 A3 P4AH2 CKB
Tryptophan metabolism 5 0.00446 WARS HADHSC WBSCR22 AOC ALDH1 A3
2D-14D down Haematopoietic cell lineage 6 0.00430 MME CD44 HLA-DRA HLA-DRB1  ITGA5 IL1R1
Complement and coagulation cascades 6 0.00134 F2R SERPING1  C1S C1R TFPI CFI
Table  4.12:  WebGestalt  results  for  significantly  over-represented  KEGG 
pathways throughout the time  course  of MSC  undergoing  chondrogenesis 
(N=number of genes).
1354.6 MANUAL ANNOTATION OF MICROARRAY DATA
Gene ontology analysis was useful  in  providing a global overview of 
the processes occurring in chondrogenesis but for more in-depth analysis of 
the function  of each  gene,  manual  analysis was  performed.  All  the  genes 
found to change  expression  were  annotated  using  OMIM  and  Gene  Card 
searches in the first instance, in order to get an impression of their function. 
Consequently  a  search  for  publications  was  performed  for  each  gene 
through  PubMed, to check if any reference implicating the gene in skeletal 
development  or  differentiation  could  be  found  and  to  obtain  a  better 
understanding of the gene function.  Some novel  patterns emerged through 
this manual analysis, such as an over-representation of genes regulated by 
hypoxia.  In  addition,  a  group  of  genes  was  identified  that  would  make 
potentially  interesting  targets  for  further  examination  of  their  role  in 
chondrogenesis.
4.6.1  Hypoxic genes in chondrogenesis
Many  of the  genes  that  significantly  changed  expression  as  MSC 
were undergoing chondrogenesis are regulated by low oxygen levels (Figure 
4.8).  From  the  in  vitro  studies,  it was  clear that  oxygen  tension  affected 
chondrogenesis  because lower oxygen  levels induced  matrix accumulation 
and differentiation (Section 3.4.2).
Included  in  the  hypoxia-responsive  genes  are  VEGF,  DEC1,  PGF, 
ANGPTL4,  HOX1,  STC1,  TIMP3,  ITGA5,  ADORA2B,  JUNB,  SHB  and  F3 
(Figure 4.8).  This group of genes were  all  upregulated  at 3H  and  mostly 
downregulated either by 2D or 14D. The genes include some that are known 
to play a part in chondrogenesis such as DEC1  and STC1 -  both present in 
the earliest stages of mesenchymal condensations (180) (194) and  ITGA5, 
the  fibronectin  receptor,  but  also  genes  not  previously  implicated  in 
chondrogenesis such as ADORA2B.
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Figure 4.8: A selection of hypoxia responsive genes, the expression  levels 
of which changed significantly as MSC underwent chondrogenesis, selected 
from the overall heatmap in figure 4.2.B
4.6.2  Interesting candidate genes for future investigation
Genes  identified  in  this  study,  that  have  not  been  implicated  in 
chondrogenesis  but may be of interest for further study are  summarized  in 
Table 4.13. These genes have been selected as remarkable for a variety of 
reasons (Table 4.13).
The N-myc downstream regulated gene  1   (NDRG1) is involved in cell 
cycle arrest and differentiation of epithelial cells (195).  Mutations in  NDRG1 
have  been  associated  with  Charcot-Marie-Tooth  disease  (OMIM:  601455), 
the symptoms of which include hand and foot deformities as well as muscle 
weakness  and  atrophy,  making  it  a  possible  candidate  for  involvement  in
137MSC  differentiation.  NDRG1  is  also  highly  upregulated  under  low  oxygen 
conditions (196).
DNA damage-inducible transcript 3  (DDIT3)  is  a  dominant  negative 
inhibitor of C/EBP transcription factors, which are essential for the induction 
of  adipogenesis;  hence,  DDIT3  blocks  adipogenesis  and  induces 
osteogenesis (197).  DDIT3’s  role in chondrogenesis  is unknown  but it has 
been found to be expressed in the growth plate, which strongly suggests its 
involvement in the process (198).
Thioredoxin interacting protein (TXNIP) is another potential inhibitor of 
adipogenesis,  as  a  nonsense  mutation  in  TXNIP  leads  to  hyperlipidemia. 
Therefore, the protein  could  play a role in decreasing  lipid  levels and  may 
influence MSC differentiation away from adipogenesis (199).
Endothelin  Receptor A (ETRA)  has  been found to  be  indispensable 
for craniofacial development from neural crest cells (200). The activation of 
ETRA by Endothelin stimulates the upregulation of alkaline phosphatase and 
collagen 1  production in bone cells, and proteoglycan synthesis in monolayer 
rat  articular  chondrocytes  and  therefore  could  be  a  positive  regulator  of 
chondrogenic differentiation (201;202).
On the other hand,  emopamil  binding  protein  (EBP)  probably  has a 
role as a  negative  regulator of chondrogenesis  and  therefore  needs to  be 
downregulated for chondrogenesis to proceed. Point mutations in EBP lead 
to a dominant disorder, chondrodysplasia punctata 2,  which includes short 
stature  and  other  skeletal  abnormalities  among  its  symptoms  (OMIM: 
302960).
All 4 ID proteins showed significant changes in their expression levels 
during the time course and, as they are normally associated with regulation 
of  differentiation,  are  also  likely  candidates  for  involvement  in  MSC 
differentiation. The ID proteins have previously been found to be expressed 
in the cartilage primordia of mice (184).
Kruppel-like factor 4 (KLF4) and T-box 2(TBX2) expression has also 
been found in mouse limbs (203;204). TBX2 acts alongside BMP and Sonic
138hedgehog (SHH) signalling to specify digit identity (205). The DUSP4 gene is 
involved  in  MAPK signaling,  providing feedback control of MAPK mediated 
signaling events (206).
The  most  promising  candidates  identified  for  future  investigations 
were the  hairy and  enhancer of splitl  (HES1)  and  hairy/enhancer of split 
related with YRPW motif (HEY1) genes. These genes are targets of Notch 
signalling,  a  pathway  involved  in  differentiation  and  cell  fate  decisions  in 
many  lineages,  but  to  date  mainly  investigated  in  neural  differentiation. 
Nevertheless,  Notch  receptors  and  ligands  have  been  shown  to  be 
expressed  by  developing  cartilage  (207).  Therefore,  further  experiments 
were performed to determine the role of Notch signalling in chondrogenesis, 
and these are presented in Chapter 5.
Name Timing Interesting features
NDRG1 Up at 3H Hypoxia regulated and involved in cell cycle regulation 
and differentiation. Mutations in this gene lead to hand 
and foot deformities
DDIT3 Up at 12H down at 
14D
Role in lineage commitment. Inhibitor of adipogenesis, 
inducer of osteogensis
TXNIP Up at 12H Inhibitor of adipogenesis
Endothelin RA U{3 at 12H down at Role in craniofacial development
EBP Down at 12H Point mutations lead to a dominant disorder, including 
short stature and other skeletal abnormalities
ID proteins Up at 3H and  12H Preventing premature differentiation of cells by 
inhibiting HLH transcription factors
DUSP4 Up at 3H down at 
12H
Involved in MAPK signalling
TBX2 Up at 3H down at 
12H
Involved in mesoderm differentiation
KLF4 Up at 3H Detected in mesenchymal cells in limb bud
HES1  and HEY1 Up at 3h Notch signalling targets.
Table  4.13:  List  of  genes  identified  as  differentially  expressed  as  MSC 
undergo chondrogenesis that may be of interest for further investigation into 
their roles in cartilage development.
1394.7 NHAC MICROARRAYS
Beside the multipotent MSC, committed NHAC were also exposed to 
the  chondrogenic  stimuli  in  vitro  (Section  3.6).  Both  NHAC  and  MSC 
responded  to  the  chondrogenic  in  vitro  conditions  by  adopting  a 
chondrogenic morphology and  producing large amounts of ECM.  However, 
NHAC produced more matrix than MSC and did not show any hypertrophic 
cells that were  seen  after  MSC  underwent  chondrogenic  differentiation.  It 
was  therefore  of  interest  to  compare  the  expression  profiles  of  the 
differentiated  MSC  (14D)  and  the  differentiated  NHAC  (14D)  to  see  the 
differences in the cartilage produced by these 2 cell types. As NHAC can not 
differentiate  into  adipocytes  or osteocytes while the  MSC  can,  there  must 
also be molecular differences in the expression profiles of the two cell lines 
prior to differentiation (OH).
In  this  section,  cRNA  from  OH  and  14D  time  points  of  NHAC 
undergoing chondrogenesis was hybridized to the HGU133A gene chips. As 
with the MSC experiments, these 2 time points were performed in triplicate. 
The results obtained for these microarray experiments were then compared 
to  the  microarray  results  obtained  for  MSC  undergoing  cartilage 
differentiation presented in the previous sections (Sections 4.5 and 4.6)
As  with  the  MSC  time  course  experiment,  a  cluster  dendrogram 
(Section 4.2.3) was produced showing how the NHAC time points relate to 
the  MSC time  points  (Figure 4.9).  Overall,  NHAC  microarray  results  most 
resembled their equivalent  MSC time  point.  OH  NHAC  were  on  the  same 
branch as the OH and 3H MSC and 14D NHAC most closely resembled 14D 
MSC.
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Figure 4.9: Cluster dendrogram showing the relationship between MSC and 
NHAC samples and time points. The height of the nodes is representative of 
the degree of difference between the two connected samples.
Lists were  compiled  of the top  100  probe  sets  which  showed  most 
significantly different (q<0.01) levels of expression between OH MSC and OH 
NHAC  and  the  same  comparison  was  done  for  the  14D  MSC  and  14D 
NHAC.  This  analysis  resulted  in  54  genes  that were  expressed  at  higher 
levels  in  OH  MSC  than  in  OH  NHAC,  and  32  genes  expressed  at  higher 
levels in OH NHAC than in OH MSC. For the 14D time points, 28 genes were 
expressed  at higher levels in  14D MSC than in  14D NHAC, and 57 genes 
were  expressed  at  higher  levels  in  14D  NHAC  than  in  14D  MSC.  The 
resulting  gene  lists  were  analysed  with  WebGestalt,  using  the  biological 
processes classification in the gene ontology module (Tables 4.14-4.17).
Comparison of the two 14D time points showed that even though the 
transcription  profiles of the  14D  MSC and the  14D  NHAC  resembled  each 
other,  there  were  important  differences  between  the  two.  Most  of  the
141differences involved developmental genes and in particular genes encoding 
extracellular  matrix  proteins.  When  analysed  with  WebGestalt,  of the  28 
genes  expressed  at  higher  levels  by  the  differentiated  MSC  than  the 
differentiated NHAC,  12 were assigned a developmental  role (p<0.0001) in 
the biological process class and  10 were located in the extracellular region 
(p=0.00089)  (Table  4.16).  Most  of  these  genes  are  known  markers  of 
hypertrophic  chondrocytes  such  as  collagen  10  (COL10A1),  osteopontin 
(SPP), bone sialoprotein (IBSP), parathyroid hormone receptor (PTHR1) and 
matrillin 3 (MATN3). Of the 57 genes expressed at higher levels in the NHAC 
than  in  the  MSC,  24  were  extracellular  (p<0.0001),  and  again  mostly 
involved  matrix  proteins  such  as  collagen  21  (COL21A1),  dermatopontin 
(DPT) and matrix Gla protein (MGP) (Table 4.17). Therefore,  even though 
MSC and NHAC were exposed to the same chondrogenic media, the matrix 
of the differentiated MSC comprised both mature and hypertrophic cartilage 
matrix  molecules  while  the  NHAC  did  not  express  genes  involved  in 
hypertrophy.
The  biological  significance  of  the  different  genes  between  the  OH 
MSC  and  OH  NHAC  was  more  difficult  to  interpret.  Undifferentiated  MSC 
expressed many extracellular genes not present on the NHAC (extracellular 
region p=0.001). These included cell adhesion proteins and members of the 
MHC  class  1   and  2 family.  MSC  also  expressed  genes  involved  in  organ 
development,  among  these  2  genes  associated  with  osteoblast 
differentiation:  CDH11  and  POSTN  (p=0.00441).  NHAC  expressed  genes 
involved  with  the  mitotic  cell  cycle  (<0.0001)  and  DNA  metabolism 
(p=0.00669) at higher levels than the MSC.
142MSC OH -  NHAC OH
GO  CATEGORY N P value GENES
Cell adhesion 9 0.00036 AMIG02 CDH11 COL5A1 CXCL12 LAMB1  POSTN SRPX TGM2 THBS2
Organ development 7 0.00441 ANGT1, CD11. GATA6, GJA1. POSTN, SERPINF1. TGM2, THBS2
Response to biotic stimulus 10 0.0023 HLA-DMA. HLA-DPA1. HLA-DRA. HLA-DRB1, HLA-DRB5, CXCL12  CXCL6. 
IF, PTGES, TRIM22
- MHC class 2 5 <0.0001 HLA-DMA, HLA-DPA1. HLA-DRA. HLA-DRB1, HLA-DRB5
NHAC OH -  MSC OH
GO  CATEGORY N P value GENES
Cell cycle 7 0.00042 BIRC5, CDC20. CDC45C. GTSE1, MKI67. PLK1, PTTG1
DNA metabolism 5 0.00669 PTTG1  TYMS RRM2 CDC45L IL7R
MSC 14D -  NHAC14D
GO  CATEGORY N P value GENES
Development 12 <0 0001 COL10A1. CSRP1  DACT1. GPC4. HEY1. IBSP, IGF1, IGFBP5. MATN3, 
PTHR1. SERPINF1  SPP1
Cell proliferation 6 0.00089 CDKN1C, CSRP2  GPC4, IGF1, SERPINF1
NHAC 14D- MSC14D
GO  CATEGORY N P value GENES
Cell Adhesion 8 0.00411 CD44, COL22A1, DPT, KAL1, MFAP4, PTPNS1, THBS3, TLN2
Skeletal develooment 5 0.00031 ETS2, FRZB, GDF10, MGP. TNFRSF11B
Table 4.14- 4.17: The WebGestalt results of significantly over-represented 
biological  processes.  The  analysis  was  performed  on  the  gene  list 
comprising  those  with  most  significantly  different  expression  between  the 
MSC  and  NHAC.  As  many  of  these  genes  have  multiple  names,  their 
recognized gene symbols are used.  Indented gene ontology categories are 
subsets of the category above.
1434.8 CONCLUSIONS AND DISCUSSION
The  MSC  in  vitro  chondrogenesis  model  system  is  a  faithful 
representation of the in vivo process, progressing in a temporal order which 
mimics  cartilage  development  and  concludes  with  cells  that  expressed 
cartilage  markers  and  which  were  both  morphologically  and  functionally 
chondrogenic.
The  power of microarray analysis  lies  in  its  ability to  offer a  global 
overview of chondrogenic development. Gene ontology analysis was used to 
this end and a summary of the results obtained is presented in Figure 4.10.
Three  phases of chondrogenesis could  be  identified -  early,  middle 
and  late.  The early phase,  represented  by the 3H  time  point,  involved the 
upregulation  of  many  transcription  factors,  signalling  pathways  and 
developmental  genes  in  response  to  the  chondrogenic  media.  The  first 
phase also involved the downregulation of a variety of transcription factors 
associated  with  development  towards  lineages  other  than  cartilage.  It  is 
interesting  that  undifferentiated  MSC  expressed  such  a  large  number  of 
developmental transcription factors. This finding suggests that MSC are in a 
poised state, expressing low levels of transcription factors that play a part in 
a variety of differentiation processes. Once MSC are induced to differentiate 
toward  a  particular  lineage,  the  transcription  factors  for  that  lineage  are 
upregulated while those involved in the differentiation toward other lineages 
are downregulated. While some of the genes upregulated by 3H are known 
to  have a chondrogenic role,  there was also a  large  number of genes not 
previously associated with chondrogenesis. This group of genes may have 
important  roles  in  early  chondrogenic  differentiation  in  particular,  or  may 
have a more general role in MSC differentiation.
The  intermediate  phase  of chondrogenesis was  represented  by the 
12H and 2D time points. MSC no longer divided in the chondrogenic cultures 
and  consistent with  this was the  downregulation  of genes  involved  in  cell 
cycle  progression.  Metabolic  pathways  were  consequently  upregulated  in
144preparation for matrix production  in the final  phase. As chondrocytes  have 
few mitochondria and largely rely on glycolysis for their energy requirements, 
glycolysis genes were also upregulated including the main glycolytic enzyme 
PGK1  (192).  During this  phase the  cells  also  lost  many of the  MSC  cell 
surface  markers and there was a downregulation of genes  involved  in  cell 
motility  as  the  previously  motile  MSC  become  fixed  in  their  role  as 
chondrocytes.  It is possible that the transcription factors upregulated  in the 
early phase were responsible for these later changes seen in the expression 
profile.
The late phase of chondrogenesis, represented by the 14D time point, 
involved  transcriptional  changes  geared  towards  extracellular  matrix 
production and skeletal development. A range of extracellular matrix proteins 
were  upregulated  including the collagens and  proteoglycans that comprise 
the extracellular matrix (e.g. collagen 2, 9, 11, aggrecan and cartilage linking 
protein). Markers of both mature and hypertrophic cartilage were expressed 
by the  14D cells, making the developmental stage of these cells somewhat 
ambiguous.
Many  of the transcripts  that significantly changed  expression  levels 
during  chondrogenesis  were  found  to  be  induced  by  low  oxygen  levels. 
However, the pellets on which the microarrays were performed were grown 
in  the  atmospheric  (21%)  oxygen  conditions  and  it  therefore  seems 
surprising that a large number of genes are upregulated that are responsive 
to hypoxic conditions. It is possible that by growing the cells in pellet culture, 
a state of hypoxia is induced in the cells close to their centres, and that this 
accounts  for the  large  number of  hypoxia  responsive  genes  seen  in  this 
node.  However,  HIF1a,  the  main  regulator of hypoxia,  has  been  shown to 
have an effect on chondrocyte growth both in culture and in vivo, regardless 
of the  oxygen  levels.  Even  in  normoxic  conditions,  chondrocytes  lacking 
HIF1a show reduced ATP levels (117). Therefore, it is likely that even if the 
cells are not in a hypoxic environment the genes regulated by HIF1 a are still 
essential for chondrogenesis
145In  addition  to  the  MSC  time  course,  microarray  analysis  was 
performed  on  the  NHAC  cell  line  before  and  after  undergoing 
chondrogenesis. NHAC are different to MSC in that they are unipotent and 
only  differentiate to cartilage whereas the  MSC  are  multipotent.  The  most 
prominent differences between the OH NHAC and OH MSC expression levels 
were  seen  in  the  genes  encoding  extracellular  proteins.  While  MSC 
expressed  a  range  of adhesion  and  cell  communication  molecules  these 
were not expressed by NHAC.  When put through the same chondrogenic in 
vitro differentiation assay as MSC, NHAC produced more extracellular matrix 
and the cells did not appear hypertrophic as the MSC did (Section 3.7). This 
finding was confirmed at the transcriptional level, where  14D NHAC did not 
express markers of hypertrophy such as collagen  10, that were expressed 
by 14D MSC. This different transcriptional response of the two cell types to 
the  same  stimulus  is  interesting  and  suggests  a  fundamental  biological 
difference between them.
Besides  providing a global  overview of the chondrogenic process  in 
MSC  and  NHAC,  the  microarray  analysis  has  also  identified  numerous 
transcripts that changed expression levels during the time course but have 
not previously been associated with chondrogenic development or the role of 
which in chondrogenesis has not been elucidated. Two such transcripts were 
the  HES1  and  HEY1  targets  of  Notch  signalling,  and  their  role  in  MSC 
differentiation is investigated in the following chapter.
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Figure 4.10: A  summary  of the  GEM  results  providing  an  overview  of the 
transcriptional  events  occurring  as  MSC  undergo  chondrogenesis, 
combining  the  gene  ontology analysis for  biological  processes  and  cellular 
localization, as well as phenotypic observations made during the time course 
experiment.
1475. INVESTIGATING NOTCH SIGNALLING
5.1  INTRODUCTION
HES1 and HEY1 genes were both found to be upregulated by 3 hours 
in  MSC  undergoing  chondrogenesis.  These  transcriptional  regulators  are 
themselves  regulated  by  Notch  signalling,  and  were  chosen  as  promising 
candidate genes to test for involvement in chondrogenesis.
Notch  signalling  is  a  pathway  commonly  involved  in  developmental 
processes,  and  is  evolutionarily  conserved  from  Drosophila  to  mammals 
(208;209).  The  Notch  receptors  interact  with  the  membrane-bound 
delta/jagged ligands, hence signalling is only activated upon direct cell to cell 
contact (Figure  5.1)(210).  The  binding  of the  ligand  to the  Notch  receptor 
results  in  proteolytic  cleavage  of  the  receptor  and  the  release  of  the 
intracellular domain.  This proteolytic cleavage is a multi-step process, with 
the  y-secretase  enzyme,  presenilin,  catalysing  the final  step.  The  cleaved 
notch intracellular domain (NICD) translocates into the nucleus and activates 
the transcription of HES and  HEY gene family.  HES and  HEY proteins are 
basic  helix-loop-helix  (bHLH)  transcriptional  regulators  that  act  as  both 
homo- and hetero-dimers in repressing the transcription of target genes. This 
inhibition  can  occur either directly  by the  HES  and  HEY dimer  binding  to 
specific repressor binding sites, or indirectly by binding to bHLH transcription 
factors,  such  as  MyoD,  and  preventing  them  from  forming  functional 
heterodimers with other bHLH family proteins (211).
The  role  of  Notch  signalling  in  the  developmental  processes  of  a 
variety of organisms  has  been studied  by the  use of y-secretase  inhibitors 
including  L-685,458  and  N-[N-(3,5-Difluorophenacetyl-L-alanyl)]-S- 
phenylglycine  f-butyl  ester  (DAPT)  (212;213).  Exposure  of  Drosophila  to 
DAPT blocks the release of NICD and produces the same phenotype as that 
resulting from mutations in the components of the Notch signalling pathway
148(214).  DAPT  is  also  an  accepted  inhibitor  of  Notch  signalling  in  in  vitro 
studies (215-217).
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Figure 5.1: Notch signaling pathway. The delta or jagged ligand  binds to the 
Notch  receptor  causing  it  to  be  cleaved  by  the  presenilin  y-secretase
enzyme.  The  intracellular domain  of the  receptor then translocates  into the 
nucleus and activates expression of target genes, such as HES1  and HEY1. 
DAPT inhibits Notch receptor cleavage by interacting with the y-secretase.
The  role  of  Notch  signalling  in  MSC  growth  and  differentiation  is 
largely unknown.  Notch signalling has been implicated in cardiomyocyte and 
neuronal  differentiation  of  rat  MSC  (218;219).  In  C2C12  mouse 
mesenchymal  cells,  Notch  target  genes  are  known  to  be  upregulated  in 
response  to  BMP2-induced  osteogenesis  and  BMP4-induced  inhibition  of 
myogenesis (220;221).
During  chondrogenesis  in  vivo,  both  the  Notch  receptors  and  the 
ligands  are  expressed,  and  mutations  in  these  genes  lead  to  defects 
including those affecting cartilage (186;222). When chondroblasts from joints 
are  isolated,  inhibiting  Notch  signalling  inhibits  matrix  deposition,  but  in 
ATDC5  prechondrocyte  cultures,  the  overexpression  of  NICD  leads  to  a
149suppression  of  chondrogenic  differentiation  as  well  as  proliferation 
(186;223). Therefore, Notch signalling appears to play a crucial and complex 
part in chondrogenesis and the effects of disrupting it vary depending on the 
phase of chondrogenesis affected.
Similar results were obtained with adipogenic model systems. Ross et 
al found that both, constitutively over-expressing and knocking down HES1, 
had an inhibitory effect on adipogenesis in the 3T3L1  preadipocyte cell line 
(224).  In  embryonic  stem  cells  and  the  MEF  cell  line,  however,  Notch 
signalling  is  not  required  for adipogenesis  (225).  Overexpressing  NICD  in 
osteogenic cell  lines  KusaA and  KusaO  as well  as  in the  MC3T3  cell  line 
suppresses differentiation.  However,  Notch 1   and 2  receptors are  known to 
be expressed by osteoblasts and Notch signalling is induced in response to 
BMPs during osteogenesis (226,227). Overall, the role that Notch signalling 
plays  in  the  differentiation  down  various  mesenchymal  lineages  is  still 
ambiguous and the results of inducing and inhibiting Notch signalling in vitro 
vary according to cell type.
5.1.2  Aims
This  section  investigates  the  involvement  of  Notch  signalling  in 
chondrogenesis. First, the DAPT Notch signalling inhibitor was used with the 
aim  of  analysing  the  effects  of  abolishing  Notch  signalling  during  MSC 
proliferation and differentiation.  In the second section of this chapter, in situ 
hybridization was employed,  with the aim  of detecting  the  region  of HES1 
and HEY1 expression in mouse cartilage development in vivo.
1505.2 DAPT NOTCH SIGNALLING INHIBITION
5.2.1  Optimizing the conditions for DAPT treatment
Due to the  variability  in  the  MSC  response  to  chondrogenic  media 
(Section 3.4), the MSC cell lines chosen for this experiment were the 24M 
and the 38M,  both of which underwent chondrogenesis efficiently.  DAPT is 
poorly  soluble  in  water  and  requires  dissolution  in  dimethyl  sulfoxide 
(DMSO),  which  is  known  to  affect  differentiation  and  cellular  processes 
(228).  There  have  also  been  some  findings  suggesting  that  both 
chondrogenesis  and  adipogenesis  could  be  affected  by  DMSO  treatment 
(229;230). Therefore, the effect of the DMSO vehicle alone was tested prior 
to treatment with the DAPT inhibitor (Methods: Section 2.3.1).
The extent of chondrogenesis was assessed by measuring the size of 
the pellets at day 7, day 14 and day 21  of the chondrogenic culture (Figure 
5.2).  The  average  percentage  size  increase  for  pellets,  representing  the 
extent of matrix accumulation, under each condition between days 7 and 21 
is presented in Figure 5.3. No size difference was observed when cells were 
treated with 1pl/ml DMSO. However, at 2pl/ml, DMSO had a significant effect 
on  pellet  growth.  This  effect  was  enhanced  by  increasing  the  DMSO 
concentration to 5pl/ml.
When  the  pellets  were  sectioned  and  stained  with  toluidine  blue, 
changes  in  cell  morphology were also  apparent (Figure  5.4).  There was a 
decrease in the amount of purple matrix accumulated in the pellets that were 
exposed to DMSO and the cells were less rounded in appearance. Because 
of these findings,  all the following experiments were  performed with  1  pl/ml 
DMSO as the control.  DAPT was solubilised  in  DMSO to make  10mM and 
20mM  stocks.  These  stocks  were  added  to  cultures  at  1  pl/ml  making  the 
final DAPT concentration  10pM  and 20pM and DMSO concentration  1  pl/ml 
(hereafter this treatment is referred to as 10pM DAPT and 20pM DAPT).
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Figure  5.2:  The  effect  of  DMSO  treatment  on  MSC  undergoing 
chondrogenesis as measured by pellet diameter size.  Pellet diameters were 
measured every week.
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Figure  5.3:  The  effect  of  DMSO  treatment  on  the  percentage  increase  in 
pellet diameters  between  day 7  and  day 21  of differentiation  (presented  in 
Figure 5.2).  Student’s t-test Control vs DMSO-treated  pellets  *** p < 0.001.
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Figure 5.4: Toluidine  blue-stained  sections  of day 21  chondrogenic  pellets 
showing  the  effect  of  DMSO  treatment  on  the  morphology  of  MSC 
undergoing  chondrogenesis.  Inset  are  higher  magnifications.  The  control 
pellets (Ctrl) were cultured under regular chondrogenic conditions.
5.2.2  DAPT effect on MSC proliferation
To  investigate  if  DAPT  affected  proliferation  of  MSC,  growth  curve 
assays,  similar  to  the  3T3  assay,  were  performed  using  the  38M  MSC 
(Figure  5.5)  (Methods:  Section  2.1.3).  MSC  were  grown  in  regular  MSC 
media  (Ctrl)  or  media  supplemented  with  1  pil/ml  DMSO,  10pM  DAPT  and 
20pM  DAPT (Methods:  Section  2.3.2).  The  addition  of  1pl/ml  of the  DMSO 
vehicle alone to growing MSC did not affect their doubling rate. However, the 
addition of 10pM DAPT slowed MSC growth and finally inhibited cell division 
after 6  passages.  Increasing  the  concentration  of  DAPT to  20pM  inhibited 
cell  division  within  4  passages  and  resulted  in  growth  arrest.  Therefore,
153although  DAPT did not immediately inhibit MSC growth,  long-term exposure 
led  to  growth  arrest  implicating  a  role  for  Notch  signalling  in  MSC 
proliferation.
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Figure 5.5: The effect of DMSO and  DAPT treatment on  MSC  proliferation 
rates  as  compared  to  untreated  MSC  (Ctrl).  MSC  were  grown  in  triplicate 
and  cell  numbers  were  counted  every  3  days.
5.2.3 DAPT effect on chondrogenesis
The effect of the  DAPT y-secretase  inhibitor on chondrogenesis was 
assessed by pellet measurements and histological staining, in the same way 
as the effect of DMSO in Section 5.2.1  (Methods: Section 2.3.3). Six pellets 
were cultured per condition and the experiment was performed on 2 different 
bone marrow samples, 38M and 24M. The MSC derived from the 38M bone 
marrow sample showed a profound response to DAPT treatment as seen by 
the pellet size measurements at days 7,  14 and 21  and the percentage size 
increase  between  day  7  and  day  21  (Figure  5.6  and  5.7).  The  addition  of 
1pl/ml  DMSO  had  no  effect  on  pellet  size  but the  addition  10pM  or 20pM 
DAPT decreased the final  pellet size  by -40%  as  compared to the  control. 
No  difference  was  observed  between  the  two  concentrations  of the  DAPT 
inhibitor.
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Figure  5.6:  The  effect  of  DAPT  treatment  on  38M  MSC  undergoing 
chondrogenesis as measured by pellet diameter size.  Pellet diameters were 
measured every week.
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Figure  5.7:  The  effect  of  DAPT  treatment  on  the  percentage  increase  in 
pellet diameters between day 7 and  day 21  of chondrogenic culture of 38M 
MSC  (presented  in  Figure  5.6).  Student’s  t-test  DMSO  vs  DAPT  ***  p  < 
0.001.
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156Figure  5.8:  Toluidine  blue-stained  sections  of day  21  38M  chondrogenic 
pellets showing the effect of DMSO and DAPT treatment on the morphology 
of  MSC  undergoing  chondrogenesis.  Inset  are  higher  magnifications.  The 
control pellets (Ctrl) were cultured under regular chondrogenic conditions.
The  24M  MSC  pellet  cultures  also  showed  a  size  decrease  when 
treated with the DAPT inhibitor. The final pellet size was about -15% lower 
for  the  pellets  treated  with  10pM  DAPT  and  -25%  lower  for  the  pellets 
treated with 20pM DAPT (Figure 5.9). Therefore, for the 24M MSC, doubling 
the  concentration  of  DAPT,  had  a  significant  impact  on  the  extent  of 
inhibition  of  chondrogenesis.  As  the  24M  MSC  responded  less  to  the 
chondrogenic media than the 38M cells, the actual effect of DAPT was better 
evaluated  as a  size  increase  between  days  7  and 21,  which was 40-50% 
lower  for  both  MSC  lines  when  cells  were  exposed  to  20pM  DAPT  as 
compared to the DMSO treated pellets (Figure 5.7 and 5.10).
Both, the 38M MSC and the 24M MSC showed a similar response to 
the  DAPT  treatment  at  the  morphological  level.  Toluidine  blue  staining 
showed that there was an  impairment in  matrix accumulation  in the  DAPT 
treated pellets, as there was less purple matrix, and the blue-staining nuclei 
were  closer together (Figure  5.8  and  5.11).  Throughout the  DAPT treated 
pellets, the cells showed an irregular, more spindled morphology rather than 
the rounded chondrocytic morphology and lacunae seen in the control. Also, 
in the DAPT treated sections, there was an outer rim of spindle-shaped cells. 
This difference in morphology could perhaps be attributed to the incomplete 
penetrance  of the  DAPT  inhibitor that  may fail  to  reach  the  inside  of the 
pellets, thereby producing a more pronounced effect in the outer layers than 
in the core.
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Figure  5.9:  The  effect  of  DAPT  treatment  on  24M  MSC  undergoing 
chondrogenesis as measured by pellet diameter size.  Pellet diameters were 
measured every week.
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Figure  5.10: The  effect of  DAPT treatment  on  the  percentage  increase  in 
pellet diameters between day 7 and day 21  of chondrogenic culture of 24M 
MSC  (presented  in  Figure  5.9).  Student’s  t-test  DMSO  vs  DAPT  ***  p  < 
0.001.
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Figure  5.11:  Toluidine  blue-stained  sections  of day  21  24M  chondrogenic 
pellets showing the effect of DMSO and DAPT treatment on the morphology 
of  MSC  undergoing  chondrogenesis.  Inset  are  higher  magnifications.  The 
control pellets (Ctrl) were cultured under regular chondrogenic conditions.
1595.2.4  RT-PCR analysis of HES1 and HEY1 targets of Notch signalling
As  DAPT is  reported to  prevent the  cleavage  of the  Notch  receptor 
and  therefore  the  translocation  of the  Notch  intracellular  domain  into  the 
nucleus, the exposure of the cells to DAPT should inhibit the transcription of 
the HES1 and HEY1 targets of Notch signalling.
The  levels  of HES1  and  HEY1  were  assessed  by  RT-PCR  in  RNA 
isolated  from  the  day  21  pellets  (Figure  5.12)  (Methods:  Section  2.3.4). 
Expression of HES1  and  HEY1  could  be detected  in  the control  pellets.  In 
the 38M MSC, a near complete inhibition of the HES1  and HEY1  transcripts 
was observed when the pellets were treated with DAPT, whereas in the 24M 
MSC,  the  HES1  and  HEY1  levels  were  lowered  but  not  completely 
abolished.  No difference could  be detected  in the transcript levels  between 
the  pellets  treated  with  different  concentrations  of  DAPT.  This  result  was 
somewhat surprising as the change in the concentration of DAPT produced 
a different morphology in the 24M cells, but RT-PCR is semi-quantitative and 
as  such  may  not  be  able  to  detect  significant  but  small  differences  in 
transcript level. The residual levels of HES1  and HEY1  could be attributed to 
the cells in the core of the pellets where the DAPT seems to have a lesser 
effect  on  the  changes  in  cell  morphology.  GAPDH  is  used  as  a  control 
marker,  and the  levels of GAPDH  remained  stable.  Collagen  2  levels also 
appeared  unchanged  by  DAPT  treatment,  which  may  be  contrary  to 
expectation. This could have two possible explanations. The first is that, due 
to the abundance of this transcript in chondrogenesis, the RT-PCR method 
was not sensitive enough to detect changes in collagen 2 levels. The second 
is  that  the  DAPT  impairment  of  chondrogenesis  did  not  alter  collagen  2 
expression.
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Figure  5.12:  Gel  electrophoresis  showing  RT-PCR  analysis  of  targets  of 
Notch  signalling and control genes using  RNA isolated from  day 21  control 
(CTRL), DMSO and DAPT treated pellets.
5.2.5  Effect of DAPT treatment on adipogenesis and osteogenesis
In  spite  of  some  differences  in  their  response  to  DAPT  during 
chondrogenesis, both 24M and 38M  bone marrow-derived  MSC showed the 
same response in the adipogenic and osteogenic cultures (Methods: Section 
2.3.5).  Therefore,  even though the experiments were  performed  in triplicate 
on  both cell  lines,  representative  photomicrographs for the  histology of only 
the 24M cultures are shown.
In the adipogenic cultures, treatment with DAPT appeared to have no 
effect  on  adipogenesis  (Figure  5.13).  Osteogenesis  also  appeared 
uninhibited  by  DAPT  as  assessed  by  alizarin  red  staining  for  calcium 
deposition  (Figure  5.14)  and  staining  for  alkaline  phosphatase  activity 
(Figure  5.15).  Both  processes  were  not  affected  by  1pl/ml  DMSO  carrier 
alone.
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Figure 5.13: The effect of DMSO and  DAPT treatment on MSC undergoing 
adipogenesis  as  compared  to  the  untreated  cells  (Ctrl).  The  extent  of 
adipogenesis was assessed by oil red O staining after 14 days of adipogenic 
differentiation.
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Figure 5.14: The effect of DMSO and DAPT treatment on MSC undergoing 
osteogenesis as compared to untreated (Ctrl) cells and undifferentiated cells 
(MSC)  not  exposed  to  the  osteogenic  media.  The  extent  of  osteogenesis 
was  assessed  by  alizarin  red  staining  after  21  days  of  osteogenic 
differentiation.
It was noted that the addition of DAPT to osteogenic cultures induced 
the formation of a large number of cells containing lipid droplets which had a 
typical adipocyte morphology under higher magnification (Figure 5.15). While 
it  was  common  to  note  an  occasional  adipocyte  in  osteogenic  cultures,
162adipogenesis  was  significantly  increased  in  the  DAPT-treated  cultures,  as 
demonstrated  by  a  7  and  12  fold  increase  in  adipocyte  numbers  in  the 
presence  of  10pM  and  20pM  DAPT  respectively  (Figure  5.16).  The 
adipocytes  were  not  spread  evenly  on  the  culture  dish  but  were  present 
throughout, accounting for the high variance in cells counts observed.
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Figure 5.15: The effect of DMSO and DAPT treatment on MSC undergoing 
osteogenesis as compared to untreated (Ctrl) cells and undifferentiated cells 
(MSC)  not  exposed  to  the  osteogenic  media.  The  extent  of osteogenesis 
was assessed  by staining for alkaline  phosphatase activity after 21  days of 
osteogenic differentiation. The formation  of adipocytes  (stained with  oil  red 
O) was seen in the DAPT treated cultures. Inset are higher magnifications of 
adipocytes.
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Figure 5.16: Quantification of number of adipocytes per field of view seen in 
Figure 5.15.  Six fields of view were counted  per condition. Student’s t-test 
DMSO vs DAPT-treated cultures  *** p < 0.001.
Exposure  of  confluent  MSC  to  DAPT  only,  in  the  absence  of 
osteogenic differentiation  media  could  not reproduce the  adipogenic effect 
seen  in  osteogenesis  (Figure  5.17 -  top  row).  However,  when  the  cells 
were  exposed  to  100nM  dexamethasone  alongside  DAPT,  adipocytes 
appeared  as  in  the  osteogenic cultures,  indicating  that the  combination  of 
these two  chemicals was  sufficient to  induce  adipogenesis  (Figure  5.17 -  
bottom row). Quantification of adipocyte cells showed an increase in number 
comparable to that seen in the osteogenic cultures -  8 fold for 10pM DAPT 
and  14  fold  for  20pM  DAPT  (Figure  5.18).  In  both  cases,  doubling  the 
concentration of DAPT, nearly doubled adipocyte numbers so the effect was 
DAPT concentration dependent. The size of the error bars reflected uneven 
distribution of adipocytes over the culture dish.
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Figure 5.17: Confluent MSC treated with  DAPT or a  combination  of DAPT 
and dexamethasone (Dex) for 21 days and stained with oil red O.
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Figure 5.18: Quantification of number of adipocytes per field of view seen in 
Figure 5.17.  Six fields of view were counted per condition. Student’s t-test 
DMSO vs DAPT-treated cultures  **p<0.005, *** p < 0.001.
RT-PCR for HES1  and  HEY1  were also performed on samples from 
adipogenesis,  osteogenesis,  and  the  DAPT-treated  MSC  samples,  but the 
levels of expression were too low to be detected and yielded no product 
(data not shown).
1655.3 LOCALISATION OF HES1 AND HEY1 TRANSCRIPTS DURING LIMB 
DEVELOPMENT USING IN SITU HYBRIDIZATION
To  investigate  if HES1  and  HEY1  play a  part  in  chondrogenesis  in 
vivo, their expression during mouse limb development was examined using 
in situ hybridization. The expression of the target genes was localised and 
quantitated  by using  labelled  probes  consisting  of RNA complementary to 
the  mRNA of the gene of interest.  If the  gene was  expressed  the  probes 
would bind to the mRNA and a signal would be detected. For the purposes 
of  this  study,  DIG-labelled  probes  were  generated,  and  the  samples 
incubated with  an alkaline  phosphatase-conjugated  DIG  antibody that was 
visualised  with  NBT/BCIP  that  stains  positive  cells  in  the  sections  blue 
(Methods: Section 2.3.6).
5.3.1  In situ hybridization controls
Mouse embryos were taken  at  15.5 days  post coitum  (dpc),  as the 
cartilage  is well formed  at this stage and the  long  bones  are  beginning to 
ossify, providing an opportunity to investigate multiple chondrogenic stages. 
In  order  to  determine  where  the  chondrogenic  cells  were  sited  and  to 
optimize  the  hybridization  process,  the  highly  expressed  collagen  2  gene 
(Col2a1) was chosen as the first target.
The Col2a1  probe hybridized specifically to all  regions in the  mouse 
limb  in  which  cartilage  was  expected.  In  a  15.5  dpc  forelimb  all  the 
developing  bones  were  labelled  positively  with  the  Col2a1  probe  (Figure 
5.19).  Because  of the  high  levels  of expression,  the  visualisation  reaction 
was only allowed to proceed for 3 hours before the slides were washed and 
fixed. Col2a1  probes also labelled the ends of long bones but not the centre 
where ossification had already occurred in the  15.5 dpc embryos, as in the 
femur (Figure 5.20). Joints, such as the hip joint, were also shown to express 
Col2a1 (Figure 5.20).
166The  expression  of Sox9,  the  main  chondrogenic transcription  factor, 
was  analysed  next.  Sox9 was  expressed  at  lower levels than  Col2a1.  The 
Sox9 probe labelled the same regions in the forelimbs as the Col2a1  probe 
(Figure  5.19)  but  as  this  transcript  was  less  abundant,  the  visualisation 
reaction  of  alkaline  phosphatase  was  allowed  to  proceed  overnight.  The 
Sox9 probe also bound to the same regions as Col2a1  in long bones and in 
the hip joint but due to the lower abundance of the transcript the staining was 
less intense (Figure 5.20 and 5.21).
Therefore,  both  Col2a1  and  Sox9  probes  could  be  used  as  control 
probes  to  identify  cartilage  tissues,  but  as  HES1  and  HEY1  are  both 
transcriptional  regulators  and  not  likely  to  show  such  high  levels  of 
expression  as  the  matrix  protein  Col2a1,  the  transcription  factor Sox9  is  a 
more appropriate control.
Figure  5.19:  In  situ  hybridization  of  15.5  dpc  mouse  embryo  forelimb 
showing the expression of Sox9,  Col2a1  and  PDGFRA  in the wrist and the 
digits in consecutive sections.
As  cartilage  and  bones  are  known  to  have  endogenous  alkaline 
phosphatase activity, a negative control was also necessary to ensure that it 
was  not simply  the  staining  process  that  dyes  the  cartilage  in  these  limbs 
blue.  Platelet-derived growth factor receptor alpha  (PDGFRA) was  used for 
this  purpose  as  it  is  a  marker of  mesenchymal  and  neural  tissues  but  not 
cartilage  or  bone.  PDGFRA  probe  hybridization  to  mouse  limb  sections 
produced  the  opposite  result  to  Sox9  and  Col2a1  probes.  This  probe 
hybridized to most tissues in the limbs but not to cartilage (Figure 5.19).  The 
PDGFRA visualisation reaction was also allowed to proceed overnight.
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167The  results  of  PDGFRA-labelled  probes  demonstrated  that  the 
distribution  of  Sox9  and  Col2a1  probes  was  due  to  the  probes  binding  to 
their  respective  mRNAs  rather  than  non-specific  alkaline  phosphatase 
activity  in  bone.  Therefore  the  in  situ  hybridization  method  was  set  up 
successfully and could be used to localise cartilage specific transcripts in the 
developing mouse limbs.
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Figure  5.20:  in  situ  hybridization  of  15.5  dpc  mouse  embryo  hindlimb 
showing  the  expression  of  Sox9  and  Col2a1  in  the  femur  in  consecutive 
sections.
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Figure  5.21:  In  situ  hybridization  of  15.5  dpc  mouse  embryo  hindlimb 
showing the  expression  of Sox9  and  Col2a1  in the  hip joint  in  consecutive 
sections.
1685.3.2 In situ hybridization of HES1 and HEY1
To  test  whether  the  HES1  and  HEY1  probes  were  effective  at 
identifying their target mRNAs, the neural tube of 11.5 dpc embryos was first 
used  as a  positive control,  as  it  is  known to  express these  genes.  As  in 
previously published data, the 11.5 dpc neural tube was found to be positive 
for Sox9,  HES1  and HEY1  (231-233) and the staining was localized to the 
ventricular zone and dorsal root ganglia (Figure 5.22). Col2a1 showed some 
labelling  of the  neural  tube  but  less  than  Sox9  and  strongly  labelled  the 
dorsal root ganglia (Figure 5.22).
HEY1  also  hybridized  to  the  dorsal  root  ganglia.  Unlike  Sox9  and 
HES1 that were expressed along the whole length of the neural tube, HEY1 
expression appeared to be more localized to the middle and ventral regions 
and not present in the dorsal part of the neural tube. At embryonic day 13.5, 
the expression  patterns were  very similar.  For all  3  genes  the  expression 
was localized to the ependymal layer of the neural tube,  but the portion of 
the neural tube showing positivity was smaller than at 11.5 dpc (Figure 5.23). 
Again, Sox9 and HES1  showed expression through the whole length of the 
neural tube while HEY1  was expressed in the ventral half. Sox9 and HEY1 
were also both expressed in dorsal root ganglia (Figure 5.23).
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Figure  5.22:  In  situ  hybridization  of  11.5  dpc  mouse  embryo  showing  the 
expression  of  Col2a1,  Sox9,  HES1  and  HEY1  in  the  neural  tube  (a)  and 
dorsal root ganglia (b) in consecutive sections.
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Figure  5.23:  In  situ  hybridization  of  13.5  dpc  mouse  embryo  showing  the 
expression of Sox9,  HES1  and  HEY1  in the neural tube (a) and dorsal  root 
ganglia (b) in consecutive sections.
Having  confirmed  that  the  probes  were  effective  at  identifying  the 
HES1  and HEY1 transcripts, the expression of these genes was assessed in 
the  regions  of cartilage and  bone  development in the  15.5  dpc embryo.  As 
shown previously, in the forelimb, all regions of cartilage primordium showed 
positivity  for  the  Sox9  probe,  however,  consecutive  sections  were  not
170positive  for  HES1  and  HEY1  expression  (Figure  5.24).  HES1  and  HEY1 
seemed  to  be  expressed  at  higher  levels  in  regions  surrounding  the 
developing bones than in the cartilage primordium  itself. At 15.5 dpc, there 
was still some residual expression in the centre of the spinal cord of all three 
genes  but far less than  in  the  younger embryos  (Figure  5.24).  Sox9  also 
showed  expression  in  the  cartilage  primordium  forming  around  the  spinal 
cord as well as lower, but nonetheless detectable, levels of expression in the 
nucleus pulposus -  both regions that did not show expression of HES1  and 
HEY1 (Figure 5.24).
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Figure  5.24:  In  situ  hybridization  of  15.5  dpc  mouse  embryo  showing  the 
expression of Sox9, HES1  and HEY1  in the forelimb and the spinal cord (a), 
cartilage primordium (b) and nucleus pulposus(c)  in consecutive sections.
The  results  for  long  bones  were  similar.  Figure  5.25  shows  the 
developing ulna where ossification has already begun  in the centre and this 
is  surrounded  by  cartilage  at  various  stages  of  development.  Sox9  was 
expressed  by  both  developing  cartilage  and  throughout  the  hypertrophic
172stages.  However,  Sox9 expression was lost as the chondrocytes apoptose 
and the regions in the centre of the bone ossified. HES1  and HEY1  showed 
opposite  patterns  of expression  to  Sox9  with  higher  levels  of expression 
present in the mesenchymal tissue surrounding the developing bones than in 
the bones themselves.  No expression of HES1  and HEY1  was seen in the 
developing or hypertrophic cartilage, although low levels of expression may 
have been present in the region undergoing ossification. Figure 5.26 shows 
the expression of Sox9, HES1 and HEY1  in the tail of the 15.5 dpc embryos. 
Sox9 probes labelled the cartilage primordium of the vertebral bodies in the 
tail as well as faintly labelling the nucleus pulposus.  HES1  and HEY1  were 
not found expressed in the cartilaginous cells in the vertebrae.  Due to their 
characteristic morphology, the chondrocytes could easily be identified under 
high magnification and were the cells that appeared palest in the HES1  and 
HEY1 probe stained sections.
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Figure  5.25:  In  situ  hybridization  of  15.5  dpc  mouse  embryo  showing  the 
expression of Sox9, HES1  and HEY1  in the ulna in consecutive sections and 
higher  magnifications  on  the  right.  This  bone  had  already  begun  to  ossify 
and regions of both cartilage (a) and bone (b) can be seen.
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Figure  5.26:  In  situ  hybridization  of  15.5  dpc  mouse  embryo  showing  the 
expression  of Sox9,  HES1  and  HEY1  in  the tail  vertebrae  (a)  and  nucleus 
pulposi (b) in consecutive sections.
As  no  expression  of  HES1  and  HEY1  was  seen  in  the  15.5  dpc 
cartilage,  13.5  dpc  embryos  were  also  sectioned  and  in  situ  hybridizations 
performed to check if expression in limbs could  be seen at an earlier stage. 
Figure 5.27 shows the results of the Sox9, HES1  and HEY1  hybridizations in
13.5  dpc  embryo  forelimb  and  hindlimb.  In  the  forelimb,  the  developing 
humerus expressed  high  levels  of Sox9 throughout.  In  contrast to the  15.5
175dpc long bones, at 13.5 dpc,  long bones have not begun to ossify and the 
entire future  bone  is  composed  of cartilage  primordium.  HES1  and  HEY1 
expression  was  seen  in  the  tissue  surrounding  the  developing  bones, 
presumably muscle tissue,  but not in the cartilage of the humerus. The hip 
joint,  femur,  and  knee joint  in  the  hindlimb  showed  the  same  pattern  of 
expression, with Sox9 being expressed throughout the developing cartilage 
and  HES1  and  HEY1  expression  surrounding the cartilage  primordium  but 
not  within  it.  Therefore,  even  at  this  earlier  stage,  no  HES1  or  HEY1 
expression could be detected in cartilage.
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Figure  5.27:  In  situ  hybridization  of  13.5  dpc  mouse  embryo  showing  the 
expression  of Sox9,  HES1  and  Hey1  in the forelimb  including the  humerus 
(a) and hindlimb including the hip joint and femur (b) in consecutive sections.
1775.4 CONCLUSIONS AND DISCUSSION
As Notch signalling plays a part in many developmental pathways and 
was found to be upregulated in the MSC undergoing chondrogenesis in vitro, 
the impact of inhibiting  Notch signalling on  MSC growth and differentiation 
was  tested.  Notch  signalling  was  inhibited  using  the  ysecretase  inhibitor 
DAPT.  This  inhibitor  acts  by  preventing  the  cleavage  of  the  Notch 
intracellular domain, thereby preventing its translocation to the nucleus and 
the transcription of its target genes.
DAPT treatment  of  proliferating  MSC  resulted  in  a  reduced  rate  of 
proliferation followed eventually by growth arrest, implicating a role for Notch 
signalling  in  MSC  self-renewal.  This  effect  of  DAPT  was  concentration- 
dependent, as doubling the levels of DAPT led to a more effective inhibition 
of MSC growth  and the  cells  growth-arrested  earlier.  Notch  signalling  has 
also  been  implicated  in  the  self-renewal  of  HSC,  where  the  interplay 
between Wnt and Notch pathways is required to maintain cell proliferation. It 
is  possible  that  a  similar  conserved  mechanism  is  involved  in  MSC 
proliferation since Wnt signalling is also known to be active and required for 
MSC expansion (234;235).
Besides  the  role  of  Notch  signalling  in  MSC  proliferation,  it  is  also 
involved  in  cell  fate  decisions.  The  addition  of DAPT to  MSC  undergoing 
chondrogenesis  significantly  impaired  their  differentiation.  Inhibiting  Notch 
signalling  did  not  inhibit  pellet  formation  but  reduced  pellet  size  due  to 
decreased  matrix  production.  The  addition  of  DAPT  also  caused 
morphological changes in the chondrocytes, in particular in the outer layers 
of the pellet where they did not appear rounded or produce the lacunae as 
seen with the untreated control pellets. This was possibly due to the partial 
penetrance  of the  inhibitor.  Some  differences  in  response  to  DAPT  were 
seen between the two different MSC lines tested. While DAPT was inhibitory 
to chondrogenesis in both lines, the inhibition was more effective in the 38M 
MSC.  This  difference  in  response  can  probably  be  attributed  to the  initial
178differences in the efficacy with which the cells undergo chondrogenesis, and 
again  re-emphasizes  the  variability  between  samples  associated  in  this 
process.  The  expression  of  downstream  Notch  target  genes  HES1  and 
HEY1, normally present during MSC chondrogenesis, was also dramatically 
reduced,  though  not  completely  abolished,  during  DAPT  treatment.  This 
residual  expression  may be  explained  by the  presence  of the  cells  in  the 
core  of the  pellet  where  the  DAPT  may  have  failed  to  penetrate.  These 
results are in accordance with previous findings where DAPT treatment was 
reported  to  impair  proteoglycan  production  in  chondroblasts  isolated  from 
joints  but  contrasts  the  results  obtained  with  the  ATDC5  cell  line  where 
HES1  overexpression  led  to  a  suppression  of chondrogenic  differentiation 
(186;236). One explanation for this might be that transient Notch signaling is 
required for chondrogenesis, and that either blocking or continually activating 
the Notch pathway results in inhibition of chondrogenesis.
Notch signalling also appears to be involved in deciding whether MSC 
undergo  osteogenic  or  adipogenic  differentiation.  The  adipogenic  effect 
brought about by the exposure of MSC  undergoing osteogenesis to  DAPT 
can be reproduced by the addition of DAPT and 10OnM dexamethasone but 
not  by the  addition  of  DAPT alone.  The  extent  of adipogenic  induction  in 
these cultures  is  dependent on  the  DAPT concentration  as the  number of 
adipocytes  nearly  doubled  when  the  DAPT  concentration  was  increased 
from  10pM  to  20pM.  When  DAPT  was  added  to  MSC  differentiating  in 
adipogenic  media,  no  further  enhancement  of  adipogenesis  was  seen. 
These cells had been exposed to a very potent adipogenic cocktail and it is 
therefore  probable  that  they  have  already  reached  their  full  adipogenic 
capacity.
Previous studies on the role of Notch signalling in adipogenesis have 
produced  contradictory  results.  Inhibition  of Notch-signalling  in  the  murine 
preadipocyte cell line 3T3L1  impaired adipogenesis, while murine embryonic 
fibroblast  and  murine  embryonic  stem  cell  adipogenesis  was  unimpaired 
(237;238).  In contrast, the experiments performed here on MSC, argue that
179Notch inhibition induces human adipogenesis. As only a small proportion of 
MSC differentiated to adipocytes in response to DAPT and dexamethasone, 
it appears that other factors are required for efficient commitment of cells to 
fat. One limiting factor could possibly be the amount of insulin present in the 
serum used.
Although  DAPT  is  a  specific  y-secretase  inhibitor,  the  function  of 
these enzymes is not exclusive to the Notch pathway(239).  Therefore, the 
possibility can not be excluded that these findings may be due to a  Notch- 
independent  effect  of  the  y-secretase  inhibition.  However,  in  the 
chondrogenic  cultures,  a  concomitant  inhibition  of  extracellular  matrix 
production and a significant decrease in HES1  and HEY1  mRNA expression 
(downstream  targets  of  Notch  signalling)  was  observed  upon  addition  of 
DAPT,  implying  a  direct  role  for  Notch  signalling  in  this  process.  No 
decrease in HES1  and  HEY1  mRNA levels in response to DAPT treatment 
was  observed  in  the  proliferation  assay,  nor  in  the  adipogenic  and 
osteogenic  cultures,  as  the  level  of  their  expression  were  below  the 
detectable threshold of the RT-PCR analysis.  In spite of this, since the HES 
and HEY family have been shown to play a part in chondrogenic, adipogenic 
and  osteogenic differentiation  in a  number of cell  lines,  it seems  plausible 
that  the  effect  of  DAPT  was  due  to  the  disruption  of  Notch  signalling 
(186;240-242).
After  demonstrating  the  role  for  Notch  signalling  in  vitro,  the 
expression of HES1 and HEY1 was investigated in vivo in developing mouse 
limbs  using  in  situ  hybridization.  The  technique  was  first  set  up  using  a 
Col2A1  and  Sox9  probe  that  successfully  identified  all  cartilage  in  the 
embryos. The HES1  and HEY1  probes labelled the developing neural tube, 
the  tissue  used  as  the  positive  control,  but  did  not  bind  to  any  of  the 
developing cartilage. There are a  number of possible  explanations for this 
result.  The first factor to  be  taken  into  account  is  that these  experiments 
were performed on mouse limbs whereas the MSC work used human MSC 
and  there  could  be  interspecies  differences  in  Notch  targets  important for
180chondrogenesis.  In  addition,  the  developmental  stages  investigated  (13.5 
and  15.5 dpc) may be too  late to show  HES1  and  HEY1  expression.  The 
latter may be the case if HES1  and HEY1  are involved in the mesenchymal 
condensation  stage  of  cartilage  development  as  only  younger  embryos 
would express these genes. However, the Notch receptors and Delta ligands 
are  expressed  at  the  later  stages  of  development  of  cartilage,  including 
hypertrophy. Therefore it would be expected that it is at this stage that the 
HES1  and HEY1  targets of Notch signalling are also expressed (243).  It is, 
however, possible that, while Notch signalling is active in developing mouse 
limbs, the targets are HES and HEY family members other than HES1  and 
HEY1. This would explain the in vitro effect of DAPT on chondrogenesis (as 
DAPT  would  inhibit  any  HES  and  HEY  family  member transcription)  but 
would not account for the high levels of HES1  and HEY1 expressed in MSC 
chondrogenesis.
Another explanation for not detecting HES1  and  HEY1  expression in 
mouse  limbs  could  be  that  the  transcription  of  HES1  and  HEY1  may  be 
characteristic to human chondrogenesis or even MSC chondrogenesis.  It is 
also possible that, in vivo,  HES1  and  HEY1  are expressed in  mouse limbs 
but at levels too low to be detected by the probes, as the signal produced by 
these  probes,  even  on  the  positive  control  tissues,  is faint.  More  efficient 
probes  may  allow  the  visualization  of  HES1  and  HEY1  expression  in 
cartilage primoridium.
The in vitro effect of DAPT infers a direct role of Notch signalling  in 
the control of MSC proliferation and cell fate determination, playing a positive 
role in chondrogenic and a negative role in adipogenic differentiation.  Notch 
signalling  is  likely  to  interact  with  the  other  signalling  pathways  already 
implicated in MSC function as a means of regulating stem cell function.  Due 
to  previously  demonstrated  expression  of  Notch  receptors  and  ligands  in 
mouse  embryonal  cartilage,  it  was  expected  that  HES1  and  HEY1 
expression  would  be detected  in  mouse  limbs  using  in situ hybridizations. 
However, the results of this experiment failed to support this hypothesis. This
181could be due to insufficient sensitivity of the probes, interspecies differences 
between mouse and human cells, or differences between the differentiation 
of adult MSC and embryonic chondroprogenitors. Also,  only  13.5 and  15.5 
dpc stages of mouse development were analysed at and it is possible that a 
different stage of embryonic development may have yielded different results.
1826. IDENTIFICATION OF BRACHYURY AS A 
MARKER OF CHORDOMAS
6.1  INTRODUCTION
Connective  tissue  tumours  show  a  striking  range  of  morphologies 
both between and within tumour types, which frequently overlap. Therefore, 
histological examination  may not always provide sufficient information for a 
diagnosis,  especially when  performed  on small  amounts of tissue such  as 
that  obtained  by  needle  core  biopsy.  Gene  expression  microarray  (GEM) 
technology is commonly used in the analysis of disease states, in particular 
in  cancer biology.  A  recently  published  project  involved  the  use  of GEM 
technology to analyse tumours of connective tissues with two primary aims: 
to determine the relationships between different lesions and to identify novel 
markers  that  could  be  used  in  the  diagnosis  of  particular  tumours  (134) 
(Section 1.4.5).
Chordomas are rare malignant neoplasms, occurring along the spine 
and  thought  to  derive  from  notochordal  remnants.  Although  they  are  not 
considered  classical  mesenchymal  tumours,  chordomas  were  among  the 
range  of  lesions  tested  in  the  above-mentioned  study  (Section  1.4). 
Morphologically,  chordomas  most  closely  resemble  chondroid  lesions, 
especially chondrosarcomas.  Therefore,  it was  not surprising to find these 
two groups of tumours resembling each other at the transcriptional  level  in 
the GEM analysis (Figure 1.4).
Brachyury was identified as a marker distinguishing chordomas from 
all  other  lesions tested  (Section  1.4.6).  Brachyury  is  a  transcription  factor 
that plays a crucial role in the development of the notochord, the presumed 
tissue of origin for chordomas. The identification of brachyury as a chordoma 
marker supports  the  theory  of the  tumour’s  notochordal  origin  and  recent
183findings  have  identified  notochordal  remnants,  from  which  these  tumours 
could stem, at a surprisingly high incidence (151).
In spite of extensive immunohistochemical studies, no unique marker 
exists that can reliably distinguish chordomas from other lesions. However, a 
combination  of S100 and  cytokeratin  expression  is  the  currently accepted 
method  for  discounting  the  possibility  of  the  lesion  being  a  renal  cell 
carcinoma  or  a  chondrosarcomas  respectively,  the  two  most  common 
differential diagnoses (Section 1.4.3). The rarity of chordomas further impairs 
their  correct  diagnosis,  as  many  surgeons  and  histopathologists  will  only 
encounter a few cases within the course of their career (244). Therefore, a 
unique chordoma marker would be an extremely useful tool in the diagnosis 
of  chordomas,  especially  in  those  lesions  showing  an  ambiguous 
morphology,  such  as  chordomas  with  extensive  areas  of  chondroid 
differentiation.
6.1.1 Aims
It  is  the  aim  of  this  section  to  investigate  further  the  relationship 
between  chondroid  neoplasms  and  chordomas.  As  the  brachyury 
transcription  factor  was  uniquely  expressed  by  chordomas,  the  second 
objective of this part of the project was to establish whether the expression 
of this molecule would be a useful means of distinguishing chordomas from 
other tumours.
1846.2  MICROARRAY  ANALYSIS  OF  CHORDOMAS  AND  CHONDROID 
NEOPLASMS
Microarray analysis of a  range of mesenchymal neoplasms indicated 
that,  at  a  transcriptional  level,  chordomas  resembled  chondroid  lesions 
(chondroblastomas,  chondrosarcomas  and  chondromyxoid  fibromas)  more 
closely than  the  other connective  tissue  tumours  (Methods:  Section  2.4.1) 
(Figure 1.4) (134).
When  the  transcriptional  relationship  between  the  chordomas  and 
chondroid  neoplasms was visualised  on  an  MDS  plot, the gene expression 
profile of chordomas most closely resembled that of chondrosarcomas. This 
finding was not surprising, as chordomas have a morphological appearance 
not dissimilar to  chondrosarcomas,  particularly for those  showing  areas  of 
chondroid differentiation (Section 1.4.2).
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Figure 6.1:  Multi-dimensional scaling plot showing the relationship between 
chordomas  (green)  and  chondroid  neoplasms  (chondrosarcomas  -   black, 
chondroblastomas  -   red  and  chondromyxoid  fibromas  -   blue).  (Figure 
adapted from (245))
185The list of the top 40 probe sets distinguishing chondroid neoplasms 
and chordomas from other mesenchymal tumours tested (q<0.00000679) is 
presented in the form of a heat map in the appendix (Figure A.6.1). To obtain 
this  list of probe sets,  a  moderated  standard  deviation test was  used that 
was corrected for the false discovery rate (Methods: Section 2.4.1; Section 
4.2.4). A selection of genes of particular interest is presented in Table 6.1. 
Many  of  these  genes  have  known  roles  in  chondrogenesis  -   often 
representing an ECM protein.
Collagen  2  and  Sox9  were  not  among  the  40  most  differentially 
expressed  probe sets.  However,  as these genes  are  known to  play a  key 
role  in  chondrogenesis  (Section  1.2.4),  their  expression  values  were 
analysed  and  found  to  be  significantly  upregulated  in  the  chordomas  and 
chondroid lesions as compared to other tumours (q<0.05).
Gene name Function
Agg recan 1
Cartilage linking protein 1  
S100 calcium binding protein A1 
Chondroitin sulfate proteoglycan 4 (melanoma- 
associated)
Proline arginine-rich end leucine-rich repeat
protein
Chondroitin 6
Integrin, alpha 10
Fibromodulin
Cartilage oligomeric matrix protein (COMP) 
Collagen II 
SRY-box 9
Extracellular matrix protein 
Extracellular matrix protein 
Calcium binding 
Extracellular matrix protein
Extracellular matrix protein
Extracellular matrix protein 
Extracellular matrix protein 
Extracellular matrix protein 
Extracellular matrix protein 
Extracellular matrix protein 
Transcription factor
Table  6.1:  A  selection  of  genes  expressed  in  chordomas  and  chondroid 
lesions,  not  expressed  in  a  panel  of  other  sarcomas  (p<0.05).  The  full 
heatmap  of the  top  40  differentially  expressed  genes  is  presented  in  the 
appendix (Figure A.6.1)
186Although chordomas were most closely related to chondrosarcomas, 
the  two  tumour  types  could  be  distinguished  at  the  transcriptional  level. 
Figure 6.2 shows a selection of differentially expressed genes in the form of 
a  heatmap  (see  appendix for the full  heat  map,  Figure A.6.2).  Chordomas 
did  not  express  high  levels  of the  hypertrophic  ECM  protein  collagen  10, 
platelet-derived growth factor alpha, a mitogen for connective tissue cells, or 
reticulocalbin 3, a putative endoplasmic reticulum protein.
Chordomas  expressed  brachyury,  CD24  and  cytokeratins  8,  15,  18 
and  19,  at  much  higher  levels  than  the  chondroid  neoplasms  (134).  In 
addition,  periplakin,  a  molecule  known  to  interact  with  cytokeratins,  and 
DDR1,  a  collagen  receptor  reported  to  be  overexpressed  in  breast 
carcinoma  and  osteosarcoma,  distinguished  chordomas  from  chondroid 
tumours (246;247).
An  interesting  finding  was  that  chondroblastomas  also  expressed 
cytokeratins  8  and  18,  albeit  at  far  lower  levels  than  those  seen  in 
chordomas (Figure 6.2).
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PDG* A Platelet Derived Growth factor A
CGL10A1 Collagen Type X. Alpha-1
COL10A1 Collagen Type X, Alpha-I
DDR1 DiscokJm Domain Receptor 1
PPL Penplakin
KRT15 Keratin 15
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KRT19 Keratin 19
KRT8 Keratin 8
KRT18 Keratin 18
CD 24 CD24
CD 24 CD24
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Figure  6.2.  Genes  distinguishing  between  chondroid  neoplasms  (CHS  -  
chondrosarcoma,  CHB -  chondroblastoma,  CMF -  chondromyxoidfibroma) 
and chordomas (CMA) (q<0.01). (Figure adapted from (248))
1876.3 THE SPECIFICITY OF BRACHYURY
GEM  studies  identified  brachyury  as  a  specific  chordoma  marker 
because its level of expression was significantly greater in chordomas than 
in  any  of the  other 92  connective  tissue  tumours  analysed.  The  levels  of 
brachyury expression in the 4 chordomas (mean Log2 expression = 11.32), 
15  chondroid  neoplasms  (mean  Log2  expression  =  7.20)  and  77  other 
tumours (mean  Log2 expression  = 7.13) tested  is  plotted  in  Figure 6.3.  In 
this ‘box and whiskers’ plot, the median level of expression is represented by 
the central line and the box surrounding it represents the interquartile range 
(25%  either  side  of the  mean).  The  whiskers  cover  the  95%  confidence 
range with any outliers shown as small circles. As the expression values are 
Log2 transformed, the numbers presented  here account for 16-fold greater 
levels  of brachyury  expression  in  chordomas  than  in  chondroid  and  other 
neoplasms. These results were validated using  RT-PCR (Methods:  Section
2.4.2)  (Figure 6.4). Brachyury could only be detected in chordoma cDNA and 
not in a range of other sarcoma samples, including a chondrosarcoma. The 
control GAPDH product was detected in all samples tested, while a reaction 
run  without  reverse  transcriptase  showed  no  product  indicating  that there 
was no contaminating genomic DNA.
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Figure  6.3:  Box  and  whiskers  plot  representing  GEM  values  of  brachyury 
expression  in  chordomas  (CMA),  chondroid  neoplasms  (CHON)  and  other 
tumours  (OTHER).  The  box and whisker plots show the  interquartile  range 
as the box and the 95% confidence range as the whiskers; samples outside 
this  range  (outliers)  are  shown  as  small  circles.  The  central  line  is  the 
median.  The  units  of  expression  in  this  plot  are  Log2  expression  units 
calculated using the RMA algorithm (Figure adapted from (249))
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Figure  6.4:  Gel  electrophoresis  showing  RT-PCR  validation  of  brachyury 
expression  in  chordomas  and  not  in  other  sarcomas.  GAPDH  control  is 
expressed  in  all  tumours.  MPNST  -   malignant  peripheral  nerve  sheath 
tumour. CMF -  chondromyxoid fibroma. (Figure adapted from (250))
1896.4  IMMUNOHISTOCHEMISTRY  WITH  A  POLYCLONAL  ANTIBODY 
AGAINST BRACHYURY
As brachyury was exclusively expressed  by chordomas from a large 
number  of  mesenchymal  neoplasms,  a  commercially  available  antibody 
against  brachyury was  optimised  for immunohistochemistry  (IHC) with  the 
aim of testing the value of brachyury as a diagnostic marker. The polyclonal 
antibody was tested at various concentrations on  both frozen and  paraffin- 
embedded  chordoma  tissue  (Methods:  Section  2.4.2).  The  antibody  most 
effectively  bound  to  sections  of  paraffin-embedded  samples  when  these 
were  pre-treated  by  pressure  cooking  in  antigen  unmasking  solution for 2 
minutes and  the  antibody was  used  at a  1:100  dilution  (Methods:  Section 
2.4.3).
Since  brachyury  is  known  to  have  a  crucial  role  in  notochordal 
development  (Section  1.4.6),  a  whole  mount  of  a  human  embryo  of  6-8 
weeks gestation  was  used  as  a  positive  control  for  brachyury expression. 
Sagittal sections of the embryo, in which the notochord could be seen, were 
incubated  with  the  brachyury  primary  antibody  followed  by  a  biotinylated 
secondary  and  a  streptavidin-horseradish  peroxidise  conjugate.  The 
resulting  images  are  presented  in  Figure  6.5.  Brachyury  is  a  transcription 
factor, therefore a  positive signal,  represented  by  DAB  (brown) staining,  is 
restricted to the nuclei, whereas the nuclei which do not express brachyury 
are  dark  blue  as  a  consequence  of haematoxylin  staining.  The  notochord 
was first localised by cytokeratin expression (Figure 6.5.A and B) and could 
clearly  be  seen  in  the  centre  of  the  spinal  column.  The  nuclei  of  the 
notochord  were  also  positive  for  brachyury  expression  (Figure  6.5.C  and 
6.5.D).  Unlike  cytokeratins,  that were  also  expressed  by  other,  epithelial, 
tissues, brachyury expression was restricted to the notochord.
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Figure 6.5:  Immunohistochemical analysis on sections of the notochord of a 
6-8  week  human  embryo,  showing  it  to  express  cytokeratin  (AE1/3)  (A,B) 
and  brachyury  (C,D).  The  arrow  in  A  and  C  points  to  the  notochord. 
Brachyury  is  a  transcription factor,  therefore the  staining  is  localised  to the 
nuclei.
A  variety  of  chordomas  were  tested  for the  presence  of  brachyury, 
and  an  overview of them  is  presented  in  Table  6.2.  The tumours  analysed 
included  full  resections  and  needle  core  biopsies.  The  cases  included 
decalcified and  non-decalcified  material,  chordomas located at both  ends of 
the  spine  and  cases  with  areas  showing  chondroid  differentiation.  The 
amount  of  chondroid  differentiation  within  chordomas  varied.  The 
classification used in the cases in this study was as follows:
-  a classical chordoma: showing no chondrogenic 
differentiation.
191- focally chondroid  chordoma:  showing  minor  (not  comprising  more 
than  10%  of  the  total  tumour)  dispersed  areas  with  a  chondroid 
phenotype.
- chondroid chordomas: where at least 60%  of the tumour shows a 
cartilaginous-type matrix in which the cells are embedded singly.
in addition, 5 chordoma metastasis, not located on the axial skeleton 
and  3  chordomas  showing  areas  of  dedifferentiation  comprising  spindle- 
shaped cells, were also analysed for brachyury expression.
Chordoma type  Site  Number  Number tested  %S100  +ve
of cases  for Si 00
Classical  chordoma  (no  chondroid 
differentiation)
Sacral 23 18 28
Clival 3 3 100
Chordomas  with  focal  areas  of 
chondroid differentiation
Sacral 10 6 67
Clival 3 2 50
Chondroid chordoma Clival 6 5 100
Dedifferentiated chordoma Sacral 3 1 100
Metastatic chordoma 5 2 0
Total 53 37 51.4
Table  6.2:  Summary  of  chordoma  samples  analysed  by  IHC.  S100 
expression was analysed in some samples and was found to be present  in 
-50%  of  the  samples  tested.  All  53  chordomas  were  found  to  express 
brachyury.
All the chordomas tested were positive for brachyury expression. Two 
representative  conventional  chordomas  showing  no  chondroid-type 
differentiation,  both  located  in  the  sacrum  are  shown  in  Figure  6.6. 
Brachyury and cytokeratin were both expressed throughout the tumours but 
were  not  present  in  the  reactive  fibroblasts  surrounding  the  tumour  area. 
S100 is also expressed by the tumour cells (Figure 6.6.D).
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193Figure 6.6: Two cases of classical  chordoma,  located  in the sacrum.  H&E 
staining (A,E) shows areas of physalipherous cell morphology (a) and pale- 
staining  myxoid  matrix  (b),  both  characteristic  of  chordomas.  Areas  of 
reactive fibroblasts were  seen  surrounding the tumour (c).  These tumours 
expressed  brachyury  (B,F,G),  cytokeratins  AE1/3  (C,H)  and  S100  (D). 
Images A-D correspond to the first case and E-H to the second.
Cases of chordomas that showed epitheliod differentiation were also 
positive for brachyury and cytokeratin expression throughout (Figure 6.7.A- 
D).  However, epitheliod chordomas were negative for S100.  Similar results 
were obtained for chordomas showing nuclear pleomorphism (Figure 6.7. E- 
H). In these tumours, brachyury expression was not seen in all nuclei but the 
majority  did  express  this  transcription  factor.  The  pleomorphic  chordomas 
were negative for S100.
Of  particular  interest,  in  terms  of  diagnostic  use,  was  a  subset  of 
chordomas  showing  extensive  regions  of  chondroid  differentiation.  These 
tumours  usually occur at the  base of the skull  and  may be mistaken for a 
chondrosarcoma.  Chondroid  chordomas  were  positive  for  cytokeratin  and 
brachyury expression throughout (Figure 6.8 A-C).
Five cases of metastatic chordomas were also analysed and found to 
be diffusely positive for brachyury and cytokeratin expression (Figure 6.9).
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195Figure 6.7: An epitheliod chordoma (A-D) and a pleomorphic chordoma (E- 
H)  stained  with  H&E  (A,  E)  and  immunohistochemically  analysed  for  the 
expression  of brachyury  (B,  F),  cytokeratins  AE1/3  (C,G)  and  S100  (D,H). 
These  tumours  showed  overlapping  regions  of  cytokeratin  and  brachyury 
expression but did not express S100.
Figure  6.8:  A  chondroid  chordoma  stained  with  H&E  (A)  and
immunohistochemically  analysed  for  the  expression  of  brachyury  (B)  and 
MNF116  (C).  MNF116  and  brachyury  were  expressed  by  all  the  tumour 
cells.
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Figure  6.9:  A  metastatic  chordoma  stained  with  H&E  (A,B),  and 
immunohistochemically analysed for the  expression of brachyury (C,D) and 
MNF116  (E).  Brachyury  and  MNF116  expression  was  seen  throughout the 
tumour.
Rarely,  cases  of  dedifferentiated  chordomas  occur,  such  variants 
comprise areas of both conventional chordoma in which physalipherous cells 
are  present  and  an  undifferentiated  spindle  cell  component.  Three
197dedifferentiated cases are included in this study and a representative one is 
shown  in  Figure  6.10.  As  in  the  previous  cases  the  classical  chordoma 
component  shows  brachyury  and  cytokeratin  expression,  whereas  the 
spindle  cell  component shows  no  expression  of either of these  molecules. 
These  results  indicate  that  the  dedifferentiated  component,  besides  losing 
the chordoma  morphology had also lost expression of chordoma  markers -  
cytokeratin and brachyury.
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Figure  6.10:  A  dedifferentiated  chordoma  stained  with  H&E  (A),  also 
showing  brachyury  (B,C)  and  MNF  116  (D)  expression.  The  classical 
chordoma  component  is  marked  with  ‘a’  whereas  the  dedifferentiated 
component is marked ‘b’.
One  tumour,  previously  diagnosed  as  a  chondroid  chordoma  was 
found not to express brachyury. However, the cytokeratin IHC also proved to 
be  negative,  hence  this  neoplasm  was  reclassified  as  a  base  of  skull 
chondrosarcoma.
198The S100 antigen IHC was mostly performed prior to this project as a 
part  of the  routine  immunohistochemical  analysis to  aid  diagnosis  prior to 
treatment.  Not all  the  chordomas  used  in  this  study were tested for S100 
expression, and of the 70% that were, just over 50% expressed S100 (Table
6.2). The lowest levels of S100 positivity were found in classical chordomas 
located  in  the  sacrum,  whereas  all  the  chondroid  chordomas  tested  were 
positive.  This  finding  indicates  that  S100  can  not  be  relied  upon  as  a 
diagnostic marker for chordomas.
A wide variety of normal  human tissues was tested  including  brain, 
breast, hyaline articular and fibrocartilage, squamous and endocervial cervix, 
endometrium,  myometrium,  Fallopian tube, ovary, gallbladder,  kidney,  liver, 
lung,  lymph  node,  large bowel,  skin, glandular, transitional and  metaplastic 
squamous epithelium, testis, sciatic nerve, tonsil, thyroid and salivary gland 
(Figure 6.11).  None of these tissues expressed  brachyury,  leaving the only 
non-malignant  brachyury  expressing  tissue  as  the  above  mentioned 
embryonic notochord. In some tissues, such as the kidney and osteoclasts, a 
weak diffuse cytoplasmic staining has been detected but this was interpreted 
as non-specific rather than true brachyury expression (Figure 6.11.C).
As the nucleus pulposus is proposed to derive from the notochord, it 
was of particular interest to test this tissue for the expression of brachyury. 
Brachyury was  not found to be expressed  in  any of the 7  nucleus  pulposi 
tested  (Figure  6.12.C).  The  presence  of  cytokeratin  expression  was  also 
tested and the nucleus pulposi were found to be negative for these (6.12.B).
199Figure  6.11:  A  selection  of  normal  tissue  sections,  analysed  for  the 
expression  of  brachyury:  nerve  (A),  endometrium  (B),  kidney  (C),  lymph 
node  (D),  cartilage  (E),  bladder  (F).  All  of these  tissues  were  negative  for 
brachyury expression
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Figure  6.12:  Nucleus  pulposus  stained  with  H&E  (A),  and  analysed  for 
brachyury (B) and cytokeratin (MNF116) (C) expression.
In  addition  to  the  normal  tissues,  a  broad  range  of tumours,  with  a 
particular  emphasis  on  those  neoplasms  that  are  easily  mistaken  for  a 
chordoma  diagnostically,  were  also  analysed  for  brachyury  expression 
(n=323) (Table 6.3). A range of chondroid lesions was tested,  including  102 
chondrosarcomas, comprising tumours grades l-lll (251).
In spite of their morphological similarity to chondroid chordomas, base 
of skull  chondrosarcomas  did  not  express  brachyury  (Figure  6.13).  Sacral 
chondrosarcomas  were  also  negative  for  brachyury  expression  (Figure 
6.14).  In  addition,  brachyury expression was absent in  clear cell  sarcomas, 
chondromyxoid fibromas  and  renal  carcinomas,  which  provide  a  differential 
diagnosis for epitheliod sacral chordomas (Figure 6.14)
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Figure  6.13.  Base  of  skull  chondrosarcoma  stained  with  H&E  (A)  and 
analysed for brachyury expression (B).
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Figure  6.14:  A  range  of  neoplasms  analysed  for  brachyury  expression: 
chondrosarcoma  (A),  renal  carcinoma  (B),  clear  cell  sarcoma  (C), 
chondromyxoid fibroma (D).
202Tumour category  Subcategory  Number  of  cases
_________________________________________________________________ analysed________
Chondroid neoplasms  Chondroblastoma  14
Chondromyxoid fibroma  18
Chondrosarcoma  appendicular:  grade  0.5  55
(n=12)  grade  1   (n=10),  grade  2  (n=22),  grade 
3(n=11)
Chondrosarcoma - base of skull  9
Chondrosarcoma - clear cell  11
Chondrosarcoma - dedifferentiated  5
Chondrosarcoma - extraskeletal myxoid  5
Chondrosarcoma - mesenchymal (bone)  9
Chondrosarcoma - myxoid  8
Enchondroma  12
Periosteal chondroma  5
Synovial chondromatosis  12
Subtotal  163
Other  Adenoma - pituitary  6
Astrocytoma - gemistocytic  2
Carcinoma - neuroendocrine  4
Carcinoma - renal  6
Carcinoma - squamous cell  2
Ependymoma  4
Ependymoma  - myxopapillary  4
Giant cell tumor  2
Glioblastoma multiforme  5
Leiomyosarcoma  6
Lipoma - chondroid  2
Liposarcoma - myxoid  (grade 2)  6
Malignant melanoma  2
Mesenchymal phosphaturic neoplasm  2
Myoepithelial  tumor  /  outside  salivary glands  -  4
malignant
Myoepithelial  tumor /  outside  salivary glands  -  7
benign
Mixed  tumor/pleomorphic  adenoma  of  salivary  25
glands
Myxofibrosarcoma  5
Myxoma - intramuscular  5
Myxoma -  Mazabraud syndrome  5
Oligodendroglioma  2
Osteofibrous dysplasia  10
Osteosarcoma - osteoblastic  3
Osteosarcoma - chondroblastic  10
Paraganglioma  1
Sarcoma - clear cell  8
Sarcoma - epithelioid  3
Sarcoma -  low-grade fibromyxoid  10
Sarcoma  - Ewing/PNET  6
Sarcoma - spindle cell  3
Subtotal  160
Total  323
(Figure legend on following page)
203Table  6.3:  Complete  list  of  all  non-chordoma  cases  assessed
immunohistochemically for brachyury expression. None of these neoplasms 
expressed brachyury.
2046.5 THE CASE OF AN EXTRA-AXIAL CHORDOMA
A point of particular interest is whether chordomas can occur extra- 
axially.  A  recent  case  of  a  tumour  located  in  the  tibia  metaphysis,  was 
diagnosed  as  a  benign  osteoid  or  chondroid  lesion  in  the  first  instance 
following  magnetic  resonance  imaging  that  showed  a  well-marginated, 
intracortical  lesion  with  some  matrix  mineralization  (252).  A  needle  core 
biopsy  revealed  atypical  cells  with  prominent  nuclei  embedded  in  a 
chondroid  matrix  and  was  tested  for  expression  of  immunohistochemical 
markers. While the tumour was found to express S100, which is consistent 
with  a  diagnosis  of  a  chondroid  neoplasm,  it  also  expressed  epitheliod 
markers including cytokeratins CK19, AE1/3 and MNF116. A diagnosis of a 
renal  tumour was  excluded  by  ultrasound  imaging  of the  kidneys  and  the 
absence  of  renal  cell  antigen  and  CD10  expression  on  the  tumour  cells 
(Figure  6.15)  (157;252).  The  tumour  was  diagnosed  as  a  clear  cell 
chondrosarcoma  by  the  British  Bone  Tumour  panel,  in  spite  of  the 
expression  of cytokeratins and the metaphyseal  site of this lesion  being at 
odds with such a diagnosis (252).
Following the  identification of brachyury as a chordoma  marker,  the 
lesion was found to be strongly positive for this transcription factor, indicating 
the chordoid nature of the tumour (Figure 6.15.F). The diagnosis of an extra- 
axial  chordoma  was  in  keeping  with  both  the  appearance  and  the 
immunohistochemical  profile  of  the  lesion,  but  could  only  be  made 
retrospectively following evidence of notochordal differentiation as provided 
by brachyury expression (252).
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Figure 6.15: An extra-axial chordoma stained with H&E (A,B) and analysed 
for cytokeratin  MNF116  (C) and  CK19  (D),  S100  (E),  brachyury expression 
(F).  Brachyury was expressed by most of the tumour cells that also showed 
expression of cytokeratins.
2066.6 CONCLUSIONS AND DISCUSSION
As  an  embryonic  structure,  the  notochord  most  closely  resembles 
cartilage,  as  it is a tissue designed to provide tensile strength and  rigidity. 
The notochord also expresses a multitude of cartilaginous matrix molecules, 
such  as the  collagens and  proteoglycans,  and  can  be  considered  to  be  a 
primitive  form  of  cartilage  at  an  evolutionary  level  (147).  This  close 
relationship of the notochord and cartilage accounts for the similarity noted 
between  the  tumours  arising  from  these  structures  -  chordomas  and 
cartilaginous  neoplasms.  In the  microarray analysis  performed,  chordomas 
closely resembled chondroid neoplasms and in particular chondrosarcomas, 
a tumour for which chordomas can be mistaken. The shared genes between 
these two tumours that distinguish them from other mesenchymal neoplasms 
mostly comprise of genes with a known chondrogenic role, especially matrix 
genes,  the  expression  of  which  is  known  to  be  shared  between  the 
notochord and cartilage (147).
The main distinction  between  cells of the notochord  and cartilage is 
that  the  matrix  proteins  produced  by  the  notochord  cells  are  stored  in 
intracellular vacuoles, whereas the chondrocytes extrude the collagens and 
proteoglycans they produce to form an extracellular matrix that is eventually 
used as a scaffold for bone formation and calcifies(147). This difference is 
also reflected in the transcriptional profile of the 2 tumours, as chordomas do 
not express the hypertrophic marker gene collagen X. Chondroid lesions, on 
the other hand, do not express a number of genes: cytokeratins - a finding 
that has been confirmed immuno-histochemically (253), periplakin - a protein 
known to  interact with cytokeratins  (246),  CD24 - another gene which  has 
recently been found to be present in chordomas (254) and brachyury.
However,  while  chordomas  share  cytokeratin  expression  with 
epitheliod tumours, such as synovial sarcomas, the expression of brachyury 
was exclusive to the chordomas. The specificity of brachyury expression to 
chordomas  was  confirmed  by  RT-PCR  analysis.  Immunohistochemistry
207showed that brachyury expression was  present in the 53 chordoma cases 
tested  but  not  in  a wide  range  of normal  tissues  or 323  other neoplasms 
including  a  range  of  chondroid  tumours  and  other  lesions  that  could  be 
included in a differential diagnosis. Chordomas with a range of morphologies 
were  analysed  including  tumours  with  marked  epitheliod  and  pleomorphic 
features and a large number of chordomas with extensive areas of chondroid 
differentiation.  Chordomas  located  at  both  ends  of the  spine  (sacral  and 
clival  regions)  were  also  tested.  Brachyury  expression  was  found  in  the 
nuclei of the majority of cells in the tumour regions, and a needle core biopsy 
was  sufficient  to  identify  brachyury  expression.  In  chordomas,  brachyury 
expression co-localized with cytokeratin expression and in some, but not all, 
cases  with  the  expression  of  S100.  Brachyury  was  also  found  to  be 
expressed  in  metastatic  chordomas  but  not  in  the  dedifferentiated 
component of chordomas in the areas in which cytokeratin expression and 
the chordoid morphology were lost.
All  chordomas  were  found  to  express  cytokeratins  throughout  the 
lesion,  with  the  exception  of the  dedifferentiated  areas  mentioned  above. 
S100 expression,  however, was not found to be so prevalent. Although the 
S100  antigen  is  normally thought of as  one of the  chordoma  markers,  we 
only found it to be expressed in about 50% of the chordoma cases studied 
(Table 6.2).  Expression of S100 was common in chondroid chordomas and 
chordomas with  focal  areas  of chondroid  differentiation,  but was  not very 
prevalent in  classical  chordomas  located  in  the  sacrum.  On  closer  review 
these figures are similar to those presented in the literature but are overall 
somewhat lower than the percentages previously published. In other studies, 
S100 was found to be expressed  in  between  64%  and  95%  of the  cases. 
However these studies included small sample numbers and did not present 
the variety of chordoma phenotypes tested here (159;255-257). Walker et al 
specifically looked at S100 expression in chondroid chordomas and found it 
expressed in all the tumours tested, which is in agreement with the findings 
presented  here  (258).  As  chondroid  lesions  generally  express  S100,  the
208upregulation of this molecule in chondroid areas of chordomas in particular is 
not  surprising.  The  finding  that  S100  is  expressed  in  a  little  over  half of 
chordomas shows that its use in diagnostics is limited.
Brachyury  is  a  useful  and  reliable  marker  of  chordomas,  and  is 
capable  of distinguishing  this tumour from  both  chondroid  neoplasms  and 
carcinomas. The clinical implications of correctly identifying a chordoma are 
important  as  the  treatment  for  chordomas  and  chondrosarcomas  differs. 
Chordomas have a very poor prognosis, with most patients not expected to 
live  longer  than  24  months  if  untreated.  Hence  patients  often  undergo 
extensive surgical  resection of the tumour, followed  by radiotherapy (244). 
Skull-base  chondrosarcomas,  on the  other hand,  have considerably  better 
survival  rates and  much slower tumour progression and the recommended 
treatment is less radical (259)
With  the  exception  of the  embryonic  notochord,  brachyury was  not 
found  to  be  expressed  in  a  wide  range  of  normal  tissues  including  the 
nucleus  pulposus,  a structure  proposed to derive from the  notochord.  The 
nucleus  pulposus  is  a  cartilaginous  structure  found  in  the  centre  of  the 
vertebrae and it is unclear whether it is formed by the notochord undergoing 
a  transformation  to  the  cartilaginous  phenotype  or  by  the  apoptosis  of 
notochordal  cells  that  are  then  replaced  by  cartilage.  As  the  nucleus 
pulposus  lacks  both  cytokeratin  and  brachyury  expression,  there  is  little 
molecular evidence of a direct link between the cells of the notochord and 
those of the nucleus pulposus.  However, a recent report found CD24 to be 
present in the nucleus pulposus and  in  chordomas,  but the notochord was 
not tested  for expression  (254).  It therefore  remains  a  possibility that the 
notochord,  upon  its  transformation  to  a  cartilaginous  phenotype  in  the 
nucleus pulposus, loses cytokeratin and brachyury expression.
While the value of a single marker gene is usually limited, brachyury 
has so far proved to be an excellent biomarker for chordomas, distinguishing 
these  from  all  other  neoplasms  so  far  tested.  Brachyury  expression  by 
chordomas  is  also  further  evidence  of  chordomas  having  a  notochordal
209differentiation,  alongside  the  morphological  and  immunophenotypical 
evidence reported previously. Recently, a potential benign precursor tumour 
-   named  the  intraosseous  benign  notochordal  cell  tumour,  was  found  by 
Yamaguchi et al at a surprisingly high  incidence (150;151;260).  It would be 
of  particular  interest  to  know  whether  these  benign  lesions  express 
brachyury,  as  it would  provide further evidence  of their  position  as  a  link 
between persistent notochordal remnants and chordomas.
Finally, a case of an unusual tibial neoplasm with some morphological 
features of a chordoma was investigated for brachyury expression.  Prior to 
brachyury  immunohistochemistry,  this  tumour  was  considered  likely  to 
represent a clear cell chondrosarcoma in spite of its cytokeratin expression 
being at odds with such a diagnosis.  In addition, the tumour was located in 
the metaphysis of the tibia, a region where clear cell chondrosarcomas are 
very rarely found, as most of them present in the epiphysis of bones. Without 
the  IHC  showing  brachyury  expression,  the  diagnosis  of  an  extra-axial 
chordoma  was  not  considered  due  to  the  rarity  of this  lesion.  When  the 
tumour was found to express brachyury,  it was classified as an extra-axial 
chordoma, emphasizing the value of this assay. The diagnosis of an extra- 
axial chordoma is in keeping with the morphology and immunophenotype of 
this neoplasm.  It seems more likely that this tumour represents notochordal 
differentiation  of a  progenitor cell,  rather than  that an  ectopic  notochordal 
remnant was present in the tibia.
2107. CONCLUSIONS AND DISCUSSION
7.1 MSC CHONDROGENESIS
This  study was  started  with  the  aim  of setting  up  a  in  vitro  model 
system for chondrogenic differentiation of MSC and analysing it through the 
use of GEM technology. Such an in vitro system has two primary uses: the 
first is as a representation of in vivo chondrogenic development and disease 
and the second as a potential method for obtaining cartilage for therapeutic 
purposes.
Upon  isolation and  differentiation of MSC with the use of previously 
published  protocols, a variability in the MSC proliferative and differentiation 
potential  was  noted.  There  was  also  a  correlation  between  the  rate  of 
proliferation and the extent of chondrogenic differentiation an MSC line could 
undergo.  This  variability  is  an  important factor to  take  into  account when 
considering the use of MSC for therapeutic purposes, as some patients may 
benefit  more from  autologous transplants than  others.  There  may also  be 
room for further improvements to the culture conditions used for both MSC 
expansion  and  differentiation,  such  as  the  use  of combinations  of growth 
factors or varying the oxygen concentration that the MSC are grown under.
Cartilage is an avascular tissue, with oxygen levels as low as  1% in 
certain regions (114).  Culturing  human  MSC at 3% oxygen  rather than the 
21% ordinarily used in tissue culture augments chondrogenesis, stimulating 
matrix  production.  HIF1a,  the  main  transcription  factor  associated  with 
hypoxic conditions,  is an essential factor in chondrogenesis,  promoting the 
transcription  of  ECM  molecules  such  as  collagen  2  (116).  The  results 
presented  here are the first to show an  impact of lower oxygen on  human 
MSC differentiation to chondrocytes.
For therapeutic regeneration of cartilage both MSC isolated from the 
bone  marrow and chondrocytes  isolated from  knee cartilage (NHAC)  have
211been used, and a comparison of the chondrogenic potential between these 
two  cell  types  is  presented  here.  When  grown  in  monolayer  culture  the 
NHAC  lose the  phenotypic characteristics of cartilage,  reverting to a  more 
spindle-shaped appearance and losing expression of matrix molecules. The 
NHAC can be induced to undergo chondrogenesis with the same stimuli as 
MSC,  but  the  pellets  generated  are  larger,  comprising  more  ECM.  The 
NHAC are unipotent and can not be induced to differentiate into adipocytes 
or osteocytes with the established  MSC conditions.  This  may indicate that 
NHAC  are  better suited  for use  in  cartilage  regeneration  as they  produce 
more  chondrogenic  matrix  and  only  differentiate  down  a  chondrogenic 
lineage,  however, the proliferative  potential  of NHAC  is much  more  limited 
than that of the MSC.
A comparison of the GEM profiles of the MSC and the NHAC both in 
their undifferentiated  state  and  after they have  undergone chondrogenesis 
was performed. The main differences noted in the expression profiles of the 
undifferentiated cells were  in the cell surface  proteins expressed,  but MSC 
also expressed genes involved in organ development not expressed by the 
NHAC.  The differentiated  14D cells mostly differed in the matrix molecules 
they expressed, with the  MSC  expressing  hypertrophic matrix  proteins  not 
expressed by the NHAC. This reflected histological observations of the two 
cell types, as the NHAC did not show the enlarged cell morphology typical of 
hypertrophic  cells,  as  seen  with  differentiated  MSC.  Therefore,  the  same 
growth conditions produce slightly different outcomes in the  NHAC and the 
MSC.
In  order  to  obtain  a  global  overview  of  the  process  of  MSC 
chondrogenesis,  GEM  experiments  were  performed  where  the 
transcriptional  profile  of  MSC  at  different  points  during  chondrogenic 
differentiation was examined, with a particular emphasis on the early events, 
prior  to  the  synthesis  of  the  chondrogenic  matrix.  During  in  vitro  MSC 
culture,  it was observed that most matrix proteins are  not transcribed  until 
day 6 or 7 of chondrogenic culture, concomitant with the pellets beginning to
212increase  in  size.  This  first week  of development  is  therefore  of  particular 
interest  as  it  involves  the  transcriptional  changes  that  lead  to  matrix 
production.
Through  GEM  analysis,  three  phases  of  chondrogenesis  were 
identified. The early phase, occurring within a few hours of placing the cells 
under chondrogenic growth conditions,  primarily involves changes in mRNA 
levels  of transcription  factors  and  genes  involved  in  signalling  pathways. 
Many of the transcription factors also have known roles in development. The 
upregulated transcription factors comprise both genes known to have a role 
in  chondrogenesis  such  as  DEC1  or  Dlx5  and  genes  not  previously 
implicated  in  chondrogenesis.  The  downregulated  genes  include  many 
factors  known  to  play  a  part  in  the  differentiation  towards  other  lineages, 
such  as  neuronal,  adipogenic  or  myogenic.  The  second  phase  includes 
changes  in the levels of transcripts associated with glycolysis and  motility. 
As  chondrocytes  are  located  in  a  hypoxic  environment,  they  have  few 
mitochondria  and  mostly  rely  on  glycolysis  for  ATP  production  (192).  In 
addition,  during  this  second  phase,  the  cells  cease  to  proliferate  and 
downregulate  all  cell  cycle  genes.  The  final  phase  of  chondrogenesis 
includes all the transcriptional changes geared towards extracellular matrix 
production. Most of the significantly changing genes have confirmed roles in 
chondrogenesis.
Therefore the  chondrogenesis  of MSC  progresses from  changes  in 
transcription  factors  expressed  by  the  MSC,  to  changes  in  gene  levels 
involved in the metabolism and finally to the transcription of those genes that 
make  the  cartilage  phenotype.  The  early  changes  in  the  levels  of 
transcription  factors  are  particularly  interesting  as  they  presumably 
orchestrate subsequent events, and it is these early transcription factors that 
least is known about.  HES1  and HEY1  are two such factors, not previously 
implicated in chondrogenesis.
HES1  and  HEY1  are targets of Notch signalling, a pathway involved 
in  many  developmental  events.  Abolishing  Notch  signalling,  and  thereby
213HES1  and HEY1 transcription, during chondrogenesis in vitro impairs matrix 
production. Furthermore Notch inhibitors reduce the rate of MSC proliferation 
and  induce  adipocyte  formation  during  MSC  osteogenesis.  Hence,  Notch 
signalling  is  involved  in  both  MSC  proliferation  and  differentiation,  and 
appears  to  play  a  role  in  the  choice  of  lineage  towards  which  MSC 
differentiate. However, with the use of in situ hybridization, HES1  and HEY1 
could  not  be  shown  to  be  expressed  in  vivo  in  developing  mouse  limbs 
pointing to a  possible difference either between chondrogenic regulation of 
mouse and human or embryonic and adult cells. As the Notch receptors and 
ligands  have  been  reported  to  be  expressed  by  developing  embryonic 
cartilage, the most likely explanation  is that Notch signalling  may either act 
through other HES and HEY family members in developing mouse limbs or 
that the probes used were not sensitive enough to detect the levels of HES 1  
and  HEY1  in  mouse limbs in spite of a signal  being detected  in the neural 
tissues used as controls.
2147.2 BRACHYURY EXPRESSION IN CHORDOMAS
A separate part of the project was based upon a previously published 
study of GEM profiles of a range of connective tissue neoplasms. This study 
identified  that  cartilaginous  neoplasms  closely  resembled  chordomas, 
tumours  thought  to  be  derive  from  notochordal  remnants,  at  a  gene 
expression level. Brachyury, a protein essential for notochordal development 
and embryonal survival, was found to be uniquely expressed by chordomas 
of all  the  neoplasms tested.  It was the  aim  of this  project to examine the 
relationship  between  the  chordomas  and  cartilaginous  neoplasms  and  to 
assess  the  usefulness  of  brachyury  as  a  potential  diagnostic  marker  for 
chordomas.
Just like their presumed tissues of origin, the notochord and cartilage, 
chordomas  and  chondroid  neoplasms  both  express  a  range  of  molecules 
with known roles in chondrogenesis including matrix proteins (e.g. aggrecan, 
collagen 2, COMP) and the main transcriptional regulator of chondrogenesis 
Sox9.  The  cells  of  the  notochord  however,  retain  the  collagens  and 
proteoglycans within their vacuoles whereas the chondrocytes extrude them, 
producing an  extracellular matrix that can  be calcified,  after the cells  have 
undergone  hypertrophy.  Therefore,  chondroid  neoplasms  express 
collagen 10,  a  marker of  hypertrophy,  whereas  chordomas  do  not.  This  is 
consistent with the absence of calcification seen in chordomas. Chordomas 
on  the  other  hand  express  cytokeratins,  periplakin,  DDR1,  CD24  and 
brachyury,  not expressed  by chondroid  neoplasms.  Cytokeratin  expression 
has  been  confirmed  immunohistochemically  and  is  used  in  chordoma 
diagnosis  (261).  Periplakin  has  not  previously  been  associated  with 
chordomas but is a protein known to interact with cytokeratins, in particular 
cytokeratin 8 that is one of the cytokeratins seen upregulated in chordomas 
(246). DDR1  acts as a collagen receptor, is regulated by p53 and has been 
found  to  be  overexpressed  in  breast  carcinoma  and  osteosarcoma 
(247;262;263).  It  may  therefore  be  an  interesting  candidate  for  future
215investigations.  While this work was  being  completed,  Fujita  et al reported 
that  CD24  expression  was  present  in  both  chordomas  and  the  nucleus 
pulposus, confirming the results shown here (254).
The relationship between the notochord and the nucleus pulposus is 
of  interest,  as  it  is  unclear  whether  the  notochord  cells  give  rise  to  the 
nucleus  pulposus during  development or if the  notochordal  cells  apoptose 
and are replaced by the nucleus pulposus. The nucleus pulposus does not 
express  cytokeratins  or  brachyury,  both  found  in  the  notochord  and 
chordomas, which argues against it being derived from the notochord.  The 
recent finding of CD24 expression in the nucleus pulposus and chordomas 
however  provides  an  expressional  link  and  CD24  expression  in  the 
notochord should be verified. It is, of course possible that, as the notochordal 
cells  differentiate  into  the  nucleus  pulposus,  they  lose  cytokeratins  and 
brachyury  expression.  Hence  the  relationship  between  the  notochord  and 
the nucleus pulposus remains unclear.
In the diagnosis of chordomas, cytokeratins and S100 are commonly 
employed.  These  markers  are  however  not  specific  to  chordomas  as 
cytokeratins are expressed  by carcinomas and S100 expression  is seen  in 
cartilaginous neoplasms. Furthermore, the combination of these two markers 
is  not diagnostic as  S100  is only expressed  by about 50%  of chordomas. 
Brachyury is the first published  marker that uniquely  identifies  chordomas, 
and was found to be expressed in all the chordoma cases tested. Brachyury 
was  expressed  by  classical  chordomas,  chondroid  chordomas  and 
metastatic  chordomas.  Brachyury  expression  was  also  detected  in  the 
classical  component  of  dedifferentiated  chordomas  but  not  in  the 
dedifferentiated area where cytokeratin expression  is also lost. This finding 
indicates  that  the  transformation  that  the  tumour  cells  undergo  as  they 
become ‘dedifferentiated’ also includes a transcriptional change that results 
in the chordoma morphology and markers no longer being expressed.
The final case considered is that of an enigmatic neoplasm presenting 
in  the  cortex  of the  tibia.  This  is  an  extra-axial  lesion  found  to  express
216brachyury,  with  a  morphology  and  immunophenotype  consistent  with  a 
diagnosis of an extra-axial chordoma. There are 2 possible explanations as 
to  how  a tumor showing  notochordal  differentiation  can  arise  at an  extra- 
axial site. The first is that there may have been notochordal  remnants that 
persisted  at the  tumour site,  which,  through  mutations  acquired  a  growth 
advantage  and  formed  a  neoplasm.  Hence,  detecting  the  expression  of 
brachyury in this neoplasm is consistent with the cell of origin. The second 
possibility is that an undifferentiated cell within the tibia acquired the ability to 
differentiate  into  notochordal  tissue.  There  are  reported  examples  of 
neoplasms occurring with a morphology different to the surrounding tissue in 
which the tumour arose, such as bone, cartilage and muscle formation in a 
malignant peripheral nerve sheath tumour (264).  Hence the latter possibility 
is favoured with respect to the origins of this tumour.
The  identification  of  brachyury  as  a  marker  gene  for  chordomas 
provides  evidence  of  the  notochordal  origin  of  chordomas  and  has  a 
practical application in diagnostics. These experiments, however, also show 
the value of microarray data as a starting point for tumour classification and 
the discovery of novel markers.
2177.3 FUTURE WORK
Microarray experiments generate vast amounts of data and the work 
presented here could give rise to many new projects. An area that could be 
looked at in more detail is that of the role of hypoxia and its target genes in 
chondrogenesis.  Many transcription  factors  were  found  to  be  upregulated 
during MSC chondrogenesis that could be investigated further for their role 
in cartilage development. This could be performed through knockdown with 
RNA interference or overexpression studies.
Notch signalling  involvement in  MSC  proliferation  and  differentiation 
also  warrants  further  investigation.  An  interesting  experiment  to  perform 
would  be  to  overexpress  NICD,  thereby  constitutively  activating  Notch 
signalling,  and  investigate  how  this  affects  the  growth  rate  and  the 
chondrogenic, adipogenic and osteogenic differentiation of MSC.
In relation to the work on chordomas presented here, the regulation of 
brachyury expression would be of interest for future investigation, as it could 
be implicated in the mechanism of chordoma tumorogenesis. This question 
is  particularly  intriguing  in  the  extra-axial  neoplasms  showing  notochordal 
differentiation  as  it is  likely that a  mutation  occurs  upstream  of brachyury, 
inducing  brachyury expression and thereby changing the  phenotype of the 
cell to a chordoid one.
Finally,  another appealing  project to  undertake with this work would 
be the comparison between the microarray results for the MSC undergoing 
chondrogenesis  and  the  chondroid  tumours.  Recent  evidence  points  to 
tumours originating from a ‘stem celMike cell and it would be exciting to see 
if  the  microarray  data  presented  here  would  support  such  a  hypothesis 
(265).  For this  purpose  statistical  analysis  could  be  performed  to  check 
which genes,  if any, are commonly expressed  by the undifferentiated  MSC 
and the neoplasms, not shared by the fully differentiated MSC.
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Figure A.6.2: Top 100 probe sets distinguishing between chondroid lesions 
and chordomas (highlighted in yellow). In this heatmap high levels of gene 
expression are shown as red, values close to the mean are shown as black 
and low levels as green.9. SUPPLEMENTARY DATA
The supplementary data is presented on a CD-ROM attached to the 
back cover of this thesis. It includes information relevant to Chapter 4:
-  Differentially expressed genes during the MSC time course
o  Full  heatmap of all the  1394 differentially expressed  probe 
sets
o  Lists of significantly upregulated and downregulated genes 
between all time points
o  Treeview  files  that  can  be  viewed  using  the  Treeview 
software  available  to  download  from 
http://rana.lbl.aov/EisenSoftware.htm  This  software 
creates the heatmap of the 1394 changing genes presented 
as .jpg image describe above. The advantage of using the 
software  to  view  this  data  is  that  it  can  be  searched  for 
genes of interest.
-  Differentially expressed genes between MSC and NHAC
o  Lists of significantly differentially expressed genes between 
the  MSC  and  the  NHAC  before  (OH)  and  after they  have 
undergone chondrogenesis (14D)
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